The Mechanisms of Action of PPARs

Annual Review of Medicine
53, 409-435
DOI: 10.1146/annurev.med.53.082901.104018

Citation Report

#	Article	IF	Citations
1	New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 2001, 414, 821-827.	13.7	913
2	PEX11Î± Is Required for Peroxisome Proliferation in Response to 4-Phenylbutyrate but Is Dispensable for Peroxisome Proliferator-Activated Receptor Alpha-Mediated Peroxisome Proliferation. Molecular and Cellular Biology, 2002, 22, 8226-8240.	1.1	149
3	Pharmacogenetic Evidence That Cd36Is a Key Determinant of the Metabolic Effects of Pioglitazone. Journal of Biological Chemistry, 2002, 277, 48501-48507.	1.6	55
4	How best to counteract the enemies? By controlling inflammation in the coronary circulation. European Heart Journal Supplements, 2002, 4, G53-G65.	0.0	2
5	Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 207-210.	1.0	4
6	Peroxisome Proliferator-Activated Receptor Î³-Mediated NF-ÎºB Activation and Apoptosis in Pre-B Cells. Journal of Immunology, 2002, 169, 6831-6841.	0.4	53
7	Command centers for metabolic control can be in the most unexpected places. Current Opinion in Clinical Nutrition and Metabolic Care, 2002, 5, 357-358.	1.3	0
8	A role for the peroxisome proliferator-activated receptor Î± in T-cell physiology and ageing immunobiology. Proceedings of the Nutrition Society, 2002, 61, 363-369.	0.4	26
9	Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions. Current Cardiology Reports, 2002, 4, 514-521.	1.3	29
10	Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPIC-Heidelberg cohort. European Journal of Nutrition, 2002, 41, 210-221.	1.8	99
11	Gene Expression Changes Induced in Mouse Liver by Di(2-ethylhexyl) Phthalate. Toxicology and Applied Pharmacology, 2002, 185, 180-196.	1.3	69
12	Use of the Peroxisome Proliferator-Activated Receptor (PPAR) Î³ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study. Breast Cancer Research and Treatment, 2003, 79, 391-397.	1.1	212
13	Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 45-73.	1.0	62
14	Peroxisome Proliferator Activated Receptor-Î³ (PPAR-Î³) Ligands and Angiogenesis. Angiogenesis, 2003, 6, 165-169.	3.7	77
15	Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Expert Opinion on Investigational Drugs, 2003, 12, 1489-1500.	1.9	38
16	Cerivastatin: a cellular and molecular drug for the future?. Cellular and Molecular Life Sciences, 2003, 60, 144-164.	2.4	9
17	Combined effects of PPARÎ³2 P12A and PPARÎ± L162V polymorphisms on glucose and insulin homeostasis: the QuÃ©bec Family Study. Journal of Human Genetics, 2003, 48, 614-621.	1.1	10
18	Lysophosphatidic acid signaling: how a small lipid does big things. Trends in Biochemical Sciences, 2003, 28, 377-383.	3.7	64

#	Article	IF	Citations
19	Gamma (Î³) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (Î³) expression in SW 480 human colon cancer cell lines. BMC Cancer, 2003, 3, 25.	1.1	117
20	Localization of PPARÎ´ in murine central nervous system: expression in oligodendrocytes and neurons. Brain Research, 2003, 975, 10-21.	1.1	107
21	Prostaglandin D2 synthase enzymes and PPARÎ³ are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins and Other Lipid Mediators, 2003, 70, 267-284.	1.0	43
22	Genetics and nutrition. Clinical Nutrition, 2003, 22, 429-435.	2.3	39
23	Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer, 2003, 98, 2251-2256.	2.0	145
24	Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice. Journal of Cellular Biochemistry, 2003, 90, 347-360.	1.2	15
25	Benzoxazinones as PPARÎ³ agonists. part 1: SAR of three aromatic regions. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2359-2362.	1.0	23
26	O-Arylmandelic acids as highly selective human PPAR Î±/Î³ agonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3185-3190.	1.0	29
27	Synthesis of a high-affinity Fluorescent PPARÎ³ ligand for high-throughput fluorescence polarization assays. Bioorganic and Medicinal Chemistry, 2003, 11, 4325-4332.	1.4	21
28	Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovascular Diabetology, 2003, 2, 4.	2.7	76
29	Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IÎºBÎ± induction and block of NFÎºB and iNOS activation. Journal of Neurochemistry, 2004, 88, 494-501.	2.1	347
30	PPAR-Î± and -Î³ but not -Î´ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-Îº B-independent effect. British Journal of Pharmacology, 2003, 139, 163-171.	2.7	138
31	Proton-sensing G-protein-coupled receptors. Nature, 2003, 425, 93-98.	13.7	616
32	Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-Î±. Nature, 2003, 425, 90-93.	13.7	985
33	Nutrigenetics: where next for the foods industry?. Pharmacogenomics Journal, 2003, 3, 191-193.	0.9	16
34	Dexamethasone induction of hypertension and diabetes is PPAR-Î± dependent in LDL receptorâ€“null mice. Nature Medicine, 2003, 9, 1069-1075.	15.2	187
35	5-Aryl thiazolidine-2,4-diones as selective PPARÎ³ agonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1801-1804.	1.0	34
36	Pioglitazone, a Specific Ligand of the Peroxisome Proliferator-Activated Receptor Gamma Reduces Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rat. Scandinavian Journal of Gastroenterology, 2003, 38, 468-476.	0.6	47

#	Article	IF	Citations
37	Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein Î³ Selective Modulator. Molecular Endocrinology, 2003, 17, 662-676.	3.7	314
38	Peroxisome proliferator-activated receptor-Î² signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology, 2003, 124, 184-201.	0.6	120
39	Mechanisms of Troglitazone Hepatotoxicity. Chemical Research in Toxicology, 2003, 16, 679-687.	1.7	189
40	Differential expression of Akt, PPARÎ³, and PGC-1 during hibernation in bats. Biochemistry and Cell Biology, 2003, 81, 269-274.	0.9	69
41	The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. American Journal of Medicine, 2003, 115, 12-19.	0.6	29
42	Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends in Pharmacological Sciences, 2003, 24, 530-534.	4.0	26
43	The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1receptor antagonists. FEBS Letters, 2003, 536, 145-150.	1.3	12
44	Peroxisome-Proliferator-Activated Receptor Î´ Activates Fat Metabolism to Prevent Obesity. Cell, 2003, 113, 159-170.	13.5	1,221
45	A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochemical and Biophysical Research Communications, 2003, 301, 406-410.	1.0	325
46	Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-Î³ expression in splenic T cells. Biochemical and Biophysical Research Communications, 2003, 304, 378-384.	1.0	40
47	The effect of rosiglitazone on serum lipoprotein(a) levels in korean patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2003, 52, 731-734.	1.5	26
48	Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clinical Therapeutics, 2003, 25, B64-B80.	1.1	34
49	Fostering orphan receptors: an indispensable role for integrative, in vivo, haemodynamic studies. Current Opinion in Pharmacology, 2003, 3, 140-145.	1.7	8
50	Liver Peroxisome Proliferator-activated Receptor Î³ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass. Journal of Biological Chemistry, 2003, 278, 34268-34276.	1.6	672
51	Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer. Xenobiotica, 2003, 33, 767-787.	0.5	4
52	Insulin Resistance Syndrome in Children. Paediatric Drugs, 2003, 5, 291-299.	1.3	21
53	Activation and Binding of Peroxisome Proliferator-Activated Receptor Î³ by Synthetic Cannabinoid Ajulemic Acid. Molecular Pharmacology, 2003, 63, 983-992.	1.0	122
54	Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor Î±. Journal of Biological Chemistry, 2003, 278, 48283-48291.	1.6	149

#	Article	IF	Citations
55	Peroxisome Proliferator-Activated Receptor Î± Negatively Regulates T-bet Transcription Through Suppression of p38 Mitogen-Activated Protein Kinase Activation. Journal of Immunology, 2003, 171, 196-203.	0.4	56
56	Peroxisome Proliferator-Activated Receptor-Î³ Activator 15-Deoxy-Î”12,14-Prostaglandin J2 Inhibits Neuroblastoma Cell Growth through Induction of Apoptosis: Association with Extracellular Signal-Regulated Kinase Signal Pathway. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 505-517.	1.3	73
57	Peroxisome Proliferator-Activated Receptor Ligands Affect Growth-Related Gene Expression in Human Leukemic Cells. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 932-942.	1.3	45
58	Controlling muscle mitochondrial content. Journal of Experimental Biology, 2003, 206, 4385-4391.	0.8	75
59	Molecular Determinants of the Balance between Co-repressor and Co-activator Recruitment to the Retinoic Acid Receptor. Journal of Biological Chemistry, 2003, 278, 43797-43806.	1.6	28
60	Pharmacological Agents That Directly Modulate Insulin Secretion. Pharmacological Reviews, 2003, 55, 105-131.	7.1	217
61	Evidence That Peroxisome Proliferatorâ€“Activated Receptor Delta Influences Cholesterol Metabolism in Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 637-643.	1.1	125
62	Chapter 8. Modulators of peroxisome proliferator-activated receptors (PPARs). Annual Reports in Medicinal Chemistry, 2003, 38, 71-80.	0.5	19
63	Activation of PPARÂ and PPARÂ by Environmental Phthalate Monoesters. Toxicological Sciences, 2003, 74, 297-308.	1.4	440
64	Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opinion on Investigational Drugs, 2003, 12, 1925-1937.	1.9	75
65	Role of Redox Imbalance in the Molecular Mechanisms Responsible for Immunosenescence. Antioxidants and Redox Signaling, 2003, 5, 537-548.	2.5	24
66	The Peroxisome Proliferator-Activated Receptor Î²/Î´ Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells. Molecular Endocrinology, 2003, 17, 2477-2493.	3.7	342
67	PEROXISOMEBIOGENESISDISORDERS. Annual Review of Genomics and Human Genetics, 2003, 4, 165-211.	2.5	176
68	Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation. Journal of Biological Chemistry, 2003, 278, 46261-46269.	1.6	92
69	Ligand and Coactivator Identity Determines the Requirement of the Charge Clamp for Coactivation of the Peroxisome Proliferator-activated Receptor Î³. Journal of Biological Chemistry, 2003, 278, 8637-8644.	1.6	60
70	Cell cross-talk mediates PPARÂ null hepatocyte proliferation after peroxisome proliferator exposure. Carcinogenesis, 2003, 25, 107-112.	1.3	13
71	Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects. Diabetes, 2003, 52, 283-290.	0.3	144
72	Correction of Fatty Acid Oxidation in Carnitine Palmitoyl Transferase 2â€“Deficient Cultured Skin Fibroblasts by Bezafibrate. Pediatric Research, 2003, 54, 446-451.	1.1	55

#	Article	IF	Citations
73	Lovastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Induces Apoptosis and Differentiation in Human Anaplastic Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3021-3026.	1.8	65
74	Peroxisome Proliferator-Activated Receptor-Î³ Is Deficient in Alveolar Macrophages from Patients with Alveolar Proteinosis. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 677-682.	1.4	121
75	Properties and physiological significance of fatty acid binding proteins. Advances in Molecular and Cell Biology, 2003, 33, 99-122.	0.1	14
76	Lipid metabolism: inflammatory-immune responses in atherosclerosis. Current Opinion in Lipidology, 2003, 14, 337-339.	1.2	6
77	What is the role for insulin therapy in type 2 diabetes?. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 99-103.	0.6	5
78	Peroxisome proliferator-activated receptor-Î³ agonists in atherosclerosis: current evidence and future directions. Current Opinion in Lipidology, 2003, 14, 567-573.	1.2	41
79	Peroxisome Proliferator-Activated Receptors and the Cardiovascular System. Vitamins and Hormones, 2003, 66, 157-188.	0.7	44
80	SDP1 is a peroxisome-proliferator-activated receptor gamma2 co-activator that binds through its SCAN domain. Biochemical Journal, 2003, 370, 719-727.	1.7	19
81	Delayed-Onset Heparin-Induced Thrombocytopenia. Annals of Internal Medicine, 2003, 139, 790.	2.0	2
82	Peroxisome Proliferator-Activated Receptors, Fatty Acid Oxidation, Steatohepatitis and Hepatocarcinogenesis. Current Molecular Medicine, 2003, 3, 561-572.	0.6	163
83	Anti-Inflammatory Drug Therapy Alters Î²-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease. Journal of Neuroscience, 2003, 23, 7504-7509.	1.7	473
84	Dual PPARÎ±/Î³ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E841-E854.	1.8	61
85	Fungal Endocarditis due to Scopulariopsis. Annals of Internal Medicine, 2003, 139, W-77.	2.0	14
86	Paradoxical Lowering of High-Density Lipoprotein Cholesterol Level in 2 Patients Receiving Fenofibrate and a Thiazolidinedione. Annals of Internal Medicine, 2003, 139, W-80.	2.0	20
87	Laboratory Monitoring of High-Dose Factor VIIa Therapy. Annals of Internal Medicine, 2003, 139, 791.	2.0	13
89	Gene expression profiling of potential PPARÎ³ target genes in mouse aorta. Physiological Genomics, 2004, 18, 33-42.	1.0	47
90	Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E941-E949.	1.8	53
91	Authorsâ€™ Response: Bezafibrate and Simvastatin: Different Beneficial Effects for Different Therapeutic Aims. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1978-1979.	1.8	1

#	Article	IF	Citations
92	Authorsâ€™ Response: Serum Resistin (FIZZ3) Protein Is Increased in Obese Humans. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1977-1978.	1.8	1
93	Fatty Acid Synthesis and its Regulation. , 2004, , 99-103.		2
94	Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. Journal of Biomedicine and Biotechnology, 2004, 2004, 156-166.	3.0	93
95	Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from nâ^'3 fatty acids. American Journal of Clinical Nutrition, 2004, 79, 1190S-1198S.	2.2	87
96	Bezafibrate and Simvastatin: Different Beneficial Effects for Different Therapeutic Aims. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1978-1978.	1.8	7
97	Peroxisome Proliferator-Activated Receptor-Î³ Calls for Activation in Moderation: Lessons from Genetics and Pharmacology. Endocrine Reviews, 2004, 25, 899-918.	8.9	251
98	Serum Resistin (FIZZ3) Protein Is Increased in Obese Humans. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1977-1977.	1.8	15
99	Repression of Oxidant-Induced Nuclear Factor-ÎºB Activity Mediates Placental Cytokine Responses in Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3585-3594.	1.8	55
100	Nutritional Effects on Host Response to Lung Infections with Mucoid Pseudomonas aeruginosa in Mice. Infection and Immunity, 2004, 72, 1479-1486.	1.0	23
101	Adipose Tissue Expression of the Lipid Droplet-Associating Proteins S3-12 and Perilipin Is Controlled by Peroxisome Proliferator-Activated Receptor-Â. Diabetes, 2004, 53, 1243-1252.	0.3	186
102	Molecular Cues to Implantation. Endocrine Reviews, 2004, 25, 341-373.	8.9	956
103	A Novel Selective Peroxisome Proliferator-Activated Receptor Î± Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 970-977.	1.3	35
104	Temporal Recruitment of Transcription Factors and SWI/SNF Chromatin-Remodeling Enzymes during Adipogenic Induction of the Peroxisome Proliferator-Activated Receptor Î³ Nuclear Hormone Receptor. Molecular and Cellular Biology, 2004, 24, 4651-4663.	1.1	168
105	Evidence of differing genotypic effects of PPARÂ in women and men. Journal of Medical Genetics, 2004, 41, e79-e79.	1.5	9
106	Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D 1A Receptor in Obese Zucker Rats. Hypertension, 2004, 43, 376-382.	1.3	23
107	Peroxisome Proliferatorâ€“Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. Circulation, 2004, 109, 2197-2202.	1.6	157
108	The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARÂ pathway. Carcinogenesis, 2004, 25, 1805-1812.	1.3	26
109	The PPARÂ Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis, 2004, 26, 579-585.	1.3	42

#	Article	IF	Citations
110	Peroxisome Proliferator-Activated Receptor Î³ Controls Muc1 Transcription in Trophoblasts. Molecular and Cellular Biology, 2004, 24, 10661-10669.	1.1	76
111	Tissue-Selective, Bidirectional Regulation of PEX11Î± and Perilipin Genes through a Common Peroxisome Proliferator Response Element. Molecular and Cellular Biology, 2004, 24, 1313-1323.	1.1	62
112	A Novel Peroxisome Proliferator-Activated Receptor Î±/Î³ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis. Endocrinology, 2004, 145, 1640-1648.	1.4	55
113	Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARÎ³â€“Modulating Activity. Hypertension, 2004, 43, 993-1002.	1.3	1,009
114	Environmental and Endogenous Peroxisome Proliferator-Activated Receptor Î³ Agonists Induce Bone Marrow B Cell Growth Arrest and Apoptosis: Interactions between Mono(2-ethylhexyl)phthalate, 9-cis-Retinoic Acid, and 15-Deoxy-Î”12,14-prostaglandin J2. Journal of Immunology, 2004, 173, 3165-3177.	0.4	42
115	Severe Hypo-Â-Lipoproteinemia During Treatment With Rosiglitazone. Diabetes Care, 2004, 27, 2577-2580.	4.3	30
116	The Peroxisome Proliferator-activated Receptor Î± (PPARÎ±) Agonist Ciprofibrate Inhibits Apolipoprotein B mRNA Editing in Low Density Lipoprotein Receptor-deficient Mice. Journal of Biological Chemistry, 2004, 279, 28662-28669.	1.6	28
117	Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor Î± (PPAR-Î±). Journal of Biological Chemistry, 2004, 279, 27849-27854.	1.6	295
118	Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³) Ligands and Their Therapeutic Utility. Progress in Medicinal Chemistry, 2004, 42, 1-53.	4.1	21
119	Actions of PPARÎ³ agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R1116-R1123.	0.9	44
120	Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (PPARs) by Phthalate Monoesters. Toxicological Sciences, 2004, 82, 170-182.	1.4	185
121	Differences in the metabolism and pharmacokinetics of two structurally similar PPAR agonists in dogs: involvement of taurine conjugation. Xenobiotica, 2004, 34, 665-674.	0.5	4
122	Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARÎ± and PPARÎ³ agonists. International Journal of Clinical Practice, 2004, 58, 22-29.	0.8	35
123	Dysfunctional fat cells, lipotoxicity and type 2 diabetes. International Journal of Clinical Practice, 2004, 58, 9-21.	0.8	175
124	Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. European Journal of Clinical Investigation, 2004, 34, 429-435.	1.7	31
125	Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. International Journal of Clinical Practice, 2004, 58, 867-876.	0.8	43
126	Peroxisome proliferator-activated receptor-Î³ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene, 2004, 23, 100-108.	2.6	190
127	Nuclear Receptors. British Journal of Pharmacology, 2004, 141, S97-S101.	2.7	0

#	Article	IF	Citations
128	Ligands for the peroxisome proliferator-activated receptor-Î³ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 116-126.	1.1	120
129	Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague–Dawley rats. Experimental Gerontology, 2004, 39, 1295-1306.	1.2	19
130	Crosstalk of oncogenic and prostanoid signaling pathways. Journal of Cancer Research and Clinical Oncology, 2004, 130, 429-44.	1.2	41
131	Population prevalence of APOE, APOC3 and PPAR-Î± mutations associated to hypertriglyceridemia in French Canadians. Journal of Human Genetics, 2004, 49, 691-700.	1.1	20
133	Synthesis and biological activity of Benzoxazole containing thiazolidinedione derivatives. Archives of Pharmacal Research, 2004, 27, 1099-1105.	2.7	30
134	A high-capacity assay for PPARÎ³ ligand regulation of endogenous aP2 expression in 3T3-L1 cells. Analytical Biochemistry, 2004, 330, 21-28.	1.1	41
135	Diastereo- and enantioselective bioreduction of ethyl 2-(4-chlorophenoxy)-3-oxobutanoate clofibrate analogues by Kluyveromyces marxianus and other whole cell biocatalysts. Tetrahedron: Asymmetry, 2004, 15, 3511-3517.	1.8	17
136	Peroxisome proliferator-activated receptor Î³ gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. Diabetologia, 2004, 47, 1126-1127.	2.9	4
137	Modulation of hepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids, 2004, 39, 143-151.	0.7	90
138	Molecular characterization of three peroxisome proliferator-activated receptors from the sea bass (Dicentrarchus labrax). Lipids, 2004, 39, 1085-1092.	0.7	69
140	Disruption of transforming growth factor ? signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor ?. Arthritis and Rheumatism, 2004, 50, 1305-1318.	6.7	190
141	An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. International Journal of Cancer, 2004, 112, 909-919.	2.3	108
142	Decreased expression of peroxisome proliferator activated receptor ? in CFTR?/? mice. Journal of Cellular Physiology, 2004, 200, 235-244.	2.0	66
143	Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs, 2004, 4, 227-246.	1.0	94
144	Recent advances in the treatment of polycystic ovary syndrome. Expert Opinion on Investigational Drugs, 2004, 13, 1295-1305.	1.9	12
145	Anti-inflammatory and antiproliferative actions of PPAR-Î³ agonists on T lymphocytes derived from MS patients. Journal of Leukocyte Biology, 2004, 75, 478-485.	1.5	85
146	Design and Synthesis of Î±-Aryloxy-Î±-methylhydrocinnamic Acids:Â A Novel Class of Dual Peroxisome Proliferator-Activated Receptor Î±/Î³ Agonists. Journal of Medicinal Chemistry, 2004, 47, 2422-2425.	2.9	58
148	The potential role of genes in nonalcoholic fatty liver disease. Clinics in Liver Disease, 2004, 8, 673-691.	1.0	44

#	Article	IF	Citations
149	Activation of PPAR Î³ and Î´ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology, 2004, 127, 777-791.	0.6	354
150	A CLAâ€™s act: Feeding away inflammation. Gastroenterology, 2004, 127, 994-996.	0.6	15
151	Benzoxazinones as PPARÎ³ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model. Journal of Medicinal Chemistry, 2004, 47, 196-209.	2.9	42
152	Peroxisome proliferator-activated receptor-Î³: therapeutic target for diseases beyond diabetes: quo vadis?. Expert Opinion on Investigational Drugs, 2004, 13, 215-228.	1.9	80
153	Thiazolidinediones. New England Journal of Medicine, 2004, 351, 1106-1118.	13.9	1,892
154	Thiazolidinediones: A Review of Their Mechanisms of Insulin Sensitization, Therapeutic Potential, Clinical Efficacy, and Tolerability. Diabetes Technology and Therapeutics, 2004, 6, 850-863.	2.4	87
155	Ligand- and Species-Dependent Activation of PPARÎ±. Cellular Physiology and Biochemistry, 2004, 14, 269-276.	1.1	17
156	Cardiovascular Pharmacogenetics. Handbook of Experimental Pharmacology, 2004, , .	0.9	0
157	(2R)-2-Ethylchromane-2-carboxylic Acids:Â Discovery of Novel PPARÎ±/Î³ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents. Journal of Medicinal Chemistry, 2004, 47, 3255-3263.	2.9	48
158	Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 463-478.	1.8	570
159	Using humans to study the physiological evolution of energy metabolism: a tribute to Peter Hochachka. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2004, 139, 487-494.	0.7	1
160	Signal transduction during amyloid-Î²-peptide neurotoxicity: role in Alzheimer disease. Brain Research Reviews, 2004, 47, 275-289.	9.1	121
161	MK-0767, a novel dual PPARÎ±/Î³ agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochemical and Biophysical Research Communications, 2004, 318, 323-328.	1.0	43
162	PPARÎ± ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochemical and Biophysical Research Communications, 2004, 324, 697-704.	1.0	173
163	The human semaphorin 6B gene is down regulated by PPARs. Genomics, 2004, 83, 1141-1150.	1.3	24
164	Nuclear prostaglandin receptors: role in pregnancy and parturition?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 70, 149-165.	1.0	35
165	Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 70, 391-397.	1.0	39
166	A new anti-inflammatory agent KL-1037 represses proinflammatory cytokine and inducible nitric oxide synthase (iNOS) gene expression in activated microglia. Neuropharmacology, 2004, 47, 243-252.	2.0	32

#	Article	IF	Citations
167	Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS. Neuroscience, 2004, 123, 131-145.	1.1	532
168	Role of adipocytokines in metabolism and disease. Nutrition Research, 2004, 24, 803-826.	1.3	38
169	PPARÎ± agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory Peptides, 2004, 120, 243-251.	1.9	8
170	The intricate interface between immune system and metabolism. Trends in Immunology, 2004, 25, 193-200.	2.9	187
171	Macrovascular complications of metabolic syndrome: an early intervention is imperative. International Journal of Cardiology, 2004, 97, 167-172.	0.8	40
172	Induction of connexin 43 by carotenoids: functional consequences. Archives of Biochemistry and Biophysics, 2004, 430, 120-126.	1.4	16
173	Enzymes of triacylglycerol synthesis and their regulation. Progress in Lipid Research, 2004, 43, 134-176.	5.3	772
174	A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clinical Therapeutics, 2004, 26, 805-818.	1.1	53
175	Dietary long-chain nâ^'3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition, 2004, 79, 935-945.	2.2	813
176	Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation, 2004, 2, 3-34.	0.0	5
177	Peroxisome Proliferator Activator Receptors (PPAR), Insulin Resistance, and Cardiomyopathy. Cardiology in Review, 2004, 12, 158-170.	0.6	26
178	Peroxisome proliferator-activated receptor-Î³ ligands: A pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndrome *. Critical Care Medicine, 2004, 32, 604-605.	0.4	32
179	Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Journal of Hypertension, 2004, 22, 2253-2261.	0.3	172
180	The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Current Opinion in Lipidology, 2004, 15, 13-18.	1.2	151
181	Noradrenaline represses PPAR (peroxisome-proliferator-activated receptor) Î²2 gene expression in brown adipocytes: intracellular signalling and effects on PPARÎ²2 and PPARÎ²1 protein levels. Biochemical Journal, 2004, 382, 597-606.	1.7	42
182	Peroxisome proliferator-activated receptor-Î³ and its ligands attenuate biologic functions of human natural killer cells. Blood, 2004, 104, 3276-3284.	0.6	42
183	Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochemical Journal, 2004, 377, 339-346.	1.7	44
184	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clinical Science, 2004, 107, 233-249.	1.8	42

#	Article	IF	Citations
185	Treatment of type 2 diabetic db/db mice with a novel PPARÎ³ agonist improves cardiac metabolism but not contractile function. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E449-E455.	1.8	83
186	CME Credit???September 2005. Southern Medical Journal, 2005, 98, 902.	0.3	0
187	The Nonthiazolidinedione PPARÎ³ Agonist L-796,449 Is Neuroprotective in Experimental Stroke. Journal of Neuropathology and Experimental Neurology, 2005, 64, 797-805.	0.9	64
188	Insulin Resistance in Polycystic Ovarian Disease. Southern Medical Journal, 2005, 98, 902-909.	0.3	11
189	Obesity and Diabetes Gene Discovery Approaches. Frontiers in Drug Design and Discovery, 2005, 2, 161-182.	0.3	0
190	Shared genetic risk factors for obstructive sleep apnea and obesity. Journal of Applied Physiology, 2005, 99, 1600-1606.	1.2	67
191	PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. NeuroReport, 2005, 16, 829-833.	0.6	31
192	2-Amino-phenoxazine-3-one Attenuates Glucose-Induced Augmentation of Embryonic Form of Myosin Heavy Chain, Endothelin-1 and Plasminogen Activator Inhibitor-1 in Human Umbilical Vein Endothelial Cells. Biological and Pharmaceutical Bulletin, 2005, 28, 797-801.	0.6	8
193	In vitro metabolism of a new oxazolidinedione hypoglycemic agent utilizing liver microsomes and recombinant human cytochrome P450 enzymes. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 351-358.	1.4	10
194	A highly efficient synthesis of antiobestic ligand GW501516 for the peroxisome proliferator-activated receptor Î´ through in situ protection of the phenol group by reaction with a Grignard reagent. Tetrahedron Letters, 2005, 46, 6683-6686.	0.7	12
195	Benzoyl 2-methyl indoles as selective PPARÎ³ modulators. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 357-362.	1.0	125
196	Selective PPARÎ³ modulators with improved pharmacological profiles. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2437-2440.	1.0	62
197	(2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARÎ± agonists as hypolipidemic agents. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3347-3351.	1.0	18
198	Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARÎ³ partial agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5035-5038.	1.0	64
199	Synthesis and biological evaluation of new clofibrate analogues as potential PPARÎ± agonists. European Journal of Medicinal Chemistry, 2005, 40, 143-154.	2.6	22
200	Effect of the Pro12Ala Polymorphism of the <I>PPAR</I>g2<I> Gene on Serum Adiponectin Changes. Endocrine, 2005, 27, 307-310.	2.2	16
201	Metabolic Syndrome: A Clinical and Molecular Perspective. Annual Review of Medicine, 2005, 56, 45-62.	5.0	538
202	A TELEOST IN VITRO REPORTER GENE ASSAY TO SCREEN FOR AGONISTS OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS. Environmental Toxicology and Chemistry, 2005, 24, 2260.	2.2	24

#	Article	IF	Citations
203	Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor Î³ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 58-68.	1.3	169
204	The selective PPARÎ³ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney International, 2005, 68, 529-536.	2.6	49
205	Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes, Obesity and Metabolism, 2005, 7, 675-691.	2.2	103
206	A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor1. International Journal of Cosmetic Science, 2005, 27, 123-132.	1.2	38
207	Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. British Journal of Cancer, 2005, 92, 113-119.	2.9	63
208	HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Reviews Drug Discovery, 2005, 4, 193-205.	21.5	418
209	Role of PPARÎ³, transcriptional cofactors, and adiponectin in the regulation of nutrient metabolism, adipogenesis and insulin action: view from the chair. International Journal of Obesity, 2005, 29, S3-S4.	1.6	39
210	Adiponectin: a relevant player in PPARÎ³-agonist-mediated improvements in hepatic insulin sensitivity?. International Journal of Obesity, 2005, 29, S17-S23.	1.6	140
211	Peroxisome proliferator-activated receptor-Î³ (PPARÎ³) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene, 2005, 24, 1412-1422.	2.6	106
212	the Peroxisome Proliferator-Activated Receptor Î³ Ligand Rosiglitazone Delays the Onset of Inflammatory Bowel Disease in Mice With Interleukin 10 Deficiency. Inflammatory Bowel Diseases, 2005, 11, 231-243.	0.9	88
213	Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS Journal, 2005, 272, 3004-3014.	2.2	79
214	Dynamin-related proteins and Pex11 proteins in peroxisome division and proliferation. FEBS Journal, 2005, 272, 5169-5181.	2.2	150
215	Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARÎ³ agonists: evidence for disparate functional effects which are independent of NF-Î°B and PPARÎ³. Cellular Signalling, 2005, 17, 1098-1110.	1.7	28
216	Anandamide induced PPARÎ³ transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology, 2005, 517, 174-181.	1.7	255
217	Pro-inflammatory properties for thiazolidinediones. Biochemical Pharmacology, 2005, 69, 255-265.	2.0	23
219	Keynote review: The adipocyte as a drug discovery target. Drug Discovery Today, 2005, 10, 1219-1230.	3.2	138
220	PPARÎ³: A Critical Determinant of Body Fat Distribution in Humans and Mice. Trends in Cardiovascular Medicine, 2005, 15, 81-85.	2.3	52
221	An essential role forRxrÎ± in the development of Th2 responses. European Journal of Immunology, 2005, 35, 3414-3423.	1.6	54

#	Article	IF	Citations
222	Peroxisome proliferator-activated receptor Î³ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis inApc1638 N/+Mlh1+/â˜ double mutant mice. International Journal of Cancer, 2005, 116, 495-499.	2.3	66
223	Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Molecular Nutrition and Food Research, 2005, 49, 405-430.	1.5	593
224	Peroxisome proliferator activated receptor-Î³ ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemotherapy and Pharmacology, 2005, 56, 400-408.	1.1	46
225	Peroxisome proliferator-activated receptor-Î± and liver cancer: where do we stand?. Journal of Molecular Medicine, 2005, 83, 774-785.	1.7	229
226	Rosiglitazone and lipid metabolism. Diabetologia, 2005, 48, 6-7.	2.9	3
227	Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. Diabetologia, 2005, 48, 2354-2364.	2.9	68
228	Regulation of food intake by oleoylethanolamide. Cellular and Molecular Life Sciences, 2005, 62, 708-716.	2.4	158
229	Reaction of caesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogues. Tetrahedron: Asymmetry, 2005, 16, 783-792.	1.8	7
230	Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (?, ?, ?) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. Basic Research in Cardiology, 2005, 100, 263-269.	2.5	27
231	CYP94A1, a plant cytochrome P450-catalyzing fatty acid Ï‰-hydroxylase, is selectively induced by chemical stress in Vicia sativa seedlings. Planta, 2005, 221, 881-890.	1.6	31
232	PPAR-Î³ agonists and diabetic nephropathy. Current Diabetes Reports, 2005, 5, 470-475.	1.7	19
233	PPAR ligands: Potential therapies for metabolic syndrome. Current Diabetes Reports, 2005, 5, 45-52.	1.7	49
234	Cloning and expression of PPARÎ³ and PGC-1Î± from the hibernating ground squirrel, Spermophilus tridecemlineatus. Molecular and Cellular Biochemistry, 2005, 269, 175-182.	1.4	51
235	PPAR-Î± Expression Inversely Correlates with Inflammatory Cytokines IL-1Î² and TNF-Î± in Aging Rats. Neurochemical Research, 2005, 30, 1369-1375.	1.6	32
236	Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular Diabetology, 2005, 4, 14.	2.7	209
237	Pancreatic Islet Adaptation to Fasting Is Dependent on Peroxisome Proliferator-Activated Receptor Î± Transcriptional Up-Regulation of Fatty Acid Oxidation. Endocrinology, 2005, 146, 375-382.	1.4	89
238	Drug Therapy for Insulin Resistance - a Look at the Future. , 2005, , 561-585.		0
239	Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H206-H211.	1.5	20

#	Article	IF	Citations
240	Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1137-E1145.	1.8	25
241	Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ. Current Diabetes Reviews, 2005, 1, 299-307.	0.6	49
242	The human paracellin-1 gene (hPCLN-1): renal epithelial cell-specific expression and regulation. American Journal of Physiology - Renal Physiology, 2005, 288, F272-F283.	1.3	28
243	Significance of anti-inflammatory effects of PPARÂ agonists?. Gut, 2005, 55, 1067-1069.	6.1	15
244	Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor Î± are altered by the centrosome-associated protein CAP350. Journal of Cell Science, 2005, 118, 175-186.	1.2	28
245	Dysregulation of the Peroxisome Proliferator-Activated Receptor Target Genes by XPD Mutations. Molecular and Cellular Biology, 2005, 25, 6065-6076.	1.1	377
246	Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. Journal of Lipid Research, 2005, 46, 1295-1302.	2.0	28
247	Peroxisome Proliferation-Activated Receptor (PPAR)Î³ Is Not Necessary for Synthetic PPARÎ³ Agonist Inhibition of Inducible Nitric-Oxide Synthase and Nitric Oxide. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 69-76.	1.3	44
248	Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Human Molecular Genetics, 2005, 14, 2695-2703.	1.4	87
249	Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor Î³ Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 422-430.	1.3	11
250	C75 Alters Central and Peripheral Gene Expression to Reduce Food Intake and Increase Energy Expenditure. Endocrinology, 2005, 146, 486-493.	1.4	68
251	Peroxisomal Proliferation Protects from Î²-Amyloid Neurodegeneration. Journal of Biological Chemistry, 2005, 280, 41057-41068.	1.6	137
252	Peroxisome Proliferator Activated Receptor Î´ (PPARÎ´) Agonist But Not PPARÎ± Corrects Carnitine Palmitoyl Transferase 2 Deficiency in Human Muscle Cells. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1791-1797.	1.8	57
253	Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome. Archives of Internal Medicine, 2005, 165, 1154.	4.3	299
254	Soy Protein Influences Insulin Sensitivity and Cardiovascular Risk in Male Lean SHHF Rats. Hormone and Metabolic Research, 2005, 37, 309-315.	0.7	23
255	Soy Protein Influences the Development of the Metabolic Syndrome in Male Obese ZDFxSHHF Rats. Hormone and Metabolic Research, 2005, 37, 316-325.	0.7	34
256	Chemoprevention of lung cancer: concepts and strategies. Expert Review of Anticancer Therapy, 2005, 5, 549-565.	1.1	4
257	Redox Modulation of Insulin Signaling and Endothelial Function. Antioxidants and Redox Signaling, 2005, 7, 1062-1070.	2.5	10

#	Article	IF	Citations
258	Chapter 6 Metabolite identification by lc-ms: applications in drug discovery and development. Progress in Pharmaceutical and Biomedical Analysis, 2005, 6, 123-158.	0.1	10
259	Epidermal Peroxisome Proliferator-activated Receptor Î³ as a Target for Ultraviolet B Radiation. Journal of Biological Chemistry, 2005, 280, 73-79.	1.6	37
260	The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. Journal of Neuroscience, 2005, 25, 7805-7812.	1.7	196
261	Cardiac-Specific Overexpression of Peroxisome Proliferator-Activated Receptor-Â Causes Insulin Resistance in Heart and Liver. Diabetes, 2005, 54, 2514-2524.	0.3	113
262	SPECIES DIFFERENCES IN THE ELIMINATION OF A PPAR AGONIST HIGHLIGHTED BY OXIDATIVE METABOLISM OF ITS ACYL GLUCURONIDE. Drug Metabolism and Disposition, 2005, 33, 1894-904.	1.7	8
263	Control of muscle bioenergetic gene expression: implications for allometric scaling relationships of glycolytic and oxidative enzymes. Journal of Experimental Biology, 2005, 208, 1601-1610.	0.8	28
264	Apolipoprotein C3 Deficiency Results in Diet-Induced Obesity and Aggravated Insulin Resistance in Mice. Diabetes, 2005, 54, 664-671.	0.3	95
265	Unraveling the Temporal Pattern of Diet-Induced Insulin Resistance in Individual Organs and Cardiac Dysfunction in C57BL/6 Mice. Diabetes, 2005, 54, 3530-3540.	0.3	251
266	Peroxisome Proliferator-Activated Receptors: The Nutritionally Controlled Molecular Networks that Integrate Inflammation, Immunity and Metabolism. Current Nutrition and Food Science, 2005, 1, 179-187.	0.3	15
267	Evaluation of Polycyclic Aromatic Hydrocarbons in the Activation of Early Growth Response-1 and Peroxisome Proliferator Activated Receptors. Toxicological Sciences, 2005, 85, 585-593.	1.4	63
268	Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. European Heart Journal, 2005, 26, 2032-2038.	1.0	83
269	La cintura hipertrigliceridÃ©mica. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2005, 17, 286-296.	0.4	4
271	The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Î± Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide. Molecular Pharmacology, 2005, 67, 15-19.	1.0	804
272	Role of nuclear receptors in lung tumourigenesis. European Journal of Cancer, 2005, 41, 2561-2568.	1.3	30
273	Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. Atherosclerosis, 2005, 182, 249-257.	0.4	34
274	Peroxisome proliferator-activated receptor Î³ is expressed in hippocampal neurons and its activation prevents Î²-amyloid neurodegeneration: role of Wnt signaling. Experimental Cell Research, 2005, 304, 91-104.	1.2	181
275	Design and Synthesis of Î±-Aryloxyphenylacetic Acid Derivatives:Â A Novel Class of PPARÎ±/Î³ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity. Journal of Medicinal Chemistry, 2005, 48, 4457-4468.	2.9	77
276	Inverse Relationship between 15-Lipoxygenase-2 and PPAR-Î³ Gene Expression in Normal Epithelia Compared with Tumor Epithelia. Neoplasia, 2005, 7, 280-293.	2.3	56

#	Article	IF	Citations
277	An inverse relationship between peroxisome proliferatorâ€“activated receptor Î³ and allergic airway inflammation in an allergen challenge model. Annals of Allergy, Asthma and Immunology, 2005, 95, 468-473.	0.5	37
278	PPARÎ³, Energy Balance, and Associations With Colon and Rectal Cancer. Nutrition and Cancer, 2005, 51, 155-161.	0.9	20
279	Effect of the peroxisome proliferator-activated receptor-Î³ C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. Journal of Endocrinological Investigation, 2005, 28, 129-136.	1.8	24
280	A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARÎ±-dependent and -independent pathways. Journal of Lipid Research, 2005, 46, 716-726.	2.0	67
281	Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiological Reviews, 2005, 85, 1093-1129.	13.1	1,650
282	Exploring the Binding Site Structure of the PPARÎ³ Ligand-Binding Domain by Computational Solvent Mapping. Biochemistry, 2005, 44, 1193-1209.	1.2	71
283	The Human Peroxisome Proliferator-activated Receptor Î´ Gene is a Primary Target of 1Î±,25-Dihydroxyvitamin D3 and its Nuclear Receptor. Journal of Molecular Biology, 2005, 349, 248-260.	2.0	180
284	Impaired expression of PPARÎ³ protein contributes to the exaggerated growth of vascular smooth muscle cells in spontaneously hypertensive rats. Life Sciences, 2005, 77, 3037-3048.	2.0	15
285	PPAR-Î³: A nuclear receptor with affinity for cannabinoids. Life Sciences, 2005, 77, 1674-1684.	2.0	65
286	5-(3,5-Di-tert-butyl-4-hydroxybenzylidene) thiazolidine-2,4-dione modulates peroxisome proliferators-activated receptor Î³ in 3T3-L1 adipocytes: Roles as a PPARÎ³ ligand. Molecular and Cellular Endocrinology, 2005, 242, 96-102.	1.6	8
287	Leptin rapidly activates PPARs in C2C12 muscle cells. Biochemical and Biophysical Research Communications, 2005, 332, 719-725.	1.0	25
288	Novel time-dependent vascular actions of Î”9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications, 2005, 337, 824-831.	1.0	148
289	PPARÎ± activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochemical and Biophysical Research Communications, 2005, 338, 1818-1824.	1.0	41
290	RNA interference of PPARÎ³ using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells. Gene, 2005, 348, 157-165.	1.0	37
291	â€œNewâ€•hepatic fat activates PPARÎ± to maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism, 2005, 1, 309-322.	7.2	462
292	The cyclopentenone 15-deoxy-Î”12,14-prostaglandin J2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients. Experimental Neurology, 2005, 195, 508-517.	2.0	11
293	Fatty acid metabolism as a target for obesity treatment. Physiology and Behavior, 2005, 85, 25-35.	1.0	110
294	Pioglitazone, a peroxisome proliferator-activated receptor ? activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. Journal of Molecular and Cellular Cardiology, 2005, 38, 257-265.	0.9	48

#	Article	IF	Citations
295	Common polymorphisms in the PPARÎ³2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men. Molecular Genetics and Metabolism, 2005, 84, 344-348.	0.5	25
296	New therapeutic options for the metabolic syndrome: what's next?. Trends in Endocrinology and Metabolism, 2005, 16, 254-260.	3.1	20
297	PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences, 2005, 26, 244-251.	4.0	632
298	Oleoylethanolamide, an endogenous PPAR-Î± agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology, 2005, 48, 1147-1153.	2.0	249
299	Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists. Ageing Research Reviews, 2005, 4, 103-118.	5.0	12
300	Peroxisome proliferator-activated receptors (PPARs) and ovarian function–implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reproductive Biology and Endocrinology, 2005, 3, 41.	1.4	178
301	Reversal of high dietary fructose-induced PPARalpha suppression by oral administration of lipoxygenase/cyclooxygenase inhibitors. Nutrition and Metabolism, 2005, 2, 18.	1.3	13
302	Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2005, 2, 26-33.	3.5	201
303	Neuroinflammation: a potential therapeutic target. Expert Opinion on Therapeutic Targets, 2005, 9, 887-900.	1.5	97
304	Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biological Psychiatry, 2005, 57, 885-894.	0.7	101
305	An overview on biological mechanisms of PPARs. Pharmacological Research, 2005, 51, 85-94.	3.1	580
307	Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease. Treatments in Respiratory Medicine, 2005, 4, 255-273.	1.4	31
308	Drug Treatment in the Metabolic Syndrome. , 2005, , 431-461.		1
309	Enantioselective Syntheses of Georgyone, Arborone, and Structural Relatives. Relevance to the Molecular-Level Understanding of Olfaction. Journal of the American Chemical Society, 2006, 128, 1346-1352.	6.6	51
310	Peroxisome Proliferator-Activated Receptor-?? Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2006, 6, 231-242.	1.0	29
311	The Emerging Functions of UCP2 in Health, Disease, and Therapeutics. Antioxidants and Redox Signaling, 2006, 8, 1-38.	2.5	158
312	Recent developments in the treatment of atherosclerosis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 1-15.	2.5	13
313	A Dual PPAR ??/?? Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects. Drugs in R and D, 2006, 7, 99-110.	1.1	17

#	Article	IF	Citations
314	Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opinion on Investigational Drugs, 2006, 15, 1453-1468.	1.9	15
315	Obesity, insulin resistance, Type 2 diabetes and free fatty acids. Expert Review of Endocrinology and Metabolism, 2006, 1, 499-505.	1.2	12
316	Antihypertensive effect of ragaglitazar: A novel PPARÎ± and Î³ dual activator. Pharmacological Research, 2006, 54, 129-135.	3.1	19
317	Pregnancy, Bovine Somatotropin, and Dietary n-3 Fatty Acids in Lactating Dairy Cows: III. Fatty Acid Distribution. Journal of Dairy Science, 2006, 89, 3386-3399.	1.4	52
318	Recombinant Human PPAR-Î²/Î´ Ligand-binding Domain is Locked in an Activated Conformation by Endogenous Fatty Acids. Journal of Molecular Biology, 2006, 356, 1005-1013.	2.0	79
319	Structure-Based Drug Design of a Novel Family of PPARÎ³ Partial Agonists:â€‰ Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities. Journal of Medicinal Chemistry, 2006, 49, 2703-2712.	2.9	99
320	Indenone Derivatives:â€‰ A Novel Template for Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Agonists. Journal of Medicinal Chemistry, 2006, 49, 4781-4784.	2.9	116
321	Computational Screening of Phthalate Monoesters for Binding to PPARÎ³. Chemical Research in Toxicology, 2006, 19, 999-1009.	1.7	29
322	Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R1407-R1412.	0.9	65
323	An Efficient Synthesis of a Potent PPARpan Agonist. Journal of Organic Chemistry, 2006, 71, 8302-8305.	1.7	6
324	Nuclear Hormone Receptor Modulators for the Treatment of Diabetes and Dyslipidemia. Annual Reports in Medicinal Chemistry, 2006, 41, 99-126.	0.5	16
325	Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors Î³ and Î´ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile. Journal of Medicinal Chemistry, 2006, 49, 5649-5652.	2.9	27
326	22-Hydroxycholesterols regulate lipid metabolism differently than T0901317 in human myotubes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 1515-1522.	1.2	26
327	Gene polymorphisms in the Quebec population: A risk to develop hypertriglyceridemia. Biochemical and Biophysical Research Communications, 2006, 344, 588-596.	1.0	9
328	Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-Î³. International Journal of Biochemistry and Cell Biology, 2006, 38, 766-781.	1.2	56
329	Peroxisome proliferator-activated receptor (PPAR) expression in cultured bovine endometrial cells and response to omega-3 fatty acid, growth hormone and agonist stimulation in relation to series 2 prostaglandin production. Domestic Animal Endocrinology, 2006, 30, 155-169.	0.8	52
330	PPARÎ³ as a therapeutic target in central nervous system diseases. Neurochemistry International, 2006, 49, 136-144.	1.9	97
331	Bezafibrate induces FALDH in human fibroblasts; implications for SjÃ¶gren-Larsson syndrome. Molecular Genetics and Metabolism, 2006, 89, 111-115.	0.5	31

#	Article	IF	Citations
332	From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progress in Lipid Research, 2006, 45, 120-159.	5.3	656
333	Respiratory Review of 2006 -Asthma-. Tuberculosis and Respiratory Diseases, 2006, 61, 114.	0.7	0
334	Peroxisome Proliferator-Activated Receptors and Shock State. Scientific World Journal, The, 2006, 6, 1770-1782.	0.8	8
335	An Update of the Defensive Barrier Function of Skin. Yonsei Medical Journal, 2006, 47, 293.	0.9	202
336	Peroxisome Proliferator-Activated Receptors. , 2006, , 283-300.		0
337	Cannabinoids and PPARÎ± signalling. Biochemical Society Transactions, 2006, 34, 1095-1097.	1.6	97
338	Peroxisome-proliferator-activated receptor Î± agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochemical Journal, 2006, 395, 81-88.	1.7	74
339	Peroxisome proliferator-activated receptor-Î³ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia*. Critical Care Medicine, 2006, 34, 1131-1138.	0.4	54
340	Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascular Diabetology, 2006, 5, 20.	2.7	72
341	Peroxisome Proliferator-Activated Receptors: Potential Therapeutic Targets in Lung Disease?. Pediatric Pulmonology, 2006, 41, 23-34.	1.0	38
342	Altered PPARÎ³ expression and activation after transient focal ischemia in rats. European Journal of Neuroscience, 2006, 24, 1653-1663.	1.2	131
343	Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver International, 2006, 26, 1021-1028.	1.9	140
344	15-deoxy-?12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-?-independent pathway. Journal of Neurochemistry, 2006, 99, 1389-1402.	2.1	31
345	Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-8methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. Acta Pharmacologica Sinica, 2006, 27, 597-602.	2.8	6
346	Antidiabetic effect of a novel non-thiazolidinedione PPAR ?/? agonist on ob/ob mice. Acta Pharmacologica Sinica, 2006, 27, 1346-1352.	2.8	15
347	Rosiglitazone and 15-deoxy-Î”12,14-prostaglandin J2Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 218-229.	2.4	107
348	15d-Prostaglandin J2Activates Peroxisome Proliferator-Activated Receptor-Î³, Promotes Expression of Catalase, and Reduces Inflammation, Behavioral Dysfunction, and Neuronal Loss after Intracerebral Hemorrhage in Rats. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 811-820.	2.4	222
349	Alterations in Skin and Stratified Epithelia by Constitutively Activated PPARÎ±. Journal of Investigative Dermatology, 2006, 126, 374-385.	0.3	23

#	Article	IF	Citations
350	Peroxisome Proliferator-Activated Receptors Increase Human Sebum Production. Journal of Investigative Dermatology, 2006, 126, 2002-2009.	0.3	158
351	Structure-based design of indole propionic acids as novel PPARÎ±/Î³ co-agonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4016-4020.	1.0	65
352	3,4,5-Trisubstituted isoxazoles as novel PPARÎ´ agonists. Part 2. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5488-5492.	1.0	28
353	Pyridine-2-propanoic acids: Discovery of dual PPARÎ±/Î³ agonists as antidiabetic agents. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6116-6119.	1.0	13
354	A Small-Molecule Probe for Hepatitis C Virus Replication that Blocks Protein Folding. Chemistry and Biology, 2006, 13, 1051-1060.	6.2	25
355	Synthesis and evaluation of azaindole-Î±-alkyloxyphenylpropionic acid analogues as PPARÎ±/Î³ agonists. Bioorganic and Medicinal Chemistry, 2006, 14, 866-874.	1.4	26
356	Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Expert Opinion on Emerging Drugs, 2006, 11, 379-401.	1.0	91
357	Investigational PPAR-Î³ agonists for the treatment of Type 2 diabetes. Expert Opinion on Investigational Drugs, 2006, 15, 763-778.	1.9	33
358	Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opinion on Investigational Drugs, 2006, 15, 243-250.	1.9	82
359	Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. Annual Review of Medicine, 2006, 57, 313-329.	5.0	204
360	Modulation of Fatty Acid Metabolism as a Potential Approach to the Treatment of Obesity and the Metabolic Syndrome. Endocrine, 2006, 29, 91-100.	2.2	86
361	The Pro12Ala Polymorphism of the PPAR Gamma 2 Gene Influences Sex Hormone-Binding Globulin Level and its Relationship to the Development of the Metabolic Syndrome in Young Finnish Men. Endocrine, 2006, 30, 185-190.	2.2	18
362	Potential of fibrates in the treatment of fatty acid oxidation disorders: Revival of classical drugs?. Journal of Inherited Metabolic Disease, 2006, 29, 341-342.	1.7	16
363	PPARÎ³ and Colon and Rectal Cancer: Associations with Specific Tumor Mutations, Aspirin, Ibuprofen and Insulin-Related Genes (United States). Cancer Causes and Control, 2006, 17, 239-249.	0.8	44
364	Aspects of the regulatory mechanisms of PPAR functions: Analysis of a bidirectional response element and regulation by sumoylation. Molecular and Cellular Biochemistry, 2006, 286, 33-42.	1.4	48
365	Synthesis of 2,3-Dihydrothiazolo[3,2-a]pyrimidin-5-ones by a Michael-type Tandem Reaction. Monatshefte FÃ¼r Chemie, 2006, 137, 1357-1364.	0.9	0
366	Exposure to sodium butyrate leads to functional downregulation of calcium-activated potassium channels in human airway epithelial cells. Pflugers Archiv European Journal of Physiology, 2006, 453, 167-176.	1.3	9
367	Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-Î³ agonist rosiglitazone. Diabetologia, 2006, 49, 1303-1310.	2.9	53

#	Article	IF	Citations
368	SAR studies: Designing potent and selective LXR agonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3055-3060.	1.0	15
369	Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Current Atherosclerosis Reports, 2006, 8, 356-364.	2.0	15
370	Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-Î± agonist WY14643. Free Radical Biology and Medicine, 2006, 41, 579-589.	1.3	143
371	Modulation of the oxidative stress and inflammatory response by PPAR-Î³ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European Journal of Pharmacology, 2006, 530, 70-80.	1.7	274
372	Peroxisome-proliferator-activated receptor-gamma (PPARÎ³) activation protects neurons from NMDA excitotoxicity. Brain Research, 2006, 1073-1074, 460-469.	1.1	80
373	Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARÎ³) and 15d-prostaglandin J2â€"Mediated protection of brain after experimental cerebral ischemia in rat. Brain Research, 2006, 1096, 196-203.	1.1	74
374	Novel signal transduction modulators for the treatment of airway diseases. , 2006, 109, 238-245.		52
375	Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. , 2006, 111, 145-173.		99
376	Effects of 15d-PGJ2 on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells. Prostaglandins and Other Lipid Mediators, 2006, 79, 230-244.	1.0	22
377	New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-Î³. Drug Development Research, 2006, 67, 687-697.	1.4	4
378	Intestinal-specific PPARÎ³ deficiency enhances tumorigenesis in ApcMin/+ mice. International Journal of Cancer, 2006, 119, 2339-2346.	2.3	74
379	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor Î² Receptors in Prostacyclin Sensing by Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 242-246.	1.4	79
380	PPAR Activity in the Vessel Wall: Anti-Atherogenic Properties. Current Medicinal Chemistry, 2006, 13, 3227-3238.	1.2	22
381	Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease. Current Pharmaceutical Design, 2006, 12, 4229-4245.	0.9	101
382	Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E358-E364.	1.8	170
383	Key Issues in the Role of Peroxisome Proliferatorâ€"Activated Receptor Agonism and Cell Signaling in Trichloroethylene Toxicity. Environmental Health Perspectives, 2006, 114, 1464-1470.	2.8	24
384	Agonists of the Peroxisome Proliferatorâ€"Activated Receptor Alpha Induce a Fiber-Typeâ€"Selective Transcriptional Response in Rat Skeletal Muscle. Toxicological Sciences, 2006, 92, 578-586.	1.4	40
385	Adipose-Derived Factors During Nutritional Transitions. Current Nutrition and Food Science, 2006, 2, 127-139.	0.3	6

#	Article	IF	Citations
386	Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis. Current Pediatric Reviews, 2006, 2, 107-113.	0.4	0
387	PPAR-Î³ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H390-H397.	1.5	56
388	Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor Â Action on Adipose Tissue Metabolism. Diabetes, 2006, 55, 2771-2778.	0.3	113
389	Troglitazone Regulates Peroxisome Proliferator-Activated Receptors and Inducible Nitric Oxide Synthase in Murine Ovarian Macrophages1. Biology of Reproduction, 2006, 74, 153-160.	1.2	29
390	Epithelial cell PPARÎ³ contributes to normal lung maturation. FASEB Journal, 2006, 20, 1507-1509.	0.2	98
391	Effects of luteinizing hormone on peroxisome proliferator-activated receptor Î³ in the rat ovary before and after the gonadotropin surge. Reproduction, 2006, 131, 93-101.	1.1	16
392	Regulation of Nuclear Translocation of HDAC3 by IÎºBÎ± Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor Î³ Function. Journal of Biological Chemistry, 2006, 281, 4540-4547.	1.6	131
393	A Novel Pregnane X Receptor-mediated and Sterol Regulatory Element-binding Protein-independent Lipogenic Pathway. Journal of Biological Chemistry, 2006, 281, 15013-15020.	1.6	304
394	Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARÎ±/Î³ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action. Toxicologic Pathology, 2006, 34, 903-920.	0.9	90
395	Function of PparÎ³ and Its Ligands in Lung Cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 183-202.	2.7	29
396	A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-Î± null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiological Genomics, 2006, 27, 178-186.	1.0	153
398	Peroxisome Proliferatorâ€“Activated Receptor Î³ Regulates Angiotensin IIâ€“Stimulated Phosphatidylinositol 3-Kinase and Mitogen-Activated Protein Kinase in Blood Vessels In Vivo. Hypertension, 2006, 47, 102-108.	1.3	56
399	Effects of Di(2-Ethylhexyl) Phthalate, A Widely Used Peroxisome Proliferator and Plasticizer, on Cell Growth in the Human Keratinocyte Cell Line NCTC 2544. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2006, 69, 353-365.	1.1	31
400	Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARÎ². FASEB Journal, 2006, 20, 326-328.	0.2	101
401	3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-Î³ and Promotes Adipocyte Differentiation. Molecular Endocrinology, 2006, 20, 268-278.	3.7	34
402	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 2006, 58, 726-741.	7.1	869
403	Mice Lacking Adiponectin Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome Proliferator-activated Receptor Î³ Agonists. Journal of Biological Chemistry, 2006, 281, 2654-2660.	1.6	558
404	Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248-255. Diabetes, 2007, 56, e3-e3.	0.3	4

#	Article	IF	Citations
405	Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes: Prevention of Fluid Retention. Diabetes, 2007, 56, 248-255.	0.3	42
406	Clofibric acid, a peroxisome proliferatorâ€“activated receptor Î± ligand, inhibits growth of human ovarian cancer. Molecular Cancer Therapeutics, 2007, 6, 1379-1386.	1.9	81
407	Food Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small Intestine. Journal of Biological Chemistry, 2007, 282, 1518-1528.	1.6	234
408	Role of AMP Kinase and PPARÎ´ in the Regulation of Lipid and Glucose Metabolism in Human Skeletal Muscle. Journal of Biological Chemistry, 2007, 282, 19313-19320.	1.6	157
409	Body Traffic: Ecology, Genetics, and Immunity in Inflammatory Bowel Disease. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 401-429.	9.6	37
410	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Review of Anticancer Therapy, 2007, 7, 1405-1421.	1.1	71
411	Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue ofob/oband dietary obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1118-E1128.	1.8	712
412	Peroxisome proliferator-activated receptor-Î³ ligands as investigational modulators of angiogenesis. Expert Opinion on Investigational Drugs, 2007, 16, 1561-1572.	1.9	28
413	Effects of Peroxisome Proliferator-Activated Receptor Gamma Agonists on Brain Glucose and Glutamate Transporters after Stress in Rats. Neuropsychopharmacology, 2007, 32, 1251-1260.	2.8	85
414	Hepatocyte-restricted constitutive activation of PPARÂ induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis, 2007, 28, 1171-1177.	1.3	44
415	Thiazolidinediones improve Î²-cell function in type 2 diabetic patients. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E871-E883.	1.8	167
416	Involvement of adipose tissues in the early hypolipidemic action of PPARÎ³ agonism in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R1408-R1417.	0.9	29
417	Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development. PPAR Research, 2007, 2007, 1-8.	1.1	20
418	PPARÎ± mediates the hypolipidemic action of fibrates by antagonizing FoxO1. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E421-E434.	1.8	105
419	Nuclear Hormone Receptors. , 2007, , 993-1036.		0
420	Nuclear Receptor Cofactors in PPARÎ³-Mediated Adipogenesis and Adipocyte Energy Metabolism. PPAR Research, 2007, 2007, 1-11.	1.1	50
421	Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy. Cardiovascular Research, 2007, 73, 257-268.	1.8	59
422	Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. American Journal of Physiology - Renal Physiology, 2007, 292, G1671-G1682.	1.6	62

#	Article	IF	Citations
423	Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease. Current Alzheimer Research, 2007, 4, 159-164.	0.7	101
424	Dietary supplementation with Ï‰-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovascular Research, 2007, 76, 303-310.	1.8	93
425	Peroxisome proliferator-activated receptor-Î´ polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2498-H2505.	1.5	50
426	Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R235-R241.	0.9	63
427	Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease. PPAR Research, 2007, 2007, 1-12.	1.1	39
428	PPARs Expression in Adult Mouse Neural Stem Cells: Modulation of PPARs during Astroglial Differentiaton of NSC. PPAR Research, 2007, 2007, 1-10.	1.1	27
429	Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease. Current Neuropharmacology, 2007, 5, 35-46.	1.4	56
430	The Molecular Mechanisms Underlying the Proinflammatory Actions of Thiazolidinediones in Human Macrophages. Molecular Endocrinology, 2007, 21, 1756-1768.	3.7	36
431	Osthole Improves Fat Milk-Induced Fatty Liver in Rats: Modulation of Hepatic PPAR-alpha/gamma-Mediated Lipogenic Gene Expression. Planta Medica, 2007, 73, 718-724.	0.7	29
432	Cardiac Hypertrophy Caused by Peroxisome Proliferator- Activated Receptor-Î³ Agonist Treatment Occurs Independently of Changes in Myocardial Insulin Signaling. Endocrinology, 2007, 148, 6047-6053.	1.4	42
433	Constitutive Coactivator of Peroxisome Proliferator-Activated Receptor (PPARÎ³), a Novel Coactivator of PPARÎ³ that Promotes Adipogenesis. Molecular Endocrinology, 2007, 21, 2320-2333.	3.7	37
434	Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor Î´ Agonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 359-365.	1.1	194
435	Peroxisome Proliferator-Activated Receptor-Î´ Upregulates 14-3-3Îµ in Human Endothelial Cells via CCAAT/Enhancer Binding Protein-Î². Circulation Research, 2007, 100, e59-71.	2.0	49
436	Stimulation of the pituitaryâ€“adrenal axis and of adrenocortical steroidogenesis ex vivo by administration of di-2-ethylhexyl phthalate to prepubertal male rats. Journal of Endocrinology, 2007, 192, 33-39.	1.2	28
437	Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates. Cancer Research, 2007, 67, 7113-7123.	0.4	87
438	Insights into the Mechanism of Partial Agonism. Journal of Biological Chemistry, 2007, 282, 17314-17324.	1.6	105
439	Nonclinical Safety Evaluation of Muraglitazar, a Novel PPARÎ±/Î³ Agonist. Toxicological Sciences, 2007, 100, 248-258.	1.4	43
440	Soy Protein and Isoflavones Influence Adiposity and Development of Metabolic Syndrome in the Obese Male ZDF Rat. Annals of Nutrition and Metabolism, 2007, 51, 42-52.	1.0	72

#	Article	IF	Citations
441	Oxidative Stress and Neuroinflammation in Alzheimer's Disease and Amyotrophic Lateral Sclerosis: From Biology to Therapeutic Strategies. , 2007, , 297-311.		1
442	Contribution of Hierarchical Clustering Techniques to the Modeling of the Geographic Distribution of Genetic Polymorphisms Associated with Chronic Inflammatory Diseases in the QuÃ©bec Population. Public Health Genomics, 2007, 10, 218-226.	0.6	9
443	Impact of rosiglitazone on the expression of Î²3-AR in the stable cell lines expressed Î²3-AR gene. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1511-6.	1.4	1
444	Potential role for peroxisome proliferator-activated receptor Î³ in regulating luteal lifespan in the rat. Reproduction, 2007, 133, 187-196.	1.1	5
445	Peroxisome Proliferator-Activated Receptors in Lung Cancer. PPAR Research, 2007, 2007, 1-10.	1.1	18
446	Chronic Activation of Peroxisome Proliferator-Activated Receptor-Î± with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 165-171.	1.3	55
447	Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza. Antimicrobial Agents and Chemotherapy, 2007, 51, 2965-2968.	1.4	87
448	Peroxisome proliferator-activated receptor Î± and Î³ ligands inhibit the growth of human ovarian cancer. Oncology Reports, 2007, 18, 833.	1.2	20
449	Peroxisome Proliferator-Activated Receptor-Î³ in Lung Cancer: Defining Specific Versus â€œOff-Targetâ€• Effectors. Journal of Thoracic Oncology, 2007, 2, 989-992.	0.5	28
450	PPARÎ±: its role in the human metabolic syndrome. Future Lipidology, 2007, 2, 31-53.	0.5	10
451	Design, Synthesis, and Evaluation of Tetrahydroquinoline-Linked Thiazolidinedione Derivatives as PPARÎ³ Selective Activators. Heterocycles, 2007, 71, 2131.	0.4	10
452	Dietary fatty acid intakes and the risk of ovulatory infertility. American Journal of Clinical Nutrition, 2007, 85, 231-237.	2.2	150
453	PPAR Activation: A New Target for the Treatment of Hypertension. Journal of Cardiovascular Pharmacology, 2007, 50, 120-125.	0.8	23
454	Effects of PPAR-Î³ Knock-down and Hyperglycemia on Insulin Signaling in Vascular Smooth Muscle Cells From Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2007, 49, 346-354.	0.8	16
455	Vitamin A deficiency modifies lipid metabolism in rat liver. British Journal of Nutrition, 2007, 97, 263-272.	1.2	49
456	Activation of PPARÎ³ enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes. Transplant Immunology, 2007, 18, 32-36.	0.6	8
457	Increase of peroxisome proliferator-activated receptor Î´ gene expression in the lungs of streptozotocin-induced diabetic rats. Pulmonary Pharmacology and Therapeutics, 2007, 20, 69-74.	1.1	15
458	Cytotoxicity of peroxisome proliferator-activated receptor Î± and Î³ agonists in renal proximal tubular cell lines. Toxicology in Vitro, 2007, 21, 1066-1076.	1.1	12

#	Article	IF	Citations
459	PPARÎ³ and GLUT-4 expression as developmental regulators/markers for preadipocyte differentiation into an adipocyte. Domestic Animal Endocrinology, 2007, 33, 367-378.	0.8	115
460	Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 915-925.	1.2	270
461	n-3 and n-6 Polyunsaturated fatty acids induce the expression of COX-2 via PPARÎ³ activation in human keratinocyte HaCaT cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 576-589.	1.2	53
462	Molecular basis of selective PPARÎ³ modulation for the treatment of Type 2 diabetes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1094-1107.	1.2	70
463	The next generation of PPAR drugs: Do we have the tools to find them?. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1082-1093.	1.2	88
464	An Afferent Vagal Nerve Pathway Links Hepatic PPARÎ± Activation to Glucocorticoid-Induced Insulin Resistance and Hypertension. Cell Metabolism, 2007, 5, 91-102.	7.2	90
465	Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine, 2007, 39, 184-191.	1.4	44
466	Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone, 2007, 40, 84-92.	1.4	91
467	Pro-MMP-2 activation by the PPARÎ³ agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Letters, 2007, 581, 3303-3310.	1.3	44
468	Tratamiento de enfermedades metabÃ³licas mediante la modulaciÃ³n del PPARÎ³. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2007, 19, 191-210.	0.4	1
469	Cardiac Energy Metabolism in Obesity. Circulation Research, 2007, 101, 335-347.	2.0	238
471	Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis. Clinics in Chest Medicine, 2007, 28, 331-346.	0.8	85
472	Mitochondria. , 2007, , .		4
473	The non-genomic crosstalk between PPAR-Î³ ligands and ERK1/2 in cancer cell lines. Expert Opinion on Therapeutic Targets, 2007, 11, 1071-1085.	1.5	35
474	Peroxisome proliferator-activated receptor-Î³ ligands as bone turnover modulators. Expert Opinion on Investigational Drugs, 2007, 16, 195-207.	1.9	11
475	Effects of Flavonoids and Phenolic Acids on the Inhibition of Adipogenesis in 3T3-L1 Adipocytes. Journal of Agricultural and Food Chemistry, 2007, 55, 8404-8410.	2.4	208
476	Suppression of PPAR-Î³ attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E219-E227.	1.8	111
477	1,1-Bis(3â€²-Indolyl)-1-(p-Substitutedphenyl)methanes Induce Apoptosis and Inhibit Renal Cell Carcinoma Growth. Clinical Cancer Research, 2007, 13, 6743-6752.	3.2	36

#	Article	IF	Citations
478	Glitazones: Beyond glucose lowering!. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2007, 1, 197-207.	1.8	1
479	PPARÎ±-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochimica Et Biophysica Acta - Bioenergetics, 2007, 1767, 1134-1142.	0.5	86
480	At Low Doses, a Î³-Linolenic Acid-Lipoic Acid Conjugate Is More Effective Than Docosahexaenoic Acid-Enriched Phospholipids in Preventing Neuropathy in Diabetic Rats. Journal of Nutrition, 2007, 137, 368-372.	1.3	22
481	Current Status of Carcinogenicity Assessment of Peroxisome Proliferator-Activated Receptor Agonists by the US FDA and a Mode-of-Action Approach to the Carcinogenic Potential. Journal of Toxicologic Pathology, 2007, 20, 197-202.	0.3	24
482	Rosiglitazone Suppresses Cyclosporin-Induced Chronic Transplant Dysfunction and Prolongs Survival of Rat Cardiac Allografts. Transplantation, 2007, 83, 1602-1610.	0.5	7
483	Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARÎ²/Î´ gene. International Journal of Oncology, 2007, , .	1.4	6
484	Organic Cation/Carnitine Transporters. , 0, , 35-50.		0
485	Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. Journal of Cellular Physiology, 2007, 212, 1-12.	2.0	93
486	Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology, 2008, 47, 1277-1287.	3.6	101
487	Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARÎ± and PPARÎ³ Agonist Activity. ChemMedChem, 2007, 2, 641-654.	1.6	27
488	The biology and chemistry of hyperlipidemia. Bioorganic and Medicinal Chemistry, 2007, 15, 4674-4699.	1.4	190
489	Design and synthesis of oxime ethers of Î±-acyl-Î²-phenylpropanoic acids as PPAR dual agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 937-941.	1.0	30
490	Synthesis and structureâ€“activity relationship of novel indene N-oxide derivatives as potent peroxisome proliferator activated receptor Î³ (PPARÎ³) agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5239-5244.	1.0	21
491	Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARÎ± agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6773-6778.	1.0	19
492	A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARÎ±/Î³ activator. Analytical Biochemistry, 2007, 363, 263-274.	1.1	27
493	Metabolic action of peroxisome proliferator-activated receptor Î³ agonism in rats with exogenous hypercorticosteronemia. International Journal of Obesity, 2007, 31, 1660-1670.	1.6	3
494	PPARÎ± agonists inhibit nitric oxide production by enhancing iNOS degradation in LPSâ€treated macrophages. British Journal of Pharmacology, 2007, 152, 1081-1091.	2.7	32
495	Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARÎ³ agonist pioglitazone. Laboratory Investigation, 2007, 87, 56-65.	1.7	86

#	Article	IF	Citations
496	Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with TypeÂ2 diabetes. Diabetic Medicine, 2007, 24, 962-968.	1.2	22
497	Characteristics of obese children with low content of arachidonic acid in plasma lipids. Pediatrics International, 2007, 49, 437-442.	0.2	13
498	Peroxisome Proliferator-Activated Receptor ? in the Human Pituitary Gland: Expression and Splicing Pattern in Adenomas Versus Normal Pituitary. Journal of Neuroendocrinology, 2007, 19, 552-559.	1.2	15
499	Effect of diet and ration on the relationship between plasma GH and IGF-1 concentrations in Arctic charr, Salvelinus alpinus (L.). Aquaculture Research, 2007, 38, 877-886.	0.9	33
500	Peroxisome proliferatorâ€“activated receptor-Î³ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. International Journal of Gynecological Cancer, 2007, 17, 418-425.	1.2	31
501	Modulation of amyloid-Î²-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. Journal of Neurochemistry, 2007, 103, 914-926.	2.1	90
502	Expression level and agonistâ€bbinding affect the turnover, ubiquitination and complex formation of peroxisome proliferator activated receptorâ€ƒÎ². FEBS Journal, 2007, 274, 5068-5076.	2.2	16
503	Novel PPARâ€gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induceddâ€Fit Docking and Biological Assay Study. Chemical Biology and Drug Design, 2008, 71, 57-70.	1.5	117
504	Quantitative image analysis in adipose tissue using an automated image analysis system: Differential effects of peroxisome proliferator-activated receptor-? and -? agonist on white and brown adipose tissue morphology in AKR obese and db/db diabetic mice. Pathology International, 2007, 57, 369-377.	0.6	11
505	13-Oxo-ODE is an endogenous ligand for PPARÎ³ in human colonic epithelial cells. Biochemical Pharmacology, 2007, 74, 612-622.	2.0	104
506	Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo. European Journal of Pharmacology, 2007, 555, 8-16.	1.7	1
507	Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptorâ€“Î± and Peroxisome Proliferator-Activated Receptorâ€“Î³ Agonists. American Journal of Cardiology, 2007, 99, 27-40.	0.7	119
508	Lipids, Lipoproteins, and Peroxisome Proliferator Activated Receptorâ€“Î´. American Journal of Cardiology, 2007, 100, S20-S24.	0.7	34
509	PPAR? activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGF? signalling. Journal of Cellular and Molecular Medicine, 2007, 11, 71-87.	1.6	38
510	PPARs and the Placenta. Placenta, 2007, 28, 65-76.	0.7	116
511	Synthesis and biological activity of 5-(4-[2-(Methyl-p-substituted) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 142 Td (phenylamino	2.7	22
512	Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome. Molecular and Cellular Biochemistry, 2007, 302, 43-49.	1.4	16
513	Telmisartan, An Angiotensin II Type 1 Receptor Blocker, Controls Progress of Nonalcoholic Steatohepatitis in Rats. Digestive Diseases and Sciences, 2007, 52, 3455-3464.	1.1	66

#	Article	IF	Citations
514	Pioglitazone and Nonalcoholic Steatohepatitis. Current Diabetes Reports, 2007, 7, 221-222.	1.7	0
515	Effects of thiazolidinediones on blood pressure. Current Hypertension Reports, 2007, 9, 332-337.	1.5	31
516	Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer. Oncology Reviews, 2007, 1, 3-13.	0.8	1
517	An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clinical Biochemistry, 2007, 40, 511-520.	0.8	51
518	Metabolic dysregulation in the SHROB rat reflects abnormal expression of transcription factors and enzymes that regulate carbohydrate metabolism. Journal of Nutritional Biochemistry, 2008, 19, 305-312.	1.9	11
519	PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. Journal of Inherited Metabolic Disease, 2008, 31, 217-225.	1.7	42
520	PPARÎ±/Î³ Expression and Activity in Mouse and Human Melanocytes and Melanoma Cells. Pharmaceutical Research, 2008, 25, 1327-1333.	1.7	21
521	Structure and physiological functions of the human peroxisome proliferator-activated receptor Î³. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 331-345.	1.0	98
522	Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARÎ²/Î´ ligand GW0742. Inflammation Research, 2008, 57, 314-321.	1.6	41
523	Synthesis of polymeric thiazolidinedione and fibrate conjugates. Archives of Pharmacal Research, 2008, 31, 148-153.	2.7	1
524	Emerging Roles of Peroxisome Proliferator-Activated Receptors (PPARs) in the Regulation of Neural Stem Cells Proliferation and Differentiation. Stem Cell Reviews and Reports, 2008, 4, 293-303.	5.6	69
525	A Dualâ€Response Partial Least Squares Regression QSAR Model and its Application in Design of Dual Activators of PPARÎ± and PPARÎ³. QSAR and Combinatorial Science, 2008, 27, 1291-1304.	1.5	15
526	Thiazolidinediones as antiâ€inflammatory and antiâ€atherogenic agents. Diabetes/Metabolism Research and Reviews, 2008, 24, 14-26.	1.7	90
527	Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir. Journal of Cellular Biochemistry, 2008, 103, 1598-1606.	1.2	14
528	PPARÎ³ Agonists as Therapeutics for the Treatment of Alzheimer's Disease. Neurotherapeutics, 2008, 5, 481-489.	2.1	254
529	Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. Journal of Nutritional Biochemistry, 2008, 19, 491-504.	1.9	249
530	Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARÎ±/Î³ dual agonists, and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry, 2008, 16, 4883-4907.	1.4	30
531	Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR Î±/Î³ dual agonists. Bioorganic and Medicinal Chemistry, 2008, 16, 7117-7127.	1.4	18

#	Article	IF	Citations
532	Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARÎ± and PPARÎ³ agonist activity. Bioorganic and Medicinal Chemistry, 2008, 16, 9498-9510.	1.4	18
533	Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor Î± (PPARÎ±) agonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2128-2132.	1.0	12
534	Highly functionalized 7-azaindoles as selective PPARÎ³ modulators. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4798-4801.	1.0	15
535	Discovery of a novel class of PPARÎ´ partial agonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5018-5022.	1.0	25
536	Modulation of PPAR receptor subtype selectivity of the ligands: Aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6471-6475.	1.0	11
538	Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?. Advances in Cardiology, 2008, 45, 127-153.	2.6	31
539	Crystal Structure of the Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Ligand Binding Domain Complexed with a Novel Partial Agonist: A New Region of the Hydrophobic Pocket Could Be Exploited for Drug Design. Journal of Medicinal Chemistry, 2008, 51, 7768-7776.	2.9	98
540	PPARG by Dietary Fat Interaction Influences Bone Mass in Mice and Humans. Journal of Bone and Mineral Research, 2008, 23, 1398-1408.	3.1	56
541	Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growthâ€“restricted offspring. American Journal of Obstetrics and Gynecology, 2008, 199, 271.e1-271.e5.	0.7	62
542	Interference of pollutants with PPARs: endocrine disruption meets metabolism. International Journal of Obesity, 2008, 32, S53-S61.	1.6	123
543	Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 2008, 454, 470-477.	13.7	712
544	Thiazolidinediones: effects on insulin resistance and the cardiovascular system. British Journal of Pharmacology, 2008, 153, 636-645.	2.7	117
545	Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 2008, 9, 162-176.	16.1	1,091
546	Animal Models for Human Risk Assessment: The Peroxisome Proliferator-Activated Receptor Alpha-Humanized Mouse. Nutrition Reviews, 2007, 65, S2-S6.	2.6	8
547	PPAR: a therapeutic target in Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 106, 506-518.	2.1	150
548	Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. International Journal of Urology, 2008, 15, 19-26.	0.5	29
549	Obesity and obstructive sleep apneaâ€hypopnea syndrome. Obesity Reviews, 2008, 9, 340-354.	3.1	82
550	Effects of PPAR agonists on proliferation and differentiation in human urothelium. Experimental and Toxicologic Pathology, 2008, 60, 435-441.	2.1	48

#	Article	IF	Citations
551	Pro12Ala polymorphism in PPAR Î³ 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Experimental Gerontology, 2008, 43, 1108-1113.	1.2	21
552	Impaired energetics in heart failure â€" A new therapeutic target. , 2008, 119, 264-274.		11
553	Lipid homeostasis and oxidative stress in the liver of male rats exposed to perfluorododecanoic acid. Toxicology and Applied Pharmacology, 2008, 227, 16-25.	1.3	68
554	Conjugated linoleic acid modulation of risk factors associated with atherosclerosis. Nutrition and Metabolism, 2008, 5, 22.	1.3	36
555	Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin. American Journal of Clinical Dermatology, 2008, 9, 15-31.	3.3	114
556	Lactobacillus crispatus M247-Derived H2O2 Acts as a Signal Transducing Molecule Activating Peroxisome Proliferator Activated Receptor-Î³ in the Intestinal Mucosa. Gastroenterology, 2008, 135, 1216-1227.	0.6	86
557	Therapeutic approaches for control of transcription factors in allergic disease. Journal of Allergy and Clinical Immunology, 2008, 121, 803-809.	1.5	35
558	A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2008, 40, 200-205.	0.4	206
559	Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 47-57.	1.8	67
560	Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and Leptin genes and up-regulation of the adiponectin gene. Lipids in Health and Disease, 2008, 7, 44.	1.2	44
561	Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 179-197.	1.0	72
562	Peroxisome Proliferator-Activated Receptor-Î³ Gene: A Key Regulator of Adipocyte Differentiation in Chickens. Poultry Science, 2008, 87, 226-232.	1.5	74
563	Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion, 2008, 8, 329-337.	1.6	127
564	Î±-Tocopherol modulates human umbilical vein endothelial cell expression of Cu/Zn superoxide dismutase and catalase and lipid peroxidation. Nutrition Research, 2008, 28, 671-680.	1.3	26
565	Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiology and Behavior, 2008, 94, 187-197.	1.0	64
566	Embryo yield and quality following dietary supplementation of beef heifers with n-3 polyunsaturated fatty acids (PUFA). Theriogenology, 2008, 70, 992-1003.	0.9	48
567	Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARÎ³ receptors. Experimental Neurology, 2008, 212, 93-99.	2.0	27
568	Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-Î³. Biochemical and Biophysical Research Communications, 2008, 374, 231-236.	1.0	38

#	Article	IF	Citations
569	Regulation of PPARÎ³ function by TNF-Î±. Biochemical and Biophysical Research Communications, 2008, 374, 405-408.	1.0	168
570	ModulaciÃ³n del PPARÎ± por agentes farmacolÃ³gicos y naturales y sus implicaciones metabÃ³licas. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2008, 20, 259-289.	0.4	2
571	Peroxisome Proliferator-Activated Receptor Î³ as a Novel Therapeutic Target in Asthma. Journal of Asthma, 2008, 45, 1-8.	0.9	16
572	The Role of Peroxisome Proliferator-Activated Receptor-Î³ (PPARÎ³) in Alzheimerâ€™s Disease. CNS Drugs, 2008, 22, 1-14.	2.7	155
573	Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors. Journal of Neuroscience, 2008, 28, 13985-13994.	1.7	164
574	PPAR-Î³ signaling pathway in placental development and function: A potential therapeutic target in the treatment of gestational diseases. Expert Opinion on Therapeutic Targets, 2008, 12, 1049-1063.	1.5	22
575	Prostanoid function and cardiovascular disease. Archives of Physiology and Biochemistry, 2008, 114, 201-209.	1.0	44
576	Design, Synthesis, and Structureâ^'Activity Relationships of Novel Insulin Receptor Tyrosine Kinase Activators. Journal of Medicinal Chemistry, 2008, 51, 6173-6187.	2.9	15
577	Role of the PGC-1 family in the metabolic adaptation of goldfish to diet and temperature. Journal of Experimental Biology, 2008, 211, 1448-1455.	0.8	88
578	The PPARÎ±-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARÎ±. Toxicological Sciences, 2008, 101, 132-139.	1.4	152
579	Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-Î³: Therapeutic Implications for Cardiovascular Diseases. PPAR Research, 2008, 2008, 1-11.	1.1	27
580	Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers. Cerebrovascular Diseases, 2008, 26, 106-112.	0.8	19
581	PPAR Agonists: Potential as Therapeutics for Neovascular Retinopathies. PPAR Research, 2008, 2008, 1-13.	1.1	24
582	Trans-Species Comparison of PPAR and RXR Expression by Rat and Human Urothelial Tissues. Toxicologic Pathology, 2008, 36, 485-495.	0.9	22
583	Association Study of Wnt Signaling Pathway Genes in Bipolar Disorder. Archives of General Psychiatry, 2008, 65, 785.	13.8	70
584	Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-Î³ in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-ÎºB. Molecular Pharmacology, 2008, 73, 709-717.	1.0	60
585	PPARÎ± agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 985-990.	3.3	249
586	Therapeutic Potential of Peroxisome Proliferatorsâ€“Activated Receptor-Î±/Î³ Dual Agonist With Alleviation of Endoplasmic Reticulum Stress for the Treatment of Diabetes. Diabetes, 2008, 57, 737-745.	0.3	96

#	Article	IF	Citations
587	Nuclear Receptors and Inflammatory Diseases. Experimental Biology and Medicine, 2008, 233, 496-506.	1.1	66
588	The Differential Interactions of Peroxisome Proliferator-Activated Receptor Î³ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities. Molecular Pharmacology, 2008, 73, 62-74.	1.0	68
589	PPAR Action in Human Placental Development and Pregnancy and Its Complications. PPAR Research, 2008, 2008, 1-14.	1.1	58
590	The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-Â (PPARÂ) and thiazolidinedione-PPARÂ agonists. Endocrine-Related Cancer, 2008, 15, 325-335.	1.6	59
591	PPARÎ³ Agonists for the Treatment of Alzheimer's Disease. , 2007, , 81-106.		0
592	Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells. Journal of Biological Chemistry, 2008, 283, 25628-25637.	1.6	117
593	Activation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal Development. PPAR Research, 2008, 2008, 1-10.	1.1	11
594	Enhanced angiogenesis in obesity and in response to PPARÎ³ activators through adipocyte VEGF and ANGPTL4 production. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1056-E1064.	1.8	159
595	PPAR-Î³ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L891-L901.	1.3	182
596	Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARÎ±/Î³ in fat milk-induced fatty liver rats. Journal of Asian Natural Products Research, 2008, 10, 797-802.	0.7	17
597	Peroxisome Proliferatorâ€“Activated Receptor-Î´ Agonist Enhances Vasculogenesis by Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-Kinase/Akt Pathway. Circulation, 2008, 118, 1021-1033.	1.6	85
598	Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a Î³-dominant PPAR Î±/Î³ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event. Toxicologic Pathology, 2008, 36, 218-231.	0.9	38
599	Peroxisome Proliferator-Activated Receptor-Î³ Regulates the Expression of Alveolar Macrophage Macrophage Colony-Stimulating Factor. Journal of Immunology, 2008, 181, 235-242.	0.4	51
600	Ligand Activation of Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ (PPARÎ²/Î´) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression. Toxicological Sciences, 2008, 105, 418-428.	1.4	76
601	In Vivo Imaging Reveals Selective Peroxisome Proliferator Activated Receptor Modulator Activity of the Synthetic Ligand 3-(1-(4-Chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886). Molecular Pharmacology, 2008, 73, 1434-1443.	1.0	33
602	Intestinal fatty acid binding protein regulates mitochondrion Î²-oxidation and cholesterol uptake. Journal of Lipid Research, 2008, 49, 961-972.	2.0	53
603	The genetics of gestational diabetes mellitus: evidence for relationship with type 2 diabetes mellitus. Genetics in Medicine, 2008, 10, 240-250.	1.1	121
604	Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocrine-Related Cancer, 2008, 15, 1003-1011.	1.6	39

#	Article	IF	Citations
605	Cholesterol Reduction and Atherosclerosis Inhibition by Bezafibrate in Low-Density Lipoprotein Receptor Knockout Mice. Hypertension Research, 2008, 31, 999-1005.	1.5	7
606	Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress. Current Topics in Medicinal Chemistry, 2008, 8, 1483-1507.	1.0	77
607	Beyond the classic angiotensin-receptor-blocker profile. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S19-S26.	3.3	30
608	FoxO1 integrates insulin signaling to VLDL production. Cell Cycle, 2008, 7, 3162-3170.	1.3	117
609	The Expression of GPIHBP1, an Endothelial Cell Binding Site for Lipoprotein Lipase and Chylomicrons, Is Induced by Peroxisome Proliferator-Activated Receptor-Î³. Molecular Endocrinology, 2008, 22, 2496-2504.	3.7	51
610	Effects of Osthole on Protein Expression of CYP7A1, DGAT2 and PPARalpha/gamma in Fat Milk-Induced Fatty Liver Rats. , 2008, , .		0
611	Chronic Effects of Berberine on Blood, Liver Glucolipid Metabolism and Liver PPARs Expression in Diabetic Hyperlipidemic Rats. Biological and Pharmaceutical Bulletin, 2008, 31, 1169-1176.	0.6	132
614	Effects of the PPARÎ³ agonist GW1929 on muscle wasting in tumour-bearing mice. Oncology Reports, 0, , .	1.2	4
615	Peroxisome Proliferator-Activated Receptor Î³ and Lung Cancer Biology. Journal of Investigative Medicine, 2008, 56, 528-533.	0.7	28
616	Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury. Current Molecular Medicine, 2008, 8, 562-579.	0.6	39
617	Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2008, 7, 217-223.	1.1	3
618	Fibrate Therapy. Cardiology in Review, 2008, 16, 129-141.	0.6	71
619	Pioglitazone and the Risk of Myocardial Infarction and Other Major Adverse Cardiac Events: A Meta-Analysis of Randomized, Controlled Trials. American Journal of Therapeutics, 2008, 15, 506-511.	0.5	32
620	Bioisosteric Replacement of Molecular Scaffolds: From Natural Products to Synthetic Compounds. Natural Product Communications, 2008, 3, 1934578X0800300.	0.2	2
622	Fasting regulates the expression of adiponectin receptors in young growing pigs1. Journal of Animal Science, 2008, 86, 3377-3384.	0.2	21
623	Effect of Thiazolidinediones on the Erythropoeitic and Germinal Cells in the Male Wistar Rats. Clinical Medicine Oncology, 2008, 2, CMO.S678.	0.2	4
624	Relationships among ET-1, PPAR.GAMMA., oxidative stress and endothelial dysfunction in diabetic animals. Journal of Smooth Muscle Research, 2008, 44, 41-55.	0.7	48
625	Peroxisome proliferatorâ€“activated receptor Î± genetic variation interacts with nâ^'6 and long-chain nâ^'3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. American Journal of Clinical Nutrition, 2008, 87, 1926-1931.	2.2	48

#	Article	IF	Citations
626	The Role of PPAR in the Cyclooxygenase Pathway in Lung Cancer. PPAR Research, 2008, 2008, 1-7.	1.1	26
627	PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility. PPAR Research, 2008, 2008, 1-19.	1.1	36
628	PPAR: The Portrait of a Target Ally to Cancer Chemopreventive Agents. PPAR Research, 2008, 2008, 1-10.	1.1	9
629	Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle. PPAR Research, 2008, 2008, 1-7.	1.1	34
630	Role of Peroxisome Proliferator-Activated Receptor Alpha in the Control of Cyclooxygenase 2 and Vascular Endothelial Growth Factor: Involvement in Tumor Growth. PPAR Research, 2008, 2008, 1-10.	1.1	13
631	Therapeutic Potential of PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Activation in Stroke. PPAR Research, 2008, 2008, 1-9.	1.1	14
632	Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Ligands in Lung Cancer. PPAR Research, 2008, 2008, 1-8.	1.1	25
633	Peroxisome Proliferator-Activated Receptor-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold">Î³</mml:mi></mml:math>Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Research, 2008, 2008, 1-12.	1.1	29
634	BAG-1 inhibits PPARÎ³-induced cell death, but not PPARÎ³-induced transcription, cell cycle arrest or differentiation in breast cancer cells. Oncology Reports, 2008, , .	1.2	3
635	Effects of Wy14643 on hepatic ischemia reperfusion injury in rats. World Journal of Gastroenterology, 2008, 14, 6936.	1.4	23
636	Fibrates. , 2009, , 315-325.		3
637	The Podocyte in Diabetic Kidney Disease. Scientific World Journal, The, 2009, 9, 1127-1139.	0.8	98
638	Skeletal Muscle Characteristics of Rats with Obesity, Diabetes, Hypertension, and Hyperlipidemia. Journal of Atherosclerosis and Thrombosis, 2009, 16, 576-585.	0.9	35
639	Activation of PPARÎ³ induces profound multilocularization of adipocytes in adult mouse white adipose tissues. Experimental and Molecular Medicine, 2009, 41, 880.	3.2	50
640	Metabolomics of the interaction between PPARâ€Î± and age in the PPARâ€Î±â€null mouse. Molecular Systems Biology, 2009, 5, 259.	3.2	69
641	The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. Journal of Lipid Research, 2009, 50, 439-445.	2.0	95
642	Deletion of PPARÎ³ in Alveolar Macrophages Is Associated with a Th-1 Pulmonary Inflammatory Response. Journal of Immunology, 2009, 182, 5816-5822.	0.4	106
643	Peroxisome Proliferator-Activated Receptor Î³ Ligands Enhance Human B Cell Antibody Production and Differentiation. Journal of Immunology, 2009, 183, 6903-6912.	0.4	37

#	Article	IF	Citations
644	The Peroxisome Proliferator-Activated Receptor Î³ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus. Journal of Immunology, 2009, 183, 2729-2740.	0.4	49
645	Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 219-236.	0.6	6
646	The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients. PPAR Research, 2009, 2009, 1-15.	1.1	18
647	Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 706-711.	1.1	113
648	Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats. Toxicologic Pathology, 2009, 37, 521-535.	0.9	206
649	Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a Î³-Dominant PPAR Î±/Î³ Agonist. Toxicologic Pathology, 2009, 37, 741-753.	0.9	20
650	Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARÎ³-dependent and PPARÎ³-independent pathways. Cell Cycle, 2009, 8, 268-277.	1.3	51
651	New Target Genes for the Peroxisome Proliferator-Activated Receptor-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>(PPAR<mml:math) Tj ETQq1 1 0.784314 rgBT Activity: Perspectives from the Insulin Receptor. PPAR Research, 2009, 2009, 1-8.	1.1	3
652	Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury. Current Alzheimer Research, 2009, 6, 238-251.	0.7	20
653	Rosiglitazone Prevents High Glucose-Induced Vascular Endothelial Growth Factor and Collagen IV Expression in Cultured Mesangial Cells. Experimental Diabetes Research, 2009, 2009, 1-11.	3.8	28
654	Genetic Variation of PPARs. PPAR Research, 2009, 2009, 1-1.	1.1	1
655	Regulation of Translational Efficiency by Disparate<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msup><mml:mn>5</mml:mn><mml:mo>â€²</mml:mo></mml:msup></mml:math> of PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Splice Variants. PPAR Research, 2009, 2009, 1-8.	1.1	25
656	PPARs in Viral Disease. PPAR Research, 2009, 2009, 1-2.	1.1	1
657	Tissue-specific postprandial clearance is the major determinant of PPARÎ³-induced triglyceride lowering in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R57-R66.	0.9	37
658	Hormonal regulation of CYP1A expression. Drug Metabolism Reviews, 2009, 41, 547-572.	1.5	86
659	Peroxisome Proliferator-Activated Receptor Î³ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention. Clinical Cancer Research, 2009, 15, 2-8.	3.2	120
660	Synthesis of Lipoxin A₄by 5-Lipoxygenase Mediates PPARÎ³-Dependent, Neuroprotective Effects of Rosiglitazone in Experimental Stroke. Journal of Neuroscience, 2009, 29, 3875-3884.	1.7	115
661	Role of the Histone Variant H2A.Z/Htz1p in TBP Recruitment, Chromatin Dynamics, and Regulated Expression of Oleate-Responsive Genes. Molecular and Cellular Biology, 2009, 29, 2346-2358.	1.1	77

#	Article	IF	Citations
662	Review Paper: The Role of Inflammation in Mouse Pulmonary Neoplasia. Veterinary Pathology, 2009, 46, 369-390.	0.8	22
663	Neuronal PPARÎ³ Deficiency Increases Susceptibility to Brain Damage after Cerebral Ischemia. Journal of Neuroscience, 2009, 29, 6186-6195.	1.7	148
664	Peroxisome proliferatorâ€activated receptorâ€Î³ abrogates Smadâ€dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB Journal, 2009, 23, 2968-2977.	0.2	113
665	Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. , 2009, 122, 246-263.		127
666	Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. , 2009, 123, 281-291.		27
667	Transcriptional Regulation of the Processes of Human Labour and Delivery. Placenta, 2009, 30, 90-95.	0.7	59
668	A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplasic effect of iodine in mammary cancer. Prostaglandins and Other Lipid Mediators, 2009, 89, 34-42.	1.0	29
669	Effects of the PPARÎ³ agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse. Toxicology and Applied Pharmacology, 2009, 237, 83-90.	1.3	21
670	Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of Human. BMC Genomics, 2009, 10, S5.	1.2	39
671	Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. Virology, 2009, 394, 130-142.	1.1	57
672	Leptin effects on testis and epididymis in the lizard Podarcis sicula, during summer regression. General and Comparative Endocrinology, 2009, 160, 168-175.	0.8	17
673	Metabolic modulation and cellular therapy of cardiac dysfunction and failure. Journal of Cellular and Molecular Medicine, 2009, 13, 811-825.	1.6	20
674	Rapid pain modulation with nuclear receptor ligands. Brain Research Reviews, 2009, 60, 114-124.	9.1	55
675	Pioglitazone: More than just an insulin sensitizer. Hepatology, 2009, 49, 1427-1430.	3.6	9
676	Characterization of New PPARÎ³ Agonists: Analysis of Telmisartanâ€™s Structural Components. ChemMedChem, 2009, 4, 445-456.	1.6	38
677	From Molecular Shape to Potent Bioactive Agents I: Bioisosteric Replacement of Molecular Fragments. ChemMedChem, 2009, 4, 41-44.	1.6	20
678	From Molecular Shape to Potent Bioactive Agents II: Fragmentâ€Based deâ€...novo Design. ChemMedChem, 2009, 4, 45-48.	1.6	26
679	Characterization of New PPARÎ³ Agonists: Benzimidazole Derivatives - the Importance of Positionâ€...2. ChemMedChem, 2009, 4, 1136-1142.	1.6	22

#	Article	IF	Citations
680	Peroxisome Proliferatorâ€Activated Receptorâ€g Agonist Treatment Increases Septation and Angiogenesis and Decreases Airway Hyperresponsiveness in a Model of Experimental Neonatal Chronic Lung Disease. Anatomical Record, 2009, 292, 1045-1061.	0.8	22
681	Antitumor activity of a novel series of Î±-aryloxy-Î±-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Investigational New Drugs, 2009, 27, 223-232.	1.2	9
682	Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)Î± agonist fenofibrate and the PPARÎ³ agonist pioglitazone. BMC Endocrine Disorders, 2009, 9, 10.	0.9	58
683	Is there an interaction between PPARD T294C and PPARGC1A Gly482Ser polymorphisms and human endurance performance?. Experimental Physiology, 2009, 94, 1147-1152.	0.9	36
684	Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor Î³. Cell Research, 2009, 19, 720-732.	5.7	23
685	Emerging role of adipose tissue hypoxia in obesity and insulin resistance. International Journal of Obesity, 2009, 33, 54-66.	1.6	446
686	Transient Receptor Potential Vanilloid-1 Signaling as a Regulator of Human Sebocyte Biology. Journal of Investigative Dermatology, 2009, 129, 329-339.	0.3	76
687	Adiponectin deficiency impairs liver regeneration through attenuating STAT3 phosphorylation in mice. Laboratory Investigation, 2009, 89, 1043-1052.	1.7	31
688	Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 2009, 458, 83-86.	13.7	273
689	Distinct modulation of voltageâ€gated and ligandâ€gated Ca²⁺ currents by PPARâ€Î³ agonists in cultured hippocampal neurons. Journal of Neurochemistry, 2009, 109, 1800-1811.	2.1	73
690	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2683-2687.	1.0	17
691	Vitamin E-modulated gene expression associated with ROS generation. Journal of Functional Foods, 2009, 1, 241-252.	1.6	34
692	Discovery of novel dual functional agent as PPARÎ³ agonist and 11Î²-HSD1 inhibitor for the treatment of diabetes. Bioorganic and Medicinal Chemistry, 2009, 17, 5722-5732.	1.4	33
693	Synthesis and evaluation of novel Î±-heteroaryl-phenylpropanoic acid derivatives as PPARÎ±/Î³ dual agonists. Bioorganic and Medicinal Chemistry, 2009, 17, 7113-7125.	1.4	21
694	Comparative LC Enantioseparation of Novel PPAR Agonists on Cellulose- and Amylose-Based Chiral Stationary Phases. Chromatographia, 2009, 70, 1327-1333.	0.7	4
695	Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Research Bulletin, 2009, 80, 242-247.	1.4	135
696	Fenofibrate causes regression of endometriotic implants: a rat model. Fertility and Sterility, 2009, 92, 2100-2102.	0.5	15
697	A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARÎ±â^'/â^' mice possibly through PGC-1 mediated PPARÎ´ coactivation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1076-1083.	1.2	15

#	Article	IF	Citations
698	Pioglitazone Attenuates Ischemia/Reperfusionâ€“Induced Liver Injury in Rats. Transplantation Proceedings, 2009, 41, 4105-4109.	0.3	36
699	Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiology of Aging, 2009, 30, 920-931.	1.5	90
700	Peroxisome proliferator-activated receptors and angiogenesis. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 751-759.	1.1	56
701	Proteome analysis of tobacco leaves under salt stress. Peptides, 2009, 30, 1651-1659.	1.2	56
702	Fish, docosahexaenoic acid and Alzheimerâ€™s disease. Progress in Lipid Research, 2009, 48, 239-256.	5.3	272
703	Bone morphogenetic protein-2 induces the differentiation of a mesenchymal progenitor cell line, ROB-C26, into mature osteoblasts and adipocytes. Life Sciences, 2009, 84, 302-310.	2.0	26
704	Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sciences, 2009, 84, 688-695.	2.0	22
705	Possible involvement of PPARÎ³ in the regulation of basal channel opening of P2X7 receptor in cultured mouse astrocytes. Life Sciences, 2009, 84, 825-831.	2.0	10
706	PPARÎ³ stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochemistry International, 2009, 55, 496-504.	1.9	114
707	PPARÎ³ stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells. Neuroscience Letters, 2009, 454, 134-138.	1.0	34
708	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. Journal of the American College of Cardiology, 2009, 54, 585-594.	1.2	518
709	Peroxisome proliferator-activated receptor-Î³ (PPAR-Î³) ligands as potential therapeutic agents to treat arthritis. Pharmacological Research, 2009, 60, 160-169.	3.1	58
710	The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacological Research, 2009, 60, 185-194.	3.1	9
711	Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Molecular Cancer, 2009, 8, 33.	7.9	45
712	Effects of the PPAR-Î² agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. Journal of Neuroinflammation, 2009, 6, 15.	3.1	38
713	Involvement of peroxisome proliferator-activated receptor Î³ in gonadal steroidogenesis and steroidogenic acute regulatory protein expression. Reproduction, Fertility and Development, 2009, 21, 909.	0.1	54
714	Effects of Fat and Fatty Acid Intake on Inflammatory and Immune Responses: A Critical Review. Annals of Nutrition and Metabolism, 2009, 55, 123-139.	1.0	238
715	Effects of cold stress on the messenger ribonucleic acid levels of peroxisome proliferator-activated receptor-Î³ in spleen, thymus, and bursa of Fabricius of chickens. Poultry Science, 2009, 88, 2549-2554.	1.5	12

#	Article	IF	Citations
716	Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes. Journal of Alzheimer's Disease, 2009, 16, 787-808.	1.2	49
717	Synthesis and Analysis of Novel Glycerolipids for the Treatment of Metabolic Syndrome. Journal of Medicinal Chemistry, 2009, 52, 1172-1179.	2.9	10
718	Practical, Highly Convergent, Asymmetric Synthesis of a Selective PPARÎ³ Modulator. Organic Process Research and Development, 2009, 13, 525-534.	1.3	29
719	Mimicking the natural doping of migrant sandpipers in sedentary quails:effects of dietary n-3 fatty acids on muscle membranes and PPAR expression. Journal of Experimental Biology, 2009, 212, 1106-1114.	0.8	69
720	Lipoprotein ontology as a functional knowledge base. , 2009, , .		1
721	Hepatic gene expression in multiparous Holstein cows treated with bovine somatotropin and fed n-3 fatty acids in early lactation. Journal of Dairy Science, 2009, 92, 4889-4900.	1.4	64
722	Peroxisome proliferator-activated receptor-Î³ activation and long-chain fatty acids alter lipogenic gene networks in bovine mammary epithelial cells to various extents. Journal of Dairy Science, 2009, 92, 4276-4289.	1.4	245
723	Synthesis and Biological Evaluation of 2-Heteroarylthioalkanoic Acid Analogues of Clofibric Acid as Peroxisome Proliferator-Activated Receptor Î± Agonists. Journal of Medicinal Chemistry, 2009, 52, 6224-6232.	2.9	22
724	Mammalian hibernation: differential gene expression and novel application of epigenetic controls. International Journal of Developmental Biology, 2009, 53, 433-442.	0.3	94
725	Effects of Lipid-Lowering Drugs on Adiponectin. Current Vascular Pharmacology, 2010, 8, 836-848.	0.8	20
726	Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus. Current Vascular Pharmacology, 2010, 8, 189-197.	0.8	44
727	Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors. Current Topics in Medicinal Chemistry, 2010, 10, 828-858.	1.0	47
728	GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?. Current Topics in Medicinal Chemistry, 2010, 10, 799-813.	1.0	42
729	High-starch diets induce precocious adipogenic gene network up-regulation in longissimus lumborum of early-weaned Angus cattle. British Journal of Nutrition, 2010, 103, 953-963.	1.2	47
730	Genomics of metabolic adaptations in the peripartal cow. Animal, 2010, 4, 1110-1139.	1.3	103
731	Peroxisome Proliferator-Activated Receptor Gamma Enhances the Activity of an Insulin Degrading Enzyme-Like Metalloprotease for Amyloid-Î². Journal of Alzheimer's Disease, 2010, 20, 1119-1132.	1.2	19
732	Discovery and development of selective PPARÎ³ modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs, 2010, 19, 489-512.	1.9	50
733	Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Heart and Vessels, 2010, 25, 229-236.	0.5	36

#	Article	IF	Citations
734	Characterization of new PPARÎ³ agonists: Benzimidazole derivativesâ€"importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry, 2010, 18, 5885-5895.	1.4	26
735	Role of Microglia in Neurotrauma. Neurotherapeutics, 2010, 7, 366-377.	2.1	541
736	Microglial Activation in Stroke: Therapeutic Targets. Neurotherapeutics, 2010, 7, 378-391.	2.1	328
737	Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. Journal of Molecular Modeling, 2010, 16, 799-804.	0.8	15
738	Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARÎ³ agonist KR62776. Archives of Pharmacal Research, 2010, 33, 433-442.	2.7	24
739	Pro12Ala polymorphism in PPAR-Î³2 and dementia in Chinese nonagenarians/centenarians. Age, 2010, 32, 397-404.	3.0	8
740	Anti-apoptotic Actions of PPAR-Î³ Against Ischemic Stroke. Molecular Neurobiology, 2010, 41, 180-186.	1.9	82
741	Elevated Production of Docosahexaenoic Acid in Females: Potential Molecular Mechanisms. Lipids, 2010, 45, 209-224.	0.7	84
742	A recombinant peroxisome proliferator response element-driven luciferase assay for evaluation of potential environmental obesogens. Biotechnology Letters, 2010, 32, 1789-1796.	1.1	21
743	The differential expression of peroxisome proliferators-activated receptors in various duck tissues. Molecular Biology Reports, 2010, 37, 1235-1240.	1.0	7
744	Orphan Nuclear Receptors as Targets for Drug Development. Pharmaceutical Research, 2010, 27, 1439-1468.	1.7	30
745	Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents. Investigational New Drugs, 2010, 28, 472-481.	1.2	2
746	Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: Possible role of peroxisome proliferator activated receptor-Ï' (PPARÏ') in Huntington's disease. Pharmacology Biochemistry and Behavior, 2010, 96, 115-124.	1.3	45
747	Osthol regulates hepatic PPARÎ±-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine, 2010, 17, 669-673.	2.3	38
748	Î²-Ecdysone has bone protective but no estrogenic effects in ovariectomized rats. Phytomedicine, 2010, 17, 884-889.	2.3	47
749	Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. European Journal of Pharmacology, 2010, 649, 390-397.	1.7	51
750	Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants. Diabetes/Metabolism Research and Reviews, 2010, 26, 297-305.	1.7	17
751	Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARÎ± agonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1156-1161.	1.0	6

#	Article	IF	Citations
752	A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6017-6019.	1.0	9
753	Selective peroxisome proliferator-activated receptor Î´ isosteric selenium agonists as potent anti-atherogenic agents in vivo. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7239-7242.	1.0	7
754	PPARÎ³ deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution. Respiratory Research, 2010, 11, 69.	1.4	28
755	3T3â€L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferatorâ€activated receptorâ€Îγâ€dependent and mediated by the caspaseâ€3â€dependent apoptotic pathway. FEBS Journal, 2010, 277, 687-696.	2.2	48
756	Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathology and Applied Neurobiology, 2010, 36, 612-622.	1.8	25
757	Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study. Clinical Pharmacology and Therapeutics, 2010, 88, 197-203.	2.3	28
758	Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular Health and Risk Management, 2010, 6, 351.	1.0	27
759	Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging. PLoS ONE, 2010, 5, e10405.	1.1	45
760	PPARÎ³ Downregulation by TGFÃŸ in Fibroblast and Impaired Expression and Function in Systemic Sclerosis: A Novel Mechanism for Progressive Fibrogenesis. PLoS ONE, 2010, 5, e13778.	1.1	158
761	PPARÎ±-Dependent Activation of Cell Cycle Control and DNA Repair Genes in Hepatic Nonparenchymal Cells. Toxicological Sciences, 2010, 118, 404-410.	1.4	28
762	Peroxisome proliferator-activated receptor translational research and clinical experience. American Journal of Clinical Nutrition, 2010, 91, 262S-266S.	2.2	36
763	Peroxisome Proliferator-Activated Receptor-Î³ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition. Molecular Cancer Therapeutics, 2010, 9, 3221-3232.	1.9	127
764	GW0742, a selective PPAR-Î²/Î´ agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. Journal of Leukocyte Biology, 2010, 88, 291-301.	1.5	34
765	Effects of Pioglitazone, a Peroxisome Proliferatorâ€“Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat. Toxicological Sciences, 2010, 113, 349-357.	1.4	73
766	PPARs and Anticancer Therapies. PPAR Research, 2010, 2010, 1-2.	1.1	5
767	Peroxisome Proliferator-Activated Receptor Alpha Target Genes. PPAR Research, 2010, 2010, 1-20.	1.1	584
768	Lipid-Activated Nuclear Receptors and Sepsis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 258-265.	0.6	3
769	Homocysteine and Hypertension in Diabetes: Does PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Have a Regulatory Role?. PPAR Research, 2010, 2010, 1-12.	1.1	43

#	Article	IF	Citations
770	Therapeutic Implications of PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>in Human Osteosarcoma. PPAR Research, 2010, 2010, 1-16.	1.1	43
771	In Situ Proteomic Analysis of Human Breast Cancer Epithelial Cells Using Laser Capture Microdissection: Annotation by Protein Set Enrichment Analysis and Gene Ontology. Molecular and Cellular Proteomics, 2010, 9, 2529-2544.	2.5	72
772	Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Experimental Lung Research, 2010, 36, 120-128.	0.5	35
773	Pparg-P465L Mutation Worsens Hyperglycemia in Ins2-Akita Female Mice via Adipose-Specific Insulin Resistance and Storage Dysfunction. Diabetes, 2010, 59, 2890-2897.	0.3	10
774	The Molecular Basis of PPAR Function. PPAR Research, 2010, 2010, 1-2.	1.1	9
775	PPARs: Nuclear Receptors Controlled by, and Controlling, Nutrient Handling through Nuclear and Cytosolic Signaling. PPAR Research, 2010, 2010, 1-10.	1.1	51
776	Differential Response to Trichloroethylene-Induced Hepatosteatosis in Wild-Type and PPARÎ±-Humanized Mice. Environmental Health Perspectives, 2010, 118, 1557-1563.	2.8	36
777	PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues. PPAR Research, 2010, 2010, 1-17.	1.1	52
778	PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Research, 2010, 2010, 1-9.	1.1	14
779	A prospective study of dietary fat consumption and endometriosis risk. Human Reproduction, 2010, 25, 1528-1535.	0.4	177
780	From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets. Current Medicinal Chemistry, 2010, 17, 1450-1467.	1.2	128
781	Current Drug Targets for Antihyperlipidemic Therapy. Mini-Reviews in Medicinal Chemistry, 2010, 10, 232-262.	1.1	18
782	Genome-wide Expression Profiling Revealed Peripheral Effects of Cannabinoid Receptor 1 Inverse Agonists in Improving Insulin Sensitivity and Metabolic Parameters. Molecular Pharmacology, 2010, 78, 350-359.	1.0	17
783	Cytotoxic Flavonoids as Agonists of Peroxisome Proliferator-Activated Receptor Î³ on Human Cervical and Prostate Cancer Cells. Journal of Natural Products, 2010, 73, 1261-1265.	1.5	16
784	Cardiotoxicity Associated with Thiazolidinediones. , 2010, , 403-411.		1
785	Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discovery Today Disease Mechanisms, 2010, 7, e175-e183.	0.8	20
786	Oleoylethanolamide affects food intake and sleepâ€“waking cycle through a hypothalamic modulation. Pharmacological Research, 2010, 61, 379-384.	3.1	25
787	PPARs: Important Regulators in Metabolism and Inflammation. , 2010, , 259-285.		1

#	Article	IF	Citations
788	Identification and Characterization of Irreversible Peroxisome Proliferator-Activated Receptor Î´ (PPARÎ´) Antagonist. Journal of Medicinal Chemistry, 2010, 53, 1857-1861.	2.9	62
789	Emerging roles of SUMO modification in arthritis. Gene, 2010, 466, 1-15.	1.0	20
790	Structural requirement for PPARÎ³ binding revealed by a meta analysis of holo-crystal structures. Biochimie, 2010, 92, 499-506.	1.3	5
791	Adipose Acyl-CoA Synthetase-1 Directs Fatty Acids toward Î²-Oxidation and Is Required for Cold Thermogenesis. Cell Metabolism, 2010, 12, 53-64.	7.2	277
792	Long-chain polyunsaturated fatty acids: Selected mechanisms of action on bone. Progress in Lipid Research, 2010, 49, 438-449.	5.3	137
793	Myocardial Fatty Acid Metabolism in Health and Disease. Physiological Reviews, 2010, 90, 207-258.	13.1	1,643
794	Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. Expert Opinion on Therapeutic Targets, 2011, 15, 943-959.	1.5	35
795	Synthesis of novel PPARÎ±/Î³ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design programprotobuild. Organic and Biomolecular Chemistry, 2011, 9, 1169-1188.	1.5	20
796	The effects of exercise training on Î³-butyrobetaine hydroxylase and novel organic cation transporter-2 gene expression in the rat. Applied Physiology, Nutrition and Metabolism, 2011, 36, 781-789.	0.9	8
797	Serum Micronutrient Concentrations and Risk of Uterine Fibroids. Journal of Women's Health, 2011, 20, 915-922.	1.5	20
798	Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecological Endocrinology, 2011, 27, 267-272.	0.7	75
799	The champions' mitochondria: is it genetically determined? A review on mitochondrial DNA and elite athletic performance. Physiological Genomics, 2011, 43, 789-798.	1.0	41
800	Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria. Expert Review of Anti-Infective Therapy, 2011, 9, 803-819.	2.0	58
803	DLBS3233 increases glucose uptake by mediating upregulation of PPARÎ³ and PPARÎ´ expression. Biomedicine and Preventive Nutrition, 2011, 1, 71-78.	0.9	7
804	Activation of Nuclear PPARÎ³ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking. Biological Psychiatry, 2011, 69, 642-649.	0.7	131
805	The safety of thiazolidinediones. Expert Opinion on Drug Safety, 2011, 10, 419-428.	1.0	48
806	Peroxisome Proliferator-Activated Receptors and Atherosclerosis. Angiology, 2011, 62, 523-534.	0.8	28
807	A Role for Astrocytes in the Central Control of Metabolism. Neuroendocrinology, 2011, 93, 143-149.	1.2	52

#	Article	IF	Citations
808	Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacological Reports, 2011, 63, 956-966.	1.5	49
809	Challenges in drug discovery for thiazolidinedione substitute. Acta Pharmaceutica Sinica B, 2011, 1, 137-142.	5.7	29
810	Protective effect of pioglitazone, a PPARÎ³ ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Research Bulletin, 2011, 85, 231-237.	1.4	39
811	Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization. Fertility and Sterility, 2011, 95, 1970-1974.	0.5	202
812	Elevated serum alpha-linolenic acid levels are associated with decreased chance of pregnancy after inÂvitro fertilization. Fertility and Sterility, 2011, 96, 880-883.	0.5	51
813	Lentivirus-ABCG1 instillation reduces lipid accumulation and improves lung compliance in GM-CSF knock-out mice. Biochemical and Biophysical Research Communications, 2011, 415, 288-293.	1.0	17
814	Exercise Genomics. , 2011, , .		1
815	Anti-inflammatory and antinociceptive activities of indoleâ€“imidazolidine derivatives. International Immunopharmacology, 2011, 11, 1816-1822.	1.7	77
816	High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-Î³ and LXR-Î±-pathways in E3 rats. Molecular and Cellular Endocrinology, 2011, 344, 69-80.	1.6	35
817	Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. Molecular Genetics and Metabolism, 2011, 104, 265-272.	0.5	27
818	Expression and functional implications of Peroxisome Proliferatorâ€"Activated Receptor Gamma (PPARÎ³) in canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced abortion. Theriogenology, 2011, 75, 877-886.	0.9	67
819	Effect of tocopherol supplementation on serum 8-epi-prostaglandin F2 alpha and adiponectin concentrations, and mRNA expression of PPARÎ³ and related genes in ovine placenta and uterus. Theriogenology, 2011, 76, 482-491.	0.9	11
820	Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Toxicology in Vitro, 2011, 25, 839-847.	1.1	73
821	High fat diet induced diabetic cardiomyopathy. Prostaglandins Leukotrienes and Essential Fatty Acids, 2011, 85, 219-225.	1.0	70
822	Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Experimental Neurology, 2011, 227, 128-135.	2.0	134
823	Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. Open Medicinal Chemistry Journal, 2011, 5, 93-98.	0.9	49
824	Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy. Medical Science Monitor, 2011, 17, BR1-BR9.	0.5	15
825	Cerebral Ischemia and Inflammation. , 2011, , 138-153.		3

#	Article	IF	Citations
826	Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression. International Journal of General Medicine, 2011, 4, 345.	0.8	23
827	The Effects of n-3 Polyunsaturated Fatty Acid-Rich Salmon on Inflammatory Bowel Diseases. , 0, , .		0
828	Specific Thiazolidinediones Inhibit Ovarian Cancer Cell Line Proliferation and Cause Cell Cycle Arrest in a PPARÎ³ Independent Manner. PLoS ONE, 2011, 6, e16179.	1.1	39
829	Small Molecule Inhibitors of the Candida albicans Budded-to-Hyphal Transition Act through Multiple Signaling Pathways. PLoS ONE, 2011, 6, e25395.	1.1	39
830	Diabetes and Alpha Lipoic Acid. Frontiers in Pharmacology, 2011, 2, 69.	1.6	182
831	PPARÎ³ is functionally expressed in clear cell renal cell carcinoma. International Journal of Oncology, 2011, 38, 851-7.	1.4	3
832	Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. British Journal of Clinical Pharmacology, 2011, 71, 365-376.	1.1	284
833	Bovine milk fat enriched in conjugated linoleic and vaccenic acids attenuates allergic dermatitis in mice. Clinical and Experimental Allergy, 2011, 41, 729-738.	1.4	19
834	The subtypes of peroxisome proliferatorâ€activated receptors expressed by human podocytes and their role in decreasing podocyte injury. British Journal of Pharmacology, 2011, 162, 111-125.	2.7	39
835	Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. British Journal of Pharmacology, 2011, 164, 68-82.	2.7	119
836	Fatty acid omegaâ€oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS Journal, 2011, 278, 182-194.	2.2	181
837	Spontaneous caloric restriction associated with increased leptin levels in obesity-resistant Î±MUPA mice. International Journal of Obesity, 2011, 35, 226-235.	1.6	19
838	Evaluation of PPARÎ³ agonists on rodent endothelial cell proliferation. Toxicology, 2011, 287, 91-98.	2.0	3
839	Selective modulation of PPARÎ³ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Journal of Diabetes and Its Complications, 2011, 25, 151-158.	1.2	72
840	Statistical analysis of data on specificity of action of oligopeptides and amino acids on tissues with different genesis and function. Journal of Evolutionary Biochemistry and Physiology, 2011, 47, 611-613.	0.2	1
841	Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. European Journal of Pharmacology, 2011, 650, 240-248.	1.7	54
842	Peroxisome proliferator-activated receptor Î²/Î´ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radical Biology and Medicine, 2011, 50, 345-353.	1.3	48
843	Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-Î³ pathway. Biochemical Pharmacology, 2011, 82, 464-475.	2.0	193

#	Article	IF	Citations
844	Effect of triterpenes and triterpene saponins from the stem bark of Kalopanax pictus on the transactivational activities of three PPAR subtypes. Carbohydrate Research, 2011, 346, 2567-2575.	1.1	22
845	Imaging of a glucose analog, calcium and NADH in neurons and astrocytes: Dynamic responses to depolarization and sensitivity to pioglitazone. Cell Calcium, 2011, 50, 548-558.	1.1	22
846	Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs, 2011, 16, 247-270.	1.0	14
847	Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFÎºB via suppression of GSK-3Î² expression. Cancer Biology and Therapy, 2011, 12, 288-296.	1.5	32
848	Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis. Digestive Diseases and Sciences, 2011, 56, 1178-1187.	1.1	81
849	Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. Journal of Computer-Aided Molecular Design, 2011, 25, 717-728.	1.3	47
850	Joint effect of peroxisome proliferator-activated receptor Î³ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a caseâ€“control study in Taiwan. Breast Cancer Research and Treatment, 2011, 127, 777-784.	1.1	19
851	Three novel SNPs in the coding region of PPARÎ³ gene and their associations with meat quality traits in cattle. Molecular Biology Reports, 2011, 38, 131-137.	1.0	21
852	Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor Î´. Journal of Molecular Modeling, 2011, 17, 2549-2558.	0.8	12
853	Identification of the Target Proteins of Rosiglitazone in 3T3-L1 Adipocytes through Proteomic Analysis of Cytosolic and Secreted Proteins. Molecules and Cells, 2011, 31, 239-246.	1.0	26
854	Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 483-498.	1.3	14
855	Ligand-based in silico 3D-QSAR study of PPAR-Î³ agonists. Medicinal Chemistry Research, 2011, 20, 1005-1014.	1.1	6
856	Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARÎ³-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. Journal of Nutritional Biochemistry, 2011, 22, 712-722.	1.9	237
857	Mitochondrial biogenesis related endurance genotype score and sports performance in athletes. Mitochondrion, 2011, 11, 64-69.	1.6	45
858	The Health Promoting Properties of the Conjugated Isomers of Î±â€Linolenic Acid. Lipids, 2011, 46, 105-119.	0.7	135
859	The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocrine Disorders, 2011, 11, 11.	0.9	55
860	Pollock oil supplementation modulates hyperlipidemia and ameliorates hepatic steatosis in mice fed a high-fat diet. Lipids in Health and Disease, 2011, 10, 189.	1.2	23
861	Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 65.	1.6	7

#	Article	IF	Citations
862	Searching ChIP-seq genomic islands for combinatorial regulatory codes in mouse embryonic stem cells. BMC Genomics, 2011, 12, 515.	1.2	6
863	Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate, 2011, 71, 964-975.	1.2	26
864	Development of Fluorescent Glucose Bioprobes and Their Application on Realâ€Time and Quantitative Monitoring of Glucose Uptake in Living Cells. Chemistry - A European Journal, 2011, 17, 143-150.	1.7	44
865	Effect of structurally constrained oximeâ€“ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. Bioorganic and Medicinal Chemistry, 2011, 19, 771-782.	1.4	15
866	Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: Relationship between absolute configuration and subtype selectivity. Bioorganic and Medicinal Chemistry, 2011, 19, 3156-3172.	1.4	12
867	Phenoxyacetic acids as PPARÎ´ partial agonists: Synthesis, optimization, and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2345-2350.	1.0	10
868	Cytotoxic and PPARs transcriptional activities of sterols from the Vietnamese soft coral Lobophytum laevigatum. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2845-2849.	1.0	19
869	Stable reporter cell lines for peroxisome proliferator-activated receptor Î³ (PPARÎ³)-mediated modulation of gene expression. Analytical Biochemistry, 2011, 414, 77-83.	1.1	46
870	Role of Class II Nuclear Receptors in Liver Carcinogenesis. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 529-542.	0.9	10
871	Pioglitazone Reduces Secondary Brain Damage after Experimental Brain Trauma by PPAR-Î³-Independent Mechanisms. Journal of Neurotrauma, 2011, 28, 983-993.	1.7	72
872	Antiobesity Effect of Oil Extract of Ginseng. Journal of Medicinal Food, 2011, 14, 573-583.	0.8	18
873	Aging Is Associated With a Shift of Fatty Metabolism Toward Lipogenesis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 1192-1200.	1.7	48
874	Improving Glucose Metabolism With Resveratrol in a Swine Model of Metabolic Syndrome Through Alteration of Signaling Pathways in the Liver and Skeletal Muscle. Archives of Surgery, 2011, 146, 556.	2.3	62
875	Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. Journal of Lipid Research, 2011, 52, 2021-2031.	2.0	90
876	Peroxisome Proliferator-activated Receptor Î± Is Responsible for the Up-regulation of Hepatic Glucose-6-phosphatase Gene Expression in Fasting and db/db Mice. Journal of Biological Chemistry, 2011, 286, 1157-1164.	1.6	48
877	Peroxisome proliferator-activated receptor-Î³ and the endothelium: implications in cardiovascular disease. Expert Review of Cardiovascular Therapy, 2011, 9, 1279-1294.	0.6	8
878	Restoration of PPARÎ³ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L73-L80.	1.3	45
879	Thermal acclimation in Antarctic fish: transcriptomic profiling of metabolic pathways. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1453-R1466.	0.9	70

#	Article	IF	Citations
880	Omega-3 Fatty Acid Supplementation Appears to Attenuate Particulate Air Pollutionâ€“Induced Cardiac Effects and Lipid Changes in Healthy Middle-Aged Adults. Environmental Health Perspectives, 2012, 120, 952-957.	2.8	80
881	Emerging PPARÎ³-Independent Role of PPARÎ³Ligands in Lung Diseases. PPAR Research, 2012, 2012, 1-13.	1.1	18
882	Lipid-Regulating Effect of Traditional Chinese Medicine: Mechanisms of Actions. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	22
883	Peroxisome Proliferatorâ€“Activated Receptors Modulate Proliferation and Angiogenesis in Human Endometrial Carcinoma. Molecular Cancer Research, 2012, 10, 441-453.	1.5	41
884	Suppression of Diet-Induced Hypercholesterolemia by Turtle Jelly, A Traditional Chinese Functional Food, in Rats. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-15.	0.5	14
885	Limiting spinal cord injury by pharmacological intervention. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 109, 463-484.	1.0	20
886	Rosiglitazone Improves Insulin Sensitivity and Baroreflex Gain in Rats with Diet-Induced Obesity. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 206-213.	1.3	21
887	Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors. Current Topics in Medicinal Chemistry, 2012, 12, 548-584.	1.0	56
888	Severe Neutropenia in a Renal Transplant Patient Suggesting an Interaction Between Mycophenolate and Fenofibrate. Current Drug Safety, 2012, 7, 24-29.	0.3	11
889	Novel Transcriptome Profiling Analyses Demonstrate that Selective Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Modulators Display Attenuated and Selective Gene Regulatory Activity in Comparison with PPARÎ³ Full Agonists. Molecular Pharmacology, 2012, 82, 68-79.	1.0	15
890	Î²-Catenin and Peroxisome Proliferator-activated Receptor-Î´ Coordinate Dynamic Chromatin Loops for the Transcription of Vascular Endothelial Growth Factor A Gene in Colon Cancer Cells. Journal of Biological Chemistry, 2012, 287, 41364-41373.	1.6	21
891	Peroxisome proliferator-activated receptor (PPAR Î±/Î³) agonists as a potential target to reduce cardiovascular risk in diabetes. Diabetes and Vascular Disease Research, 2012, 9, 89-94.	0.9	19
892	PPARÎ³as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases. PPAR Research, 2012, 2012, 1-6.	1.1	18
893	The Case for the Use of PPARÎ³ Agonists as an Adjunctive Therapy for Cerebral Malaria. PPAR Research, 2012, 2012, 1-12.	1.1	6
894	Anti-Inflammatory Effects of Epoxyeicosatrienoic Acids. International Journal of Vascular Medicine, 2012, 2012, 1-7.	0.4	79
895	PPARÎ³Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy. PPAR Research, 2012, 2012, 1-13.	1.1	16
896	The Role of Peroxisome Proliferator-Activated Receptors in the Esophageal, Gastric, and Colorectal Cancer. PPAR Research, 2012, 2012, 1-9.	1.1	23
897	Mode of Peroxisome Proliferator-Activated Receptor Î³ Activation by Luteolin. Molecular Pharmacology, 2012, 81, 788-799.	1.0	84

#	Article	IF	Citations
898	The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 1025-1044.	0.9	37
899	Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation. Current Drug Metabolism, 2012, 13, 1412-1421.	0.7	55
900	New Pharmaceutical Concepts for Sebaceous Gland Diseases: Implementing Todayâ€™s Pre-Clinical Data into Tomorrowâ€™s Daily Clinical Practice. Current Pharmaceutical Biotechnology, 2012, 13, 1898-1913.	0.9	17
901	Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability. Thrombosis and Haemostasis, 2012, 108, 74-85.	1.8	7
902	Hepatic gene expression analysis of 2-aminoanthracene exposed Fisher-344 rats reveal patterns indicative of liver carcinoma and type 2 diabetes. Journal of Toxicological Sciences, 2012, 37, 1001-1016.	0.7	13
903	Plantagiolides I and J, Two New Withanolide Glucosides from <i>Tacca plantaginea</i> with Nuclear Factor-kappaB Inhibitory and Peroxisome Proliferator-Activated Receptor Transactivational Activities. Chemical and Pharmaceutical Bulletin, 2012, 60, 1494-1501.	0.6	17
904	Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2012, 30, 368-402.	2.9	42
905	Palmitoylethanolamide Protects Against the Amyloid-Î²25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease. Neuropsychopharmacology, 2012, 37, 1784-1792.	2.8	141
906	Functional role of peroxisomeâ€proliferatorâ€activated receptor Î³ in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1665-1669.	1.4	42
907	Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. Journal of Surgical Research, 2012, 178, 460-465.	0.8	28
908	Synthesis, radiolabeling and initial in vivo evaluation of [11C]KSM-01 for imaging PPAR-Î± receptors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6233-6236.	1.0	12
909	Anti-inflammatory and PPAR Transactivational Effects of Components from the Stem Bark of Ginkgo biloba. Journal of Agricultural and Food Chemistry, 2012, 60, 2815-2824.	2.4	23
910	The role of Klotho in energy metabolism. Nature Reviews Endocrinology, 2012, 8, 579-587.	4.3	83
911	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. Journal of Medicinal Chemistry, 2012, 55, 37-54.	2.9	46
912	â€˜PUFAâ€“GPR40â€“CREB signalingâ€™ hypothesis for the adult primate neurogenesis. Progress in Lipid Research, 2012, 51, 221-231.	5.3	59
913	PPARÎ± activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2012, 56, 1033-1039.	1.8	73
914	PPARÎ³ as a therapeutic target in cystic fibrosis. Trends in Molecular Medicine, 2012, 18, 283-291.	3.5	26
915	Daidzein has neuroprotective effects through ligand-binding-independent PPARÎ³ activation. Neurochemistry International, 2012, 61, 119-127.	1.9	34

#	Article	IF	Citations
916	Liver X receptor and peroxisome proliferator-activated receptor agonist from Cornus alternifolia. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1021-1026.	1.1	12
917	Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Behavioural Brain Research, 2012, 231, 138-145.	1.2	20
918	Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice. Epilepsy Research, 2012, 101, 28-35.	0.8	41
919	Hypoxia modulation of peroxisome proliferatorâ€activated receptors (PPARs) in human glioblastoma stem cells. Implications for therapy. Journal of Cellular Biochemistry, 2012, 113, 3342-3352.	1.2	11
920	Selected nutraceutic screening by therapeutic effects on doxorubicinâ€induced chronic kidney disease. Molecular Nutrition and Food Research, 2012, 56, 1541-1558.	1.5	18
921	Impaired mitochondrial respiration and decreased fatigue resistance followed by severe muscle weakness in skeletal muscle of mitochondrial DNA mutator mice. Journal of Physiology, 2012, 590, 6187-6197.	1.3	30
922	Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. Journal of Biomedical Science, 2012, 19, 32.	2.6	125
923	Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal Peroxisome Proliferator Activated Receptors (PPARÎ± and PPARÎ³) gene expression in rats. BMC Neuroscience, 2012, 13, 109.	0.8	50
924	Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovascular Diabetology, 2012, 11, 140.	2.7	86
925	Effect of Eriodictyol on Glucose Uptake and Insulin Resistance in Vitro. Journal of Agricultural and Food Chemistry, 2012, 60, 7652-7658.	2.4	97
926	Antiâ€proliferative effect of rosiglitazone on angiotensin IIâ€induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway. Cell Biology International, 2012, 36, 305-310.	1.4	19
927	Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain, Behavior, and Immunity, 2012, 26, 1191-1201.	2.0	550
928	Design and synthesis of marine fungal phthalide derivatives as PPAR-Î³ agonists. Bioorganic and Medicinal Chemistry, 2012, 20, 4954-4961.	1.4	25
929	DEPTOR Cell-Autonomously Promotes Adipogenesis, and Its Expression Is Associated with Obesity. Cell Metabolism, 2012, 16, 202-212.	7.2	99
930	Rosiglitazone prevents graft-versus-host disease (GVHD). Transplant Immunology, 2012, 27, 128-137.	0.6	7
931	Differential susceptibility to the PPAR-Î³ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacological Research, 2012, 65, 514-522.	3.1	41
932	Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. Archives of Pharmacal Research, 2012, 35, 1241-1250.	2.7	48
933	Peroxisome Proliferator-Activated Receptor Gamma (PPAR-Î³) and Neurodegenerative Disorders. Molecular Neurobiology, 2012, 46, 114-124.	1.9	101

#	Article	IF	Citations
934	Expression of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-Î³) in Human Non-small Cell Lung Carcinoma: Correlation with Clinicopathological Parameters, Proliferation and Apoptosis Related Molecules and Patientsâ€™ Survival. Pathology and Oncology Research, 2012, 18, 875-883.	0.9	29
935	Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-ÎºB activation and PPAR transcriptional activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6681-6687.	1.0	7
936	Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells. Food and Function, 2012, 3, 49-57.	2.1	65
937	Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids in Health and Disease, 2012, 11, 116.	1.2	41
938	Oleamide activates peroxisome proliferator-activated receptor gamma (PPARÎ³) in vitro. Lipids in Health and Disease, 2012, 11, 51.	1.2	20
939	MicroRNA-141 Represses HBV Replication by Targeting PPARA. PLoS ONE, 2012, 7, e34165.	1.1	88
940	Fenofibrate Reduces Mortality and Precludes Neurological Deficits in Survivors in Murine Model of Japanese Encephalitis Viral Infection. PLoS ONE, 2012, 7, e35427.	1.1	41
941	Inhibition of Doxorubicin-Induced Senescence by PPARÎ´ Activation Agonists in Cardiac Muscle Cells: Cooperation between PPARÎ´ and Bcl6. PLoS ONE, 2012, 7, e46126.	1.1	30
942	Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation. PLoS ONE, 2012, 7, e50816.	1.1	48
943	Antidiabetic Effects ofCorni FructusExtract in Streptozotocin-Induced Diabetic Rats. Yonsei Medical Journal, 2012, 53, 691.	0.9	32
944	Mineralization Content Alters Osteogenic Responses of Bone Marrow Stromal Cells on Hydroxyapatite/Polycaprolactone Composite Nanofiber Scaffolds. Journal of Functional Biomaterials, 2012, 3, 776-798.	1.8	14
945	Analysis of the codon use frequency of peroxisome proliferator-activated receptors (PPAR) family genes from different species. African Journal of Agricultural Research Vol Pp, 2012, 7, .	0.2	0
946	Effects of Varying Doses and Times of Adding Octanoate on Differentiationof Preadipocyte Clonal Line Derived from Pig Subcutaneous Tissue. Nihon Yoton Gakkaishi, 2012, 49, 150-159.	0.1	1
947	A missense mutant of the PPAR-Î³gene associated with carcass and meat quality traits in Chinese cattle breeds. Genetics and Molecular Research, 2012, 11, 3781-3788.	0.3	11
948	A pilot study of circulating PPAR-Î³ receptor protein in elderly patients with atrial fibrillation. Archives of Medical Science, 2012, 3, 471-476.	0.4	6
949	Tributyltin increases the expression of apoptosis- and adipogenesis-related genes in rat ovaries. Clinical and Experimental Reproductive Medicine, 2012, 39, 15.	0.5	13
950	Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 2012, 55, 3756-3776.	2.9	52
951	Integrated Virtual Screening for the Identification of Novel and Selective Peroxisome Proliferator-Activated Receptor (PPAR) Scaffolds. Journal of Medicinal Chemistry, 2012, 55, 4978-4989.	2.9	28

#	Article	IF	Citations
952	A phase 1 study of efatutazone, an oral peroxisome proliferatorâ€activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer, 2012, 118, 5403-5413.	2.0	54
953	Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008â€“present). Expert Opinion on Therapeutic Patents, 2012, 22, 803-841.	2.4	60
954	The potential of dietary polyunsaturated fatty acids to modulate eicosanoid synthesis and reproduction in Daphnia magna: A gene expression approach. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2012, 162, 449-454.	0.8	51
955	Chronic exposure to contaminated drinking water stimulates PPAR expression in mice livers. Chemosphere, 2012, 88, 407-412.	4.2	5
956	Frontal affinity chromatography with MS detection of the ligand binding domain of PPARÎ³ receptor: Ligand affinity screening and stereoselective ligandâ€“macromolecule interaction. Journal of Chromatography A, 2012, 1232, 84-92.	1.8	23
957	Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. European Journal of Pharmacology, 2012, 676, 41-50.	1.7	51
958	A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) Î³ agonists: Design and synthesis of benzylpyrazole acylsulfonamides. Bioorganic and Medicinal Chemistry, 2012, 20, 714-733.	1.4	35
959	Structureâ€“activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) Î³ Agonists. Bioorganic and Medicinal Chemistry, 2012, 20, 3332-3358.	1.4	11
960	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2527-2533.	1.0	45
961	Total synthesis and dual PPARÎ±/Î³ agonist effects of Amorphastilbol and its synthetic derivatives. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4122-4126.	1.0	19
962	Ligandâ€•and Structureâ€Based Drug Design Strategies and PPARÎ´/Î± Selectivity. Chemical Biology and Drug Design, 2012, 80, 533-544.	1.5	8
963	Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats. Metabolism: Clinical and Experimental, 2012, 61, 164-174.	1.5	9
964	Alveolar macrophage activation in obese patients with obstructive sleep apnea. Surgery, 2012, 151, 107-112.	1.0	19
965	Differential effects of cobalt and mercury on lipid metabolism in the white adipose tissue of high-fat diet-induced obesity mice. Toxicology and Applied Pharmacology, 2012, 258, 32-42.	1.3	87
966	Development of docking-based 3D-QSAR models for PPARgamma full agonists. Journal of Molecular Graphics and Modelling, 2012, 36, 1-9.	1.3	13
967	Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Reality or Mirage?. Current Cardiovascular Risk Reports, 2012, 6, 21-26.	0.8	0
968	Genetic variants in candidate genes influencing NAFLD progression. Journal of Molecular Medicine, 2012, 90, 105-118.	1.7	39
969	Arginine decreases peroxisome proliferator-activated receptor-Î³ activity via c-Jun. Molecular and Cellular Biochemistry, 2012, 362, 7-13.	1.4	3

#	Article	IF	Citations
970	Adipocyte differentiation-specific gene transcriptional response to C18 unsaturated fatty acids plus insulin. Pflugers Archiv European Journal of Physiology, 2012, 463, 429-447.	1.3	16
971	Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice. Nutrition and Metabolism, 2013, 10, 16.	1.3	39
973	Blocking the Peroxisome Proliferatorâ€Activated Receptor (PPAR): An Overview. ChemMedChem, 2013, 8, 1609-1616.	1.6	22
974	Correlation between activation of PPARÎ³ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones. Toxicology in Vitro, 2013, 27, 1425-1432.	1.1	2
975	Nutritional lipidomics: Molecular metabolism, analytics, and diagnostics. Molecular Nutrition and Food Research, 2013, 57, 1319-1335.	1.5	49
976	The role of nuclear receptors in controlling the fine balance between proliferation and differentiation of neural stem cells. Archives of Biochemistry and Biophysics, 2013, 534, 27-37.	1.4	30
977	Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. , 2013, , .		8
978	Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics, 2013, 14, 405.	1.2	23
979	Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARÎ³) agonist with potent glucose-lowering properties. Diabetologia, 2013, 56, 1802-1812.	2.9	59
980	Tissue expression of PPAR-alpha isoforms in Scophthalmus maximus and transcriptional response of target genes in the heart after exposure to WY-14643. Fish Physiology and Biochemistry, 2013, 39, 1043-1055.	0.9	13
981	Retinoid X receptor (RXR), estrogen receptor (ER) and other nuclear receptors in tissues of the mussel Mytilus galloprovincialis: Cloning and transcription pattern. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2013, 165, 178-190.	0.8	14
982	Peroxisome Proliferator-Activated Receptors. , 2013, , .		5
983	Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. European Journal of Pharmacology, 2013, 698, 505-510.	1.7	12
985	The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. Life Sciences, 2013, 92, 458-462.	2.0	37
986	PPAR-Î³ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. European Journal of Pharmacology, 2013, 715, 196-203.	1.7	22
987	PPARÎ³ and stress: Implications for aging. Experimental Gerontology, 2013, 48, 671-676.	1.2	31
988	Synthesis, chemical characterization and biological activity of new histone acetylation/deacetylation specific inhibitors: A novel and potential approach to cancer therapy. Journal of Inorganic Biochemistry, 2013, 125, 16-25.	1.5	13
989	Modulation of Skeletal Muscle Performance and SERCA by Exercise and Adiponectin Gene Therapy in Insulin-Resistant Rat. DNA and Cell Biology, 2013, 32, 378-385.	0.9	24

#	Article	IF	Citations
990	Effects of 4-nonylphenol on hepatic gene expression of peroxisome proliferator-activated receptors and cytochrome P450 isoforms (CYP1A1 and CYP3A4) in juvenile sole (Solea solea). Chemosphere, 2013, 93, 1176-1181.	4.2	23
991	Effects of paeoniflorin on tumor necrosis factor-Î±-induced insulin resistance and changes of adipokines in 3T3-L1 adipocytes. FÃ¬toterapÃ¬Ã¢, 2013, 91, 44-50.	1.1	37
992	Peroxisome Proliferators Reduce Spatial Memory Impairment, Synaptic Failure, and Neurodegeneration in Brains of a Double Transgenic Mice Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 941-959.	1.2	49
993	Molecular basis of organ fibrosis: Potential therapeutic approaches. Experimental Biology and Medicine, 2013, 238, 461-481.	1.1	124
994	Formononetin Inhibited the Inflammation of LPS-Induced Acute Lung Injury in Mice Associated with Induction of PPAR Gamma Expression. Inflammation, 2013, 36, 1560-1566.	1.7	66
995	Peroxisome proliferatorâ€activated receptor (<scp>PPAR</scp>) Î³ polymorphism, vitamin <scp>D</scp>, bone mineral density and periodontitis in postmenopausal women. Oral Diseases, 2013, 19, 501-506.	1.5	10
996	Induction of Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³)-Mediated Gene Expression by Tomato (Solanum lycopersicum L.) Extracts. Journal of Agricultural and Food Chemistry, 2013, 61, 3419-3427.	2.4	30
997	PPARs: History and Advances. Methods in Molecular Biology, 2013, 952, 1-6.	0.4	18
998	Yeast and cancer cells â€“ common principles in lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 314-326.	1.2	60
999	Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARÎ±) in human hepatocarcinoma HepG2 cells by activation of NF-ÎºB pathway. Cytokine, 2013, 61, 266-274.	1.4	19
1000	Mitochondriogenesis Genes and Extreme Longevity. Rejuvenation Research, 2013, 16, 67-73.	0.9	4
1001	Myocardial substrate metabolism in obesity. International Journal of Obesity, 2013, 37, 972-979.	1.6	59
1002	Phospholipid â€“ Driven gene regulation. FEBS Letters, 2013, 587, 1238-1246.	1.3	39
1003	Consumption of soybean, soy foods, soy isoflavones and breast cancer incidence: Differences between Chinese women and women in Western countries and possible mechanisms. Food Science and Human Wellness, 2013, 2, 146-161.	2.2	190
1004	Design and synthesis of alkoxyindolyl-3-acetic acid analogs as peroxisome proliferator-activated receptor-Î³/Î´ agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 513-517.	1.0	14
1005	Fenofibrate reduces cardiac remodeling and improves cardiac function in a rat model of severe left ventricle volume overload. Life Sciences, 2013, 92, 26-34.	2.0	9
1006	Chronic exposure to paclobutrazol causes hepatic steatosis in male rockfish Sebastiscus marmoratus and the mechanism involved. Aquatic Toxicology, 2013, 126, 148-153.	1.9	37
1007	Perfluorooctane sulfonate induces neuronal and oligodendrocytic differentiation in neural stem cells and alters the expression of PPARÎ³ in vitro and in vivo. Toxicology and Applied Pharmacology, 2013, 269, 51-60.	1.3	46

#	Article	IF	Citations
1008	Fetal origin of endocrine dysfunction in the adult: The phthalate model. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 5-17.	1.2	116
1009	Peroxisome proliferator-activated receptor-Î³ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 62, 486-497.	2.6	27
1010	Structural Characterization of Amorfrutins Bound to the Peroxisome Proliferator-Activated Receptor Î³. Journal of Medicinal Chemistry, 2013, 56, 1535-1543.	2.9	61
1011	Latest research and development trends in non-insulin anti-diabetics. Archives of Pharmacal Research, 2013, 36, 145-153.	2.7	5
1012	Transient expression, purification and characterisation of human full-length PPARÎ³2 in HEK293 cells. Protein Expression and Purification, 2013, 89, 189-195.	0.6	3
1014	Peroxisome Proliferator-Activated Receptors. , 2013, , 15-23.		0
1015	Tissue Distribution and Versatile Functions of PPARs. , 2013, , 33-69.		0
1016	Molecular Aspects of PPAR Actions. , 2013, , 79-83.		0
1017	Pioglitazone potentiates development of morphine-dependence in mice: Possible role of NO/cGMP pathway. Brain Research, 2013, 1510, 22-37.	1.1	27
1018	Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 2013, 430, 225-230.	1.0	81
1019	Molecular Mechanism of Peroxisome Proliferator-Activated Receptor Î± Activation by WY14643: a New Mode of Ligand Recognition and Receptor Stabilization. Journal of Molecular Biology, 2013, 425, 2878-2893.	2.0	101
1020	Molecular properties of fatty acids related to PPAR binding and metabolic diseases. Medicinal Chemistry Research, 2013, 22, 3126-3133.	1.1	3
1021	Lipid digestion, absorption and uptake in Solea senegalensis. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2013, 166, 26-35.	0.8	30
1022	Cumulative health risk assessment of 17 perfluoroalkylated and polyfluoroalkylated substances (PFASs) in the Swedish population. Environment International, 2013, 59, 112-123.	4.8	114
1023	Dual effects of peroxisome proliferator-activated receptor Î³ on embryonic stem cell self-renewal in presence and absence of leukemia inhibitory factor. European Journal of Cell Biology, 2013, 92, 160-168.	1.6	5
1024	PPARÎ³ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha. Neuroscience, 2013, 229, 118-129.	1.1	32
1025	Plasma Dimethylglycine and Risk of Incident Acute Myocardial Infarction in Patients With Stable Angina Pectoris. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2041-2048.	1.1	92
1026	Role of PPARs in inflammatory processes associated with metabolic syndrome (Review). Molecular Medicine Reports, 2013, 8, 1611-1616.	1.1	68

#	Article	IF	Citations
1027	Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus. Hospital Practice (1995), 2013, 41, 132-147.	0.5	24
1028	Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. Mediators of Inflammation, 2013, 2013, 1-18.	1.4	257
1029	Antidiabetic Activity of Polysaccharides from Tuberous Root ofLiriope spicatavar.proliferain KKAy Mice. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-11.	0.5	15
1030	Lactobacillus plantarumLG42 Isolated from Gajami Sik-Hae Inhibits Adipogenesis in 3T3-L1 Adipocyte. BioMed Research International, 2013, 2013, 1-7.	0.9	26
1031	Interaction Effects of the Leu162Val PPARÎ±and Pro12Ala PPARÎ³2 Gene Variants with Renal Function in Metabolic Syndrome Population. PPAR Research, 2013, 2013, 1-10.	1.1	4
1032	Trans-10,cis12-Conjugated Linoleic Acid-Induced Milk Fat Depression Is Associated with Inhibition of PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold">Î³</mml:mi></mml:mrow></mml:math>Signaling and Inflammation in Murine Mammary Tissue. Journal of Lipids, 2013, 2013, 1-16.	1.9	14
1033	Curcumin Protects Neuron against Cerebral Ischemia-Induced Inflammation through Improving PPAR-Gamma Function. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	49
1034	Effects ofÏ‰-3 Polyunsaturated Fatty Acids on Plasma Proteome in Rett Syndrome. Mediators of Inflammation, 2013, 2013, 1-9.	1.4	12
1035	Attenuation of Acute Pancreatitis by Peroxisome Proliferator-Activated Receptor-Î± in Rats. Pancreas, 2013, 42, 114-122.	0.5	18
1036	Effect of Growth Factors on the Proliferation and Gene Expression of Human Meibomian Gland Epithelial Cells. , 2013, 54, 2541.		42
1037	Genetic Variation in the Inflammation and Innate Immunity Pathways and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2094-2101.	1.1	18
1038	Susceptibility of L-FABPâ^'/â^' mice to oxidative stress in early-stage alcoholic liver. Journal of Lipid Research, 2013, 54, 1335-1345.	2.0	36
1039	Sex-Specific Differences in Type 2 Diabetes Mellitus and Dyslipidemia Therapy: PPAR Agonists. Handbook of Experimental Pharmacology, 2013, , 387-410.	0.9	24
1040	Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds. Drug Metabolism and Drug Interactions, 2013, 28, 31-47.	0.3	4
1041	Curcumin Inhibits Transforming Growth Factor-Î²1-Induced EMT via PPARÎ³ Pathway, Not Smad Pathway in Renal Tubular Epithelial Cells. PLoS ONE, 2013, 8, e58848.	1.1	74
1042	Interaction between a common variant in FADS1 and erythrocyte polyunsaturated fatty acids on lipid profile in Chinese Hans. Journal of Lipid Research, 2013, 54, 1477-1483.	2.0	17
1043	Activation of <scp>PPAR</scp>Î³ by Pioglitazone Potentiates the Effects of Naltrexone on Alcohol Drinking and Relapse in ms<scp>P</scp> Rats. Alcoholism: Clinical and Experimental Research, 2013, 37, 1351-1360.	1.4	77
1044	PPARÎ³Networks in Cell Signaling: Update and Impact of Cyclic Phosphatidic Acid. Journal of Lipids, 2013, 2013, 1-6.	1.9	14

#	Article	IF	Citations
1045	Functional Role of PPARs in Ruminants: Potential Targets for Fine-Tuning Metabolism during Growth and Lactation. PPAR Research, 2013, 2013, 1-28.	1.1	136
1046	Antiâ€inflammatory and PPAR Transactivational Properties of Flavonoids from the Roots of Sophora flavescens. Phytotherapy Research, 2013, 27, 1300-1307.	2.8	22
1047	<scp>PPARâ€Î³</scp> â€“ a possible drug target for complicated pregnancies. British Journal of Pharmacology, 2013, 168, 1074-1085.	2.7	36
1048	UP780, a Chromone-Enriched Aloe Composition Improves Insulin Sensitivity. Metabolic Syndrome and Related Disorders, 2013, 11, 267-275.	0.5	20
1049	Pioglitazone alleviates the mitochondrial apoptotic pathway and mitoâ€oxidative damage in the <scp>d</scp>â€galactoseâ€induced mouse model. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 644-651.	0.9	33
1050	Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. Scientific Reports, 2013, 3, 2903.	1.6	30
1051	A practical guide for the study of human and murine sebaceous glands in situ. Experimental Dermatology, 2013, 22, 631-637.	1.4	59
1052	Fatty Acid Structure and Synthesis. , 2013, , 285-289.		7
1053	Metabolite sensing in eukaryotic <scp>mRNA</scp> biology. Wiley Interdisciplinary Reviews RNA, 2013, 4, 387-396.	3.2	10
1054	Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis. Oncologist, 2013, 18, 148-156.	1.9	116
1055	Pathogenic role of diabetes-induced PPAR-Î± down-regulation in microvascular dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15401-15406.	3.3	110
1056	Combination of peroxisome proliferator-activated receptor Î±/Î³ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion. Experimental and Therapeutic Medicine, 2013, 5, 783-788.	0.8	9
1057	Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Drug Design, Development and Therapy, 2013, 7, 279.	2.0	22
1058	Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in Mice. PLoS ONE, 2013, 8, e64258.	1.1	66
1059	PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings. PLoS ONE, 2013, 8, e64541.	1.1	41
1060	Activation of Human Stearoyl-Coenzyme A Desaturase 1 Contributes to the Lipogenic Effect of PXR in HepG2 Cells. PLoS ONE, 2013, 8, e67959.	1.1	18
1061	Cerulenin Blockade of Fatty Acid Synthase Reverses Hepatic Steatosis in ob/ob Mice. PLoS ONE, 2013, 8, e75980.	1.1	12
1062	Polyphenols: Benefits to the Cardiovascular System in Health and in Aging. Nutrients, 2013, 5, 3779-3827.	1.7	353

#	Article	IF	Citations
1063	Asiatic Acid Isolated From Centella Asiatica Inhibits TGF-Î²1-induced Collagen Expression in Human Keloid Fibroblasts via PPAR-Î³ Activation. International Journal of Biological Sciences, 2013, 9, 1032-1042.	2.6	60
1065	Effect of Coptidis Rhizoma extracts in a water-based solution on insulin resistance in 3T3-L1 adipocytes. Biomedical Research, 2014, 35, 321-327.	0.3	4
1066	Conventional Hypoglycaemic Agents and the Risk of Lung Cancer in Patients with Diabetes: A Meta-Analysis. PLoS ONE, 2014, 9, e99577.	1.1	16
1067	Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL. PLoS ONE, 2014, 9, e85337.	1.1	39
1068	The Association of Pioglitazone and Urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease. PLoS ONE, 2014, 9, e85479.	1.1	28
1069	Regulation of Insulin Degrading Enzyme Activity by Obesity-Associated Factors and Pioglitazone in Liver of Diet-Induced Obese Mice. PLoS ONE, 2014, 9, e95399.	1.1	52
1070	Molecular Modeling Study of PPARr Agonists: Dehydro-Di-Isoeugenol, Macelignan, Pioglitazone, Netoglitazone, and Rosiglitazone as Antidiabetic Drugs. International Journal of Chemistry, 2014, 6, .	0.3	6
1071	PPARα gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players. Open Access Journal of Sports Medicine, 2014, 5, 273.	0.6	10
1073	Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics, 2014, 15, 2063-2082.	0.6	37
1074	Perfluorooctanesulfonate (PFOS) Perturbs Male Rat Sertoli Cell Blood-Testis Barrier Function by Affecting F-Actin Organization via p-FAK-Tyr407: An in Vitro Study. Endocrinology, 2014, 155, 249-262.	1.4	103
1075	Whole genome association study identifies regions of the bovine genome and biological pathways involved in carcass trait performance in Holstein-Friesian cattle. BMC Genomics, 2014, 15, 837.	1.2	38
1076	The effect of nutrition and metabolic status on the development of follicles, oocytes and embryos in ruminants. Animal, 2014, 8, 1031-1044.	1.3	61
1077	Opportunities for the Development of Neuroimmune Therapies in Addiction. International Review of Neurobiology, 2014, 118, 381-401.	0.9	48
1078	Bezafibrate in skeletal muscle fatty acid oxidation disorders. Neurology, 2014, 82, 607-613.	1.5	96
1079	PPARÎ³ Agonists Improve Survival and Neurocognitive Outcomes in Experimental Cerebral Malaria and Induce Neuroprotective Pathways in Human Malaria. PLoS Pathogens, 2014, 10, e1003980.	2.1	49
1080	Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. Frontiers in Physiology, 2014, 5, 429.	1.3	94
1081	Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-Î±Agonist in Cognitive Impairment in Parkinsonâ€™s Disease: Behavioral, Biochemical, and PBPK Profile. PPAR Research, 2014, 2014, 1-9.	1.1	26
1082	Structural and Metabolic Effects of Obesity on the Myocardium and the Aorta. Obesity Facts, 2014, 7, 329-338.	1.6	16

#	Article	IF	Citations
1083	Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients. Adipocyte, 2014, 3, 314-321.	1.3	15
1084	Effects of the Peroxisome Proliferator-Activated Receptor (PPAR)-Î´ Agonist GW501516 on Bone and Muscle in Ovariectomized Rats. Endocrinology, 2014, 155, 2178-2189.	1.4	16
1085	Assessment of multiple hormonal activities in wastewater at different stages of treatment. Environmental Toxicology and Chemistry, 2014, 33, 2297-2307.	2.2	65
1086	Adipogenic differentiation potential of adiposeâ€derived mesenchymal stem cells from ovariectomized mice. Cell Proliferation, 2014, 47, 604-614.	2.4	27
1087	Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. ACS Chemical Biology, 2014, 9, 2905-2913.	1.6	9
1088	Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer?. Applied Physiology, Nutrition and Metabolism, 2014, 39, 663-678.	0.9	56
1089	Sterol Fatty Acid Esters from the Mushroom Hericium erinaceum and Their PPAR Transactivational Effects. Journal of Natural Products, 2014, 77, 2611-2618.	1.5	26
1090	Lactobacillus brevis <scp>OPK</scp>â€3 isolated from kimchi inhibits adipogenesis and exerts antiâ€inflammation in <scp>3T3â€L1</scp> adipocyte. Journal of the Science of Food and Agriculture, 2014, 94, 2514-2520.	1.7	31
1091	The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome. Progress in Molecular Biology and Translational Science, 2014, 121, 217-266.	0.9	66
1092	Lactobacillus plantarum LG42 isolated from gajami sik-hae decreases body and fat pad weights in diet-induced obese mice. Journal of Applied Microbiology, 2014, 116, 145-156.	1.4	54
1093	Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology, 2014, 59, 858-869.	3.6	80
1094	Effect of Persea americana (avocado) fruit extract on the level of expression of adiponectin and PPAR-Î³ in rats subjected to experimental hyperlipidemia and obesity. Journal of Complementary and Integrative Medicine, 2014, 11, 107-119.	0.4	22
1095	Peroxisome proliferator-activated receptor-gamma (PPARÎ³) is down regulated in trophoblast cells of gestational diabetes mellitus (GDM) and in trophoblast tumour cells BeWo in vitro after stimulation with PPARÎ³ agonists. Journal of Perinatal Medicine, 2014, 42, 179-87.	0.6	20
1096	Effect of creatine and pioglitazone on Hk-2 cell line cisplatin nephrotoxicity. Renal Failure, 2014, 36, 1104-1107.	0.8	8
1097	Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease. Acta Pharmacologica Sinica, 2014, 35, 65-73.	2.8	27
1098	WLIP derived from Lasiosphaera fenzlii Reich exhibits anti-tumor activity and induces cell cycle arrest through PPAR-Î³ associated pathways. International Immunopharmacology, 2014, 19, 37-44.	1.7	10
1099	JAZF1 regulates visfatin expression in adipocytes via PPARÎ± and PPARÎ²/Î´ signaling. Metabolism: Clinical and Experimental, 2014, 63, 1012-1021.	1.5	19
1100	The Therapeutic Potential of Nuclear Receptor Modulators for Treatment of Metabolic Disorders: PPARÎ³, RORs, and Rev-erbs. Cell Metabolism, 2014, 19, 193-208.	7.2	106

#	Article	IF	Citations
1101	The dipeptide H-Trp-Glu-OH (WE) shows agonistic activity to peroxisome proliferator-activated protein-Î± and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2957-2962.	1.0	11
1102	Bioactivity screening and mass spectrometric confirmation for the detection of PPARÎ´ agonists that increase type 1 muscle fibres. Analytical and Bioanalytical Chemistry, 2014, 406, 705-713.	1.9	4
1103	Immunological Mechanisms and Therapies in Brain Injuries and Stroke. , 2014, , .		4
1104	Fibrate treatment of eEOCs in murine AKI. Journal of Nephrology, 2014, 27, 37-44.	0.9	6
1105	PPAR Î± and PPAR Î³ Polymorphisms as risk factors for Dyslipidemia in a Chinese han population. Lipids in Health and Disease, 2014, 13, 23.	1.2	17
1106	Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney. Ageing Research Reviews, 2014, 14, 1-18.	5.0	11
1107	Identification of the first potent, selective and bioavailable PPARÎ± antagonist. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2267-2272.	1.0	8
1108	Self-condensation of Î²-(isoxazol-5-yl) enamines under treatment with acetyl chloride and acids. Synthesis of novel 1,3-diisoxazolyl-1,3-dieneamines and 1,3,5-triisoxazolyl benzenes. Tetrahedron, 2014, 70, 3915-3923.	1.0	5
1109	Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulinâ€resistant obese mice. Molecular Nutrition and Food Research, 2014, 58, 903-907.	1.5	49
1110	Cladosporol A, a new peroxisome proliferator-activated receptor Î³ (PPARÎ³) ligand, inhibits colorectal cancer cells proliferation through Î²-catenin/TCF pathway inactivation. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2361-2372.	1.1	21
1111	Lifelong Caloric Restriction Reprograms Hepatic Fat Metabolism in Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 915-922.	1.7	58
1112	Î²-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic Î²-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors. Cell Metabolism, 2014, 19, 96-108.	7.2	489
1113	A Recombinant PPRE-Driven Luciferase Bioassay for Identification of Potential PPAR Agonists. Vitamins and Hormones, 2014, 94, 427-435.	0.7	4
1114	Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion, 2014, 14, 7-17.	1.6	43
1115	Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs, 2014, 19, 471-488.	1.0	5
1116	Persimmon Tannin accounts for hypolipidemic effects of persimmon through activating of AMPK and suppressing NF-Î¹B activation and inflammatory responses in High-Fat Diet Rats. Food and Function, 2014, 5, 1536-1546.	2.1	47
1117	Lipid-lowering effects of farnesylquinone and related analogues from the marine-derived Streptomyces nitrosporeus. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5288-5293.	1.0	18
1118	Peroxisome proliferator-activated receptor Î³1 and Î³2 isoforms alter lipogenic gene networks in goat mammary epithelial cells to different extents. Journal of Dairy Science, 2014, 97, 5437-5447.	1.4	34

#	Article	IF	Citations
1119	Anti-pruritic activity of pioglitazone on serotonin-induced scratching in mice: Possible involvement of PPAR-gamma receptor and nitric oxide. European Journal of Pharmacology, 2014, 744, 103-107.	1.7	15
1120	Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARÎ³ receptors: A new indication for atorvastatin. Pesticide Biochemistry and Physiology, 2014, 114, 79-89.	1.6	18
1121	Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System. Pharmacological Reviews, 2014, 66, 815-868.	7.1	122
1122	Role of Pregnane X Receptor in Obesity and Glucose Homeostasis in Male Mice. Journal of Biological Chemistry, 2014, 289, 3244-3261.	1.6	72
1123	Transcriptome profiling of biliary atresia from new born infants by deep sequencing. Molecular Biology Reports, 2014, 41, 8063-8069.	1.0	5
1124	Down-regulation of PPARÎ± in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. Neuroscience, 2014, 278, 165-178.	1.1	22
1125	Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. European Journal of Medicinal Chemistry, 2014, 87, 814-833.	2.6	110
1126	Fenofibrate â€“ A lipid-lowering drug â€“ Reduces voluntary alcohol drinking in rats. Alcohol, 2014, 48, 665-670.	0.8	36
1127	Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2. Atherosclerosis, 2014, 237, 200-207.	0.4	7
1128	Positive and negative effects of glitazones in carcinogenesis: Experimental models vs. clinical practice. Pathology Research and Practice, 2014, 210, 465-472.	1.0	10
1129	Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Translational Psychiatry, 2014, 4, e350-e350.	2.4	80
1130	Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor Î±, Î², Î³ subtypes: an in silico approach. Journal of Applied Toxicology, 2014, 34, 754-765.	1.4	72
1131	Molecular Machines Involved in Peroxisome Biogenesis and Maintenance. , 2014, , .		2
1132	Effect of combination treatment of Sâ€“amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats. Diabetology and Metabolic Syndrome, 2014, 6, 45.	1.2	3
1133	Lipid-Metabolizing CYPs in the Regulation and Dysregulation of Metabolism. Annual Review of Nutrition, 2014, 34, 261-279.	4.3	44
1134	The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments. Neurotherapeutics, 2014, 11, 385-400.	2.1	76
1135	Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. BMC Urology, 2014, 14, 10.	0.6	7
1136	Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutrition Journal, 2014, 13, 17.	1.5	884

#	Article	IF	Citations
1137	Inhibition of HDAC3 promotes ligand-independent PPARÎ³ activation by protein acetylation. Journal of Molecular Endocrinology, 2014, 53, 191-200.	1.1	83
1138	Endogenous Ï‰-3 Polyunsaturated Fatty Acid Production Confers Resistance to Obesity, Dyslipidemia, and Diabetes in Mice. Molecular Endocrinology, 2014, 28, 1316-1328.	3.7	52
1139	Differential effects of triclosan on the activation of mouse and human peroxisome proliferator-activated receptor alpha. Toxicology Letters, 2014, 231, 17-28.	0.4	20
1140	Lipids in health and disease. Nature, 2014, 510, 47-47.	13.7	24
1141	Transgenic expression of salmon delta-5 and delta-6 desaturase in zebrafish muscle inhibits the growth of Vibrio alginolyticus and affects fish immunomodulatory activity. Fish and Shellfish Immunology, 2014, 39, 223-230.	1.6	24
1142	Peroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Hypertension Patients and the Metabolic Effects of Olmesartan. Archives of Medical Research, 2014, 45, 138-142.	1.5	5
1143	Rosiglitazone, a peroxisome proliferator-activated receptor-Î³ agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma. Immunology Letters, 2014, 157, 9-15.	1.1	33
1144	Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 811-821.	1.4	21
1145	Modulation of NRF2 signaling pathway by nuclear receptors: Implications for cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1875-1885.	1.9	83
1146	Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation. Vascular Pharmacology, 2014, 62, 162-166.	1.0	15
1147	Piroxicam and c-phycocyanin prevent colon carcinogenesis by inhibition of membrane fluidity and canonical Wnt/Î²-catenin signaling while up-regulating ligand dependent transcription factor PPARÎ³. Biomedicine and Pharmacotherapy, 2014, 68, 537-550.	2.5	36
1148	Synthesis of PPAR-Î³ Activators Inspired by the Marine Natural Product, Paecilocin A. Marine Drugs, 2014, 12, 926-939.	2.2	11
1149	Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 570.	0.8	84
1150	ThÃ©rapeutique des dÃ©sordres glycÃ©miques. , 2014, , 115-188.		0
1151	Effect of dietary lipid structure in early postnatal life on mouse adipose tissue development and function in adulthood. British Journal of Nutrition, 2014, 111, 215-226.	1.2	74
1153	Mexican Traditional Medicine: Traditions of Yesterday and Phytomedicines of Tomorrow. , 2015, , 1-37.		4
1154	A systematic analysis of human lipocalin family and its expression in esophageal carcinoma. Scientific Reports, 2015, 5, 12010.	1.6	28
1155	Diet and Inflammation in Alzheimerâ€™s Disease and Related Chronic Diseases: A Review. Journal of Alzheimer's Disease, 2016, 50, 301-334.	1.2	46

#	Article	IF	Citations
1156	PPARÎ± Stimulation Modulates Myocardial Ischemia-induced Activation of Reninâ€“Angiotensin System. Journal of Cardiovascular Pharmacology, 2015, 65, 430-437.	0.8	6
1157	Chronic Ethanolâ€Induced Impairment of Wnt/Î²â€Catenin Signaling is Attenuated by <scp>PPAR</scp>â€Î´ Agonist. Alcoholism: Clinical and Experimental Research, 2015, 39, 969-979.	1.4	16
1158	The role of PPAR activation during the systemic response to brain injury. Journal of Neuroinflammation, 2015, 12, 99.	3.1	21
1159	A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions. EJNMMI Research, 2015, 5, 50.	1.1	2
1160	DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav028-bav028.	1.4	847
1161	The paradox of obesity cardiomyopathy and the potential for weight loss as a therapy. Obesity Reviews, 2015, 16, 679-690.	3.1	18
1162	Mechanisms of Peroxisome Proliferator Activated Receptor Î³ Regulation by Non-steroidal Anti-inflammatory Drugs. Nuclear Receptor Signaling, 2015, 13, nrs.13004.	1.0	63
1163	PPARs as Modulators of Cardiac Metabolism and Inflammation. , 2015, , 155-167.		0
1164	Transcriptional Factors Mediating Retinoic Acid Signals in the Control of Energy Metabolism. International Journal of Molecular Sciences, 2015, 16, 14210-14244.	1.8	62
1165	Reporter Cell Lines for the Characterization of the Interactions between Human Nuclear Receptors and Endocrine Disruptors. Frontiers in Endocrinology, 2015, 6, 62.	1.5	65
1166	Disruption of Other Receptor Systems. , 2015, , 111-122.		2
1167	Positive association between PPARD rs2016520 polymorphism and coronary heart disease in a Han Chinese population. Genetics and Molecular Research, 2015, 14, 6350-6359.	0.3	8
1168	Structure-Based Virtual Screening and Discovery of New PPARÎ³/Î³ Dual Agonist and PPARÎ´ and Î³ Agonists. PLoS ONE, 2015, 10, e0118790.	1.1	21
1169	The Teratogenicity and the Action Mechanism of Gallic Acid Relating with Brain and Cervical Muscles. PLoS ONE, 2015, 10, e0119516.	1.1	4
1170	Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals?. Frontiers in Pharmacology, 2015, 6, 137.	1.6	43
1171	Evolutionary Pattern and Regulation Analysis to Support Why Diversity Functions Existed within PPAR Gene Family Members. BioMed Research International, 2015, 2015, 1-11.	0.9	16
1172	Application of Berberine on Treating Type 2 Diabetes Mellitus. International Journal of Endocrinology, 2015, 2015, 1-12.	0.6	179
1173	The 482Ser ofPPARGC1Aand 12Pro ofPPARG2Alleles Are Associated with Reduction of Metabolic Risk Factors Even Obesity in a Mexican-Mestizo Population. BioMed Research International, 2015, 2015, 1-14.	0.9	19

#	Article	IF	Citations
1174	The Association between Type 2 Diabetes Mellitus and Women Cancer: The Epidemiological Evidences and Putative Mechanisms. BioMed Research International, 2015, 2015, 1-12.	0.9	58
1175	Influence of Cardiorespiratory Fitness onPPARGmRNA Expression Using Monozygotic Twin Case Control. Journal of Diabetes Research, 2015, 2015, 1-7.	1.0	4
1176	Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Research, 2015, 2015, 1-18.	1.1	77
1177	Zebrafish as a Model to Study the Role of Peroxisome Proliferating-Activated Receptors in Adipogenesis and Obesity. PPAR Research, 2015, 2015, 1-11.	1.1	85
1178	Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 1012.	0.8	141
1179	Biocompounds Attenuating the Development of Obesity and Insulin Resistance Produced by a High-fat Sucrose Diet. Natural Product Communications, 2015, 10, 1934578X1501000.	0.2	2
1180	The activation of peroxisome proliferator-activated receptor Î³ is regulated by KrÃ¼ppel-like transcription factors 6 & 9 under steatotic conditions. Biochemical and Biophysical Research Communications, 2015, 458, 751-756.	1.0	25
1181	Adaptation of peroxisome proliferator-activated receptor alpha to hibernation in bats. BMC Evolutionary Biology, 2015, 15, 88.	3.2	15
1182	Various peroxisome proliferator-activated receptor (PPAR)-Î³agonists differently induce differentiation of cultured human keratinocytes. Experimental Dermatology, 2015, 24, 62-65.	1.4	8
1183	Effect of Sancaijiangtang on plasma nitric oxide and endothelin-1 levels in patients with type 2 diabetes mellitus and vascular dementia: a single-blind randomized controlled trial. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine, 2015, 35, 375-380.	0.4	15
1184	Dicaffeoylquinic Acid-Enriched Fraction of Cichorium glandulosum Seeds Attenuates Experimental Type 1 Diabetes via Multipathway Protection. Journal of Agricultural and Food Chemistry, 2015, 63, 10791-10802.	2.4	18
1185	Fenofibrate Reverses Palmitate Induced Impairment in Glucose Uptake in Skeletal Muscle Cells by Preventing Cytosolic Ceramide Accumulation. Cellular Physiology and Biochemistry, 2015, 37, 1315-1328.	1.1	12
1186	Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARÎ³ pathway. International Journal of Oncology, 2015, 46, 1131-1140.	1.4	28
1187	Salicornia herbaceaprevents weight gain and hepatic lipid accumulation in obese ICR mice fed a high-fat diet. Journal of the Science of Food and Agriculture, 2015, 95, 3150-3159.	1.7	15
1188	Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor Î´ (PPARÎ´) in human cholangiocarcinoma. Digestive and Liver Disease, 2015, 47, 62-67.	0.4	6
1189	Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 133-145.	1.0	50
1190	PPARÎ³ Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission. Neuropsychopharmacology, 2015, 40, 927-937.	2.8	67
1191	On the Metabolically Active Form of Metaglidasen: Improved Synthesis and Investigation of Its Peculiar Activity on Peroxisome Proliferatorâ€Activated Receptors and Skeletal Muscles. ChemMedChem, 2015, 10, 555-565.	1.6	23

#	Article	IF	Citations
1192	Contribution of TIMP4 rs3755724 polymorphism to susceptibility to focal epilepsy in Malaysian Chinese. Journal of Neuroimmunology, 2015, 278, 137-143.	1.1	7
1193	Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry, 2015, 92, 839-865.	2.6	188
1194	Mechanisms and Potential Therapeutic Applications of Microglial Activation after Brain Injury. CNS Neuroscience and Therapeutics, 2015, 21, 309-319.	1.9	95
1195	Plasticizer endocrine disruption: Highlighting developmental and reproductive effects in mammals and non-mammalian aquatic species. General and Comparative Endocrinology, 2015, 219, 74-88.	0.8	224
1196	The effect of PPAR-Î³ agonist on 18F-FDG PET imaging for differentiating tumors and inflammation lesions. Nuclear Medicine and Biology, 2015, 42, 85-91.	0.3	5
1197	Exploiting host immunity: the Salmonella paradigm. Trends in Immunology, 2015, 36, 112-120.	2.9	119
1198	<scp>PPARD</scp> rs2016520 polymorphism affects repaglinide response in Chinese Han patients with typeÂ2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 27-32.	0.9	5
1199	Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) and Ligand Choreography: Newcomers Take the Stage. Journal of Medicinal Chemistry, 2015, 58, 5381-5394.	2.9	75
1200	Indolyl linked meta-substituted benzylidene-based novel PPAR ligands: synthetic and docking studies. Medicinal Chemistry Research, 2015, 24, 1396-1407.	1.1	8
1201	Modulation of the Nitrergic Pathway via Activation of PPAR-Î³ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction. Journal of Molecular Neuroscience, 2015, 56, 739-750.	1.1	9
1202	Gene set enrichment analysis of pathways and transcription factors associated with diabetic retinopathy using a microarray dataset. International Journal of Molecular Medicine, 2015, 36, 103-112.	1.8	14
1203	Maternal PPARG Pro12Ala polymorphism is associated with infant's neurodevelopmental outcomes at 18 months of age. Early Human Development, 2015, 91, 457-462.	0.8	11
1204	Inflammation and Lung Cancer: Prevention. , 2015, , 95-136.		0
1205	Aryl hydrocarbon receptor deficiency protects mice from diet-induced adiposity and metabolic disorders through increased energy expenditure. International Journal of Obesity, 2015, 39, 1300-1309.	1.6	96
1206	Regulation of catalase expression in healthy and cancerous cells. Free Radical Biology and Medicine, 2015, 87, 84-97.	1.3	190
1208	Inflammation and Lung Cancer. , 2015, , .		2
1209	Effects of the PPARÎ± agonist WY-14,643 on plasma lipids, enzymatic activities and mRNA expression of lipid metabolism genes in a marine flatfish, Scophthalmus maximus. Aquatic Toxicology, 2015, 164, 155-162.	1.9	15
1210	Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor Î±/Î³. Journal of Structural Biology, 2015, 191, 332-340.	1.3	34

#	Article	IF	Citations
1211	Activation of Human Peroxisome Proliferator-Activated Nuclear Receptors (PPARÎ³1) by Semi-Volatile Compounds (SVOCs) and Chemical Mixtures in Indoor Dust. Environmental Science & Technology, 2015, 49, 10057-10064.	4.6	55
1212	PPARÎ± agonists based on stilbene and its bioisosteres: biological evaluation and docking studies. MedChemComm, 2015, 6, 1513-1517.	3.5	13
1213	Pistacia lentiscus Oleoresin: Virtual Screening and Identification of Masticadienonic and Isomasticadienonic Acids as Inhibitors of 11Î²-Hydroxysteroid Dehydrogenase 1. Planta Medica, 2015, 81, 525-532.	0.7	22
1214	Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor Î³/Î´ agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3322-3336.	1.4	12
1215	Dose apolipoprotein AV has influence on the regulation of fatty acids and triglyceride metabolism in cardiomyocyte in case of obesity. International Journal of Cardiology, 2015, 185, 109-111.	0.8	0
1216	The Dipeptide H-Trp-Arg-OH (WR) Is a PPARÎ± Agonist and Reduces Hepatic Lipid Accumulation in Lipid-Loaded H4IIE Cells. Applied Biochemistry and Biotechnology, 2015, 175, 1211-1220.	1.4	4
1217	Evaluation of anti-obesity activities of ethanolic extract of Terminalia paniculata bark on high fat diet-induced obese rats. BMC Complementary and Alternative Medicine, 2015, 15, 76.	3.7	42
1218	Ecophysiology of Omega Fatty Acids: A Lid for Every Jar. Physiology, 2015, 30, 232-240.	1.6	51
1219	Creatine Inhibits Adipogenesis by Downregulating Insulin-Induced Activation of the Phosphatidylinositol 3-Kinase Signaling Pathway. Stem Cells and Development, 2015, 24, 983-994.	1.1	21
1220	Comparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in rats. European Journal of Pharmacology, 2015, 760, 145-153.	1.7	30
1221	Critical Role of Mast Cells and Peroxisome Proliferatorâ€“Activated Receptor Î³ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. Journal of Immunology, 2015, 194, 5211-5222.	0.4	66
1222	Carnitine protects the nematode Caenorhabditis elegans from glucose-induced reduction of survival depending on the nuclear hormone receptor DAF-12. Biochemical and Biophysical Research Communications, 2015, 460, 747-752.	1.0	9
1223	Natural Products for the Treatment of Type 2 Diabetes Mellitus. Planta Medica, 2015, 81, 975-994.	0.7	339
1224	18Î²-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARÎ³ and Nrf2 upregulation. Genes and Nutrition, 2015, 10, 41.	1.2	116
1225	Dyslipidemia in Obesity. , 2015, , 1-18.		1
1226	Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results. Journal of Analytical Toxicology, 2015, 39, 734-740.	1.7	8
1227	Identification of a New Type of Covalent PPARÎ³ Agonist using a Ligand-Linking Strategy. ACS Chemical Biology, 2015, 10, 2794-2804.	1.6	28
1228	Molecular mechanisms of fatty liver in obesity. Frontiers of Medicine, 2015, 9, 275-287.	1.5	24

#	Article	IF	Citations
1229	Airway epithelial cell PPARÎ³ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L293-L304.	1.3	44
1230	Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARÎ³ and IGF-1 signaling. European Journal of Pharmacology, 2015, 768, 217-225.	1.7	25
1231	Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease. Brain Research, 2015, 1597, 220-246.	1.1	182
1232	A structural perspective on nuclear receptors as targets of environmental compounds. Acta Pharmacologica Sinica, 2015, 36, 88-101.	2.8	97
1233	Pleiotropic Role of <scp>PPAR</scp>Î³ in Intracerebral Hemorrhage: An Intricate System Involving Nrf2, <scp>RXR</scp>, and <scp>NF</scp>â€Î¹B. CNS Neuroscience and Therapeutics, 2015, 21, 357-366.	1.9	99
1234	Aging and dyslipidemia: A review of potential mechanisms. Ageing Research Reviews, 2015, 19, 43-52.	5.0	183
1235	Medium chain fatty acids from milk induce angiopoietin-like 4 (ANGPTL4) gene expression. International Dairy Journal, 2015, 42, 34-41.	1.5	9
1236	Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes. Journal of Endocrinological Investigation, 2015, 38, 163-170.	1.8	58
1237	PPAR gamma gene â€“ A review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2015, 9, 46-50.	1.8	474
1238	Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?. Saudi Pharmaceutical Journal, 2015, 23, 14-21.	1.2	5
1239	Molecular modeling design, synthesis, and anti-hyprglycemic evaluation of certain 5-(aryl-alkoxy-benzylidine)-imidazolidine-2,4-dione derivatives as potential PPARÎ³ agonists. Medicinal Chemistry Research, 2015, 24, 2115-2126.	1.1	1
1240	Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57, 140-145.	2.5	34
1241	Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. International Journal of Cardiology, 2015, 179, 360-369.	0.8	39
1242	Beneficial Health Effects of Chios Gum Mastic and Peroxisome Proliferator-Activated Receptors: Indications of Common Mechanisms. Journal of Medicinal Food, 2015, 18, 1-10.	0.8	37
1243	Proteomic and metabolomic responses of Pacific oyster Crassostrea gigas to elevated pCO2 exposure. Journal of Proteomics, 2015, 112, 83-94.	1.2	54
1244	Peroxisome proliferator-activated receptor transactivational effects in HepG2 cells of cembranoids from the soft coral Lobophytum crassum Von Marenzeller. Archives of Pharmacal Research, 2015, 38, 769-775.	2.7	7
1245	The Endocannabinoid-Like Derivative Oleoylethanolamide at the Gutâ€“Brain Interface: A â€œLipid Wayâ€• to Control Energy Intake and Body Weight. , 2016, , .		2
1246	Recent Updates on Peroxisome Proliferator-Activated Receptor Î´ Agonists for the Treatment of Metabolic Syndrome. Medicinal Chemistry, 2016, 12, 3-21.	0.7	14

#	Article	IF	Citations
1247	Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ. Drug Design, Development and Therapy, 2016, 10, 1807.	2.0	2
1248	Alterations in the Expression of Transcription Factors PPARÎ³ and NFÎºB in the Brain of Models of Chronic Pain. Biochemistry & Pharmacology: Open Access, 2016, 5, .	0.2	3
1249	Identification of polycystic ovary syndrome potential drug targets based on pathobiological similarity in the protein-protein interaction network. Oncotarget, 2016, 7, 37906-37919.	0.8	7
1250	Enhancing the Activity of Peroxisome Proliferator- Activated Receptorâ€™s (PPAR) Activity through Natural Ligand Binding in Diabetes: Substantial Computational Approach. , 2016, 04, .		2
1251	PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1. PPAR Research, 2016, 2016, 1-10.	1.1	17
1252	PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs. PPAR Research, 2016, 2016, 1-10.	1.1	16
1253	Transcriptome Analyses Reveal Lipid Metabolic Process in Liver Related to the Difference of Carcass Fat Content in Rainbow Trout (Oncorhynchus mykiss). International Journal of Genomics, 2016, 2016, 1-10.	0.8	16
1254	PPARÎ³in Bacterial Infections: A Friend or Foe?. PPAR Research, 2016, 2016, 1-7.	1.1	21
1255	PPARgene: A Database of Experimentally Verified and Computationally Predicted PPAR Target Genes. PPAR Research, 2016, 2016, 1-6.	1.1	89
1256	PPARÎ³as a Novel Therapeutic Target in Lung Cancer. PPAR Research, 2016, 2016, 1-7.	1.1	37
1257	Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR Research, 2016, 2016, 1-9.	1.1	88
1258	Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 999.	1.8	99
1259	The Deep Correlation between Energy Metabolism and Reproduction: A View on the Effects of Nutrition for Women Fertility. Nutrients, 2016, 8, 87.	1.7	139
1260	Gene expression profile of intramuscular muscle in Nellore cattle with extreme values of fatty acid. BMC Genomics, 2016, 17, 972.	1.2	49
1261	Deciphering the gene expression profile of peroxisome proliferator-activated receptor signaling pathway in the left atria of patients with mitral regurgitation. Journal of Translational Medicine, 2016, 14, 157.	1.8	16
1262	Activation of Peroxisome Proliferator-Activated Receptor Alpha Improves Aged and UV-Irradiated Skin by Catalase Induction. PLoS ONE, 2016, 11, e0162628.	1.1	30
1263	Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis. PPAR Research, 2016, 2016, 1-15.	1.1	42
1264	Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists. Chinese Journal of Chemical Physics, 2016, 29, 508-516.	0.6	3

#	Article	IF	Citations
1265	Diabetes Mellitus and Intestinal Niemann-Pick C1â€“Like 1 Gene Expression. , 2016, , 277-290.		2
1266	Genomewide approaches for <scp>BACH</scp>1 target genes in mouse embryonic fibroblasts showed <scp>BACH</scp>1â€Pparg pathway in adipogenesis. Genes To Cells, 2016, 21, 553-567.	0.5	22
1267	Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in dietâ€induced obese mice. Molecular Nutrition and Food Research, 2016, 60, 1944-1955.	1.5	35
1268	Preclinical Medication Development: New Targets and New Drugs. Alcoholism: Clinical and Experimental Research, 2016, 40, 1418-1424.	1.4	0
1269	Sex differences in pain. Pain, 2016, 157, S2-S6.	2.0	158
1270	A Novel Partial <scp>PPARÎ±</scp>/Î³ Dual Agonist <scp>SN159</scp> Improves Insulin Sensitivity. Bulletin of the Korean Chemical Society, 2016, 37, 226-233.	1.0	3
1272	Pioglitazone. Profiles of Drug Substances, Excipients and Related Methodology, 2016, 41, 379-438.	3.5	19
1273	Metabolic profiling of residents in the vicinity of a petrochemical complex. Science of the Total Environment, 2016, 548-549, 260-269.	3.9	25
1274	Omega-3 fatty acids as an adjunct for periodontal therapyâ€”a review. Clinical Oral Investigations, 2016, 20, 879-894.	1.4	29
1275	Influence of difenoconazole on lipid metabolism in marine medaka (Oryzias melastigma). Ecotoxicology, 2016, 25, 982-990.	1.1	17
1276	Biology of Preimplantation Conceptus at the Onset of Elongation in Dairy Cows1. Biology of Reproduction, 2016, 94, 97.	1.2	71
1277	Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 114, 28-34.	1.0	150
1278	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugsâ€”A mechanistic revisit to understand their mode of action. Pharmacological Research, 2016, 113, 636-674.	3.1	53
1279	Peroxisome proliferator activating receptor-Î³ and the podocyte. Nephrology Dialysis Transplantation, 2017, 32, gfw320.	0.4	21
1280	Beyond acne: Current aspects of sebaceous gland biology and function. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 319-334.	2.6	105
1281	Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?. , 2016, 168, 75-97.		25
1282	Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster. Food and Chemical Toxicology, 2016, 95, 211-218.	1.8	8
1283	Peroxisome proliferatorâ€activated receptors in cardiacÂenergy metabolism and cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 649-658.	0.9	48

#	Article	IF	Citations
1284	Peroxisome proliferator-activated receptor gamma (PPARÎ³) in brown trout: Interference of estrogenic and androgenic inputs in primary hepatocytes. Environmental Toxicology and Pharmacology, 2016, 46, 328-336.	2.0	9
1285	Licarin B from Myristica fragrans improves insulin sensitivity via PPARÎ³ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway in 3T3-L1 adipocytes. RSC Advances, 2016, 6, 79859-79870.	1.7	19
1286	Beverages Fortified with Omega-3 Fatty Acids, Dietary Fiber, Minerals, and Vitamins. Nutraceutical Science and Technology, 2016, , 801-813.	0.0	8
1287	Thioredoxin reductase 1 suppresses adipocyte differentiation and insulin responsiveness. Scientific Reports, 2016, 6, 28080.	1.6	42
1288	The effect of regulating molecules on the structure of the PPAR-RXR complex. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1852-1863.	1.2	25
1289	Role of lipids on elongation of the preimplantation conceptus in ruminants. Reproduction, 2016, 152, R115-R126.	1.1	45
1290	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. , 2016, , .		10
1291	Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice. Biochimie, 2016, 131, 1-10.	1.3	18
1292	Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of TypeÂ1 diabetic mice. Clinical Science, 2016, 130, 625-641.	1.8	128
1293	Fatty acid metabolism in fish species as a biomarker for environmental monitoring. Environmental Pollution, 2016, 218, 297-312.	3.7	70
1294	Identifying potential PPARÎ³ agonist/partial agonist from plant molecules to control type 2 diabetes using in silico and in vivo models. Medicinal Chemistry Research, 2016, 25, 1980-1992.	1.1	9
1295	Characterization of WY 14,643 and its Complex with Aldose Reductase. Scientific Reports, 2016, 6, 34394.	1.6	3
1296	Novel Podophyllotoxin Derivatives as Partial PPARÎ³ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes. Scientific Reports, 2016, 6, 37323.	1.6	6
1297	Genetic Deletion of Neuronal PPARÎ³ Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPARÎ³ Function. Journal of Neuroscience, 2016, 36, 12611-12623.	1.7	48
1298	Localization of PPAR isotypes in the adult mouse and human brain. Scientific Reports, 2016, 6, 27618.	1.6	188
1299	Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARÎ³ signalling pathway. Scientific Reports, 2016, 6, 35783.	1.6	90
1300	Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Medicine, 2016, 8, 74.	3.6	43
1301	Dietary thylakoids reduce visceral fat mass and increase expression of genes involved in intestinal fatty acid oxidation in high-fat fed rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R618-R627.	0.9	6

#	Article	IF	Citations
1302	Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARÎ± signaling and inhibiting the NF-ÎºB and ERK1/2/AP-1/STAT3 pathways. Scientific Reports, 2016, 6, 34611.	1.6	73
1303	Dietary Arachidonic Acid Has a Timeâ€Dependent Differential Impact on Adipogenesis Modulated via COX and LOX Pathways in Grass Carp Ctenopharyngodon idellus. Lipids, 2016, 51, 1325-1338.	0.7	15
1304	Screening of saponins and sapogenins from Medicago species as potential PPARÎ³ agonists and X-ray structure of the complex PPARÎ³/caulophyllogenin. Scientific Reports, 2016, 6, 27658.	1.6	17
1305	Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARÎ±. Molecular Medicine Reports, 2016, 13, 5309-5316.	1.1	17
1306	Association between peroxisome proliferator-activated receptor-alpha, delta, and gamma polymorphisms and risk of coronary heart disease. Medicine (United States), 2016, 95, e4299.	0.4	20
1307	Synthesis of Naphthylâ€, Quinolinâ€•and Anthracenyl Analogues of Clofibric Acid as <scp>PPAR</scp>Î± Agonists. Chemical Biology and Drug Design, 2016, 87, 467-471.	1.5	6
1308	The Biology of Nutrients. , 2016, , 209-225.		0
1309	PPARÎ³ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radical Biology and Medicine, 2016, 100, 153-163.	1.3	176
1310	Adipogenesis inhibitory effects of Limonium tetragonum in mouse bone marrow stromal D1 cells. Food Science and Biotechnology, 2016, 25, 125-131.	1.2	4
1311	Peroxisome proliferator-activated receptors and biotransformation responses in relation to condition factor and contaminant burden in tilapia species from Ogun River, Nigeria. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2016, 183-184, 7-19.	1.3	14
1312	Glycyrrhizic acid prevents high calorie dietâ^'induced metabolic aberrations despite the suppression of peroxisome proliferator-activated receptor Î³ expression. Nutrition, 2016, 32, 995-1001.	1.1	13
1313	PPAR Modulating Polyketides from a Chinese Plakortis simplex and Clues on the Origin of Their Chemodiversity. Journal of Organic Chemistry, 2016, 81, 5135-5143.	1.7	30
1314	Hepatoprotective effect of resveratrol against ethanol-induced oxidative stress through induction of superoxide dismutase in vivo and in vitro. Experimental and Therapeutic Medicine, 2016, 11, 1231-1238.	0.8	46
1315	The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2016, 186, 1009-1021.	0.7	17
1316	Regulation of peroxisome proliferator-activated receptor gamma on milk fat synthesis in dairy cow mammary epithelial cells. In Vitro Cellular and Developmental Biology - Animal, 2016, 52, 1044-1059.	0.7	45
1317	Evidence Linking the Role of Placental Expressions of Peroxisome Proliferatorâ€Activated Receptorâ€Î³ and Nuclear Factorâ€Kappa B in the Pathogenesis of Preeclampsia Associated With Periodontitis. Journal of Periodontology, 2016, 87, 962-970.	1.7	11
1318	Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-Î±-Dependent Inhibition of Akt/mTOR Pathway. Phytotherapy Research, 2016, 30, 963-970.	2.8	25
1319	<scp>PPAR</scp>Î³ gene polymorphism, Câ€reactive protein level, <scp>BMI</scp> and periodontitis in postâ€menopausal Japanese women. Gerodontology, 2016, 33, 44-51.	0.8	8

#	Article	IF	Citations
1320	Inflammation and Immune Response. , 2016, , 129-140.e5.		0
1321	PPAR-Î´ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. Nature Medicine, 2016, 22, 37-45.	15.2	88
1322	Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-Î³ and PPAR-Î± agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice. Diabetologia, 2016, 59, 1276-1286.	2.9	51
1323	NF-ÎºB signaling pathway as target for antiplatelet activity. Blood Reviews, 2016, 30, 309-315.	2.8	33
1324	The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2016, 10, 70-74.	0.2	1
1325	Role of Pleiotropic Properties of Peroxisome Proliferatorâ€Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection. Cardiovascular Therapeutics, 2016, 34, 37-48.	1.1	31
1326	Mechanisms underlying the effect of polysaccharides in the treatment of type 2 diabetes: A review. Carbohydrate Polymers, 2016, 144, 474-494.	5.1	185
1327	Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. Biomedicine and Pharmacotherapy, 2016, 78, 239-247.	2.5	35
1328	Dyslipidemia in Obesity. , 2016, , 525-540.		4
1329	Emerging targets for addiction neuropharmacology. Progress in Brain Research, 2016, 224, 251-284.	0.9	11
1330	The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism. Bioorganic and Medicinal Chemistry, 2016, 24, 1191-1203.	1.4	2
1331	Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway. European Journal of Pharmacology, 2016, 775, 35-42.	1.7	23
1332	15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis. Journal of Molecular Medicine, 2016, 94, 695-710.	1.7	10
1333	Mangosteen Extract Attenuates the Metabolic Disorders of High-Fat-Fed Mice by Activating AMPK. Journal of Medicinal Food, 2016, 19, 148-154.	0.8	30
1334	Chronic liquid nutrition intake induces obesity and considerable but reversible metabolic alterations in Wistar rats. Journal of Physiology and Biochemistry, 2016, 72, 225-243.	1.3	4
1335	Diabetes and Alzheimerâ€™s disease crosstalk. Neuroscience and Biobehavioral Reviews, 2016, 64, 272-287.	2.9	161
1336	New PPARÎ³ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLrâ^'/â^' mice. Pharmacological Research, 2016, 104, 49-60.	3.1	26
1337	A Brief Discussion on Lipid Activated Nuclear Receptors and their Potential Role in Regulating Microglia in Age-Related Macular Degeneration (AMD). Advances in Experimental Medicine and Biology, 2016, 854, 45-51.	0.8	10

#	Article	IF	Citations
1338	Proliferation and fission of peroxisomes â€" An update. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 971-983.	1.9	137
1339	Peroxisome homeostasis: Mechanisms of division and selective degradation of peroxisomes in mammals. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 984-991.	1.9	57
1340	Hematopoietic knockdown of PPARÎ´ reduces atherosclerosis in LDLRâ^'/â^' mice. Gene Therapy, 2016, 23, 78-85.	2.3	17
1341	Association between genetic polymorphisms of inflammatory response genes and the risk of ovarian cancer. Journal of the Formosan Medical Association, 2016, 115, 31-37.	0.8	12
1342	Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-Î²B inflammation signals. Journal of Receptor and Signal Transduction Research, 2017, 37, 94-99.	1.3	13
1343	Transforming growth factor Î² suppresses peroxisome proliferator-activated receptor Î³ expression via both SMAD binding and novel TGF-Î² inhibitory elements. Biochemical Journal, 2017, 474, 1531-1546.	1.7	44
1344	Novel indole-2-carboxylic acid linked 3-phenyl-2-alkoxy propanoic acids: Synthesis, molecular docking and in vivo antidiabetic studies. Medicinal Chemistry Research, 2017, 26, 745-759.	1.1	8
1345	Mechanistic insight into nuclear receptorâ€mediated regulation of bile acid metabolism and lipid homeostasis by grape seed procyanidin extract (GSPE). Cell Biochemistry and Function, 2017, 35, 12-32.	1.4	21
1346	Probing the intermolecular interactions of PPARÎ³-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties. Lipids in Health and Disease, 2017, 16, 17.	1.2	37
1347	Inflammation is independent of steatosis in a murine model of steatohepatitis. Hepatology, 2017, 66, 108-123.	3.6	56
1348	Obesity is positively associated with arachidonic acid-derived 5- and 11-hydroxyeicosatetraenoic acid (HETE). Metabolism: Clinical and Experimental, 2017, 70, 177-191.	1.5	71
1349	Cysteine deprivation prevents induction of peroxisome proliferator-activated receptor gamma-2 and adipose differentiation of 3T3-L1 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 623-635.	1.2	18
1350	Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Molecular and Cellular Biochemistry, 2017, 430, 1-9.	1.4	19
1351	Anti-inflammatory and antioxidant effects of polyphenols extracted from Antirhea borbonica medicinal plant on adipocytes exposed to Porphyromonas gingivalis and Escherichia coli lipopolysaccharides. Pharmacological Research, 2017, 119, 303-312.	3.1	44
1352	Structure-based design, synthesis, PPAR-Î³ activation, and molecular docking of N-substituted phthalimides. Medicinal Chemistry Research, 2017, 26, 1628-1634.	1.1	5
1353	The making of a mammalian peroxisome, version 2.0: mitochondria get into the mix. Cell Death and Differentiation, 2017, 24, 1148-1152.	5.0	15
1355	Docosahexaenoic acid inhibits IL-6 expression via PPARÎ³-mediated expression of catalase in cerulein-stimulated pancreatic acinar cells. International Journal of Biochemistry and Cell Biology, 2017, 88, 60-68.	1.2	32
1356	In vitro and in vivo pharmacology of NXT629, a novel and selective PPARÎ± antagonist. European Journal of Pharmacology, 2017, 809, 130-140.	1.7	22

#	Article	IF	Citations
1357	Ubiquitination of nuclear receptors. Clinical Science, 2017, 131, 917-934.	1.8	10
1358	Exercise-induced modification of the skeletal muscle transcriptome in Arabian horses. Physiological Genomics, 2017, 49, 318-326.	1.0	29
1359	Nuclear receptor research in zebrafish. Journal of Molecular Endocrinology, 2017, 59, R65-R76.	1.1	15
1360	Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects. International Journal of Biochemistry and Cell Biology, 2017, 82, 49-56.	1.2	9
1361	Naringenin interferes with the anti-diabetic actions of pioglitazone via pharmacodynamic interactions. Journal of Natural Medicines, 2017, 71, 442-448.	1.1	14
1362	PPARÎ³ Agonists Attenuate Trigeminal Neuropathic Pain. Clinical Journal of Pain, 2017, 33, 1071-1080.	0.8	21
1363	Nuclear receptors in neural stem/progenitor cell homeostasis. Cellular and Molecular Life Sciences, 2017, 74, 4097-4120.	2.4	27
1364	CBMG, a novel derivative of mansonone G suppresses adipocyte differentiation via suppression of PPARÎ³ activity. Chemico-Biological Interactions, 2017, 273, 160-170.	1.7	4
1365	Anti-adipogenic effects of Tropaeolum majus (nasturtium) ethanol extract on 3T3-L1 cells. Food and Nutrition Research, 2017, 61, 1339555.	1.2	25
1366	Antarctic seals: Molecular biomarkers as indicators for pollutant exposure, health effects and diet. Science of the Total Environment, 2017, 599-600, 1693-1704.	3.9	12
1367	PPAR expression throughout the oestrous cycle in the bovine endometrium. Theriogenology, 2017, 100, 88-94.	0.9	9
1368	Peroxisome proliferator-activated receptor Î³ agonism attenuates endotoxaemia-induced muscle protein loss and lactate accumulation in rats. Clinical Science, 2017, 131, 1437-1447.	1.8	13
1369	Cytotoxic effect of a family of peroxisome proliferatorâ€activated receptor antagonists in colorectal and pancreatic cancer cell lines. Chemical Biology and Drug Design, 2017, 90, 1029-1035.	1.5	21
1371	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-Î±. Future Cardiology, 2017, 13, 259-278.	0.5	120
1372	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-Î²/Î´ and PPAR-Î³. Future Cardiology, 2017, 13, 279-296.	0.5	183
1373	The effects of Bacillus coagulans-fermented and non-fermented Ginkgo biloba on abdominal fat deposition and meat quality of Peking duck. Poultry Science, 2017, 96, 2264-2273.	1.5	8
1374	Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery. Experimental Neurology, 2017, 293, 74-82.	2.0	30
1375	The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats. Neuropharmacology, 2017, 116, 364-370.	2.0	33

#	Article	IF	Citations
1376	Editorâ€™s Highlight: Collaborative Cross Mouse Population Enables Refinements to Characterization of the Variability in Toxicokinetics of Trichloroethylene and Provides Genetic Evidence for the Role of PPAR Pathway in Its Oxidative Metabolism. Toxicological Sciences, 2017, 158, 48-62.	1.4	32
1377	Structural basis for differential activities of enantiomeric PPARÎ³ agonists: Binding of S35 to the alternate site. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 674-681.	1.1	40
1378	Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. Clinical Journal of Gastroenterology, 2017, 10, 201-207.	0.4	18
1379	The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases. American Journal of Cardiovascular Drugs, 2017, 17, 273-281.	1.0	49
1380	The inhibitory effect of beta-lapachone on RANKL-induced osteoclastogenesis. Biochemical and Biophysical Research Communications, 2017, 482, 1073-1079.	1.0	13
1381	Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present. European Journal of Medicinal Chemistry, 2017, 126, 879-893.	2.6	64
1382	Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats. Biomedicine and Pharmacotherapy, 2017, 85, 155-159.	2.5	29
1383	Role of the adipose PPARÎ³-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors. Molecular Psychiatry, 2017, 22, 1056-1068.	4.1	95
1384	Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology, 2017, 19, 37.	0.7	14
1385	Brain lipid-binding protein promotes proliferation and modulates cell cycle in C6 rat glioma cells. International Journal of Oncology, 2017, 51, 1439-1448.	1.4	5
1386	Linked magnolol dimer as a selective PPARÎ³ agonist â€“ Structure-based rational design, synthesis, and bioactivity evaluation. Scientific Reports, 2017, 7, 13002.	1.6	13
1387	The association between fatty acid index and in vitro fertilization outcomes. Journal of Assisted Reproduction and Genetics, 2017, 34, 1627-1632.	1.2	15
1388	Peroxisome proliferator-activated receptors as therapeutic targets for heart failure. Biomedicine and Pharmacotherapy, 2017, 95, 692-700.	2.5	36
1389	Betulinic acid is a PPARÎ³ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. Scientific Reports, 2017, 7, 5777.	1.6	60
1390	ctPath: Demixing pathway crosstalk effect from transcriptomics data for differential pathway identification. Journal of Biomedical Informatics, 2017, 73, 104-114.	2.5	9
1391	Study of the interactions between Edaglitazone and Ciglitazone with PPARÎ³ and their antiplatelet profile. Life Sciences, 2017, 186, 59-65.	2.0	9
1392	Transcriptome Analysis of Three Sheep Intestinal Regions reveals Key Pathways and Hub Regulatory Genes of Large Intestinal Lipid Metabolism. Scientific Reports, 2017, 7, 5345.	1.6	18
1394	Rescue of PFOS-induced human Sertoli cell injury by overexpressing a p-FAK-Y407E phosphomimetic mutant. Scientific Reports, 2017, 7, 15810.	1.6	25

#	Article	IF	Citations
1395	PPARÎ± agonists acutely inhibit calcium-independent PLA2 to reduce H2O2-induced contractions in aortae of spontaneously hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 314, ajpheart.00314..	1.5	3
1396	A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. Journal of Immunology, 2017, 199, 1476-1489.	0.4	40
1397	INT131 increases dendritic arborization and protects against AÎ² toxicity by inducing mitochondrial changes in hippocampal neurons. Biochemical and Biophysical Research Communications, 2017, 490, 955-962.	1.0	6
1398	4-Hydroxyalkenal-activated PPARÎ´ mediates hormetic interactions in diabetes. Biochimie, 2017, 136, 85-89.	1.3	11
1399	Cellular and molecular effects of yeast probiotics on cancer. Critical Reviews in Microbiology, 2017, 43, 96-115.	2.7	51
1400	RNAâ€sequencing analysis reveals the hepatotoxic mechanism of perfluoroalkyl alternatives, HFPO2 and HFPO4, following exposure in mice. Journal of Applied Toxicology, 2017, 37, 436-444.	1.4	58
1401	Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. Annales Pharmaceutiques Francaises, 2017, 75, 105-111.	0.4	5
1402	Structural exploration of PPARÎ³ modulators through pharmacophore mapping, fragment-based design, docking, and molecular dynamics simulation analyses. Medicinal Chemistry Research, 2017, 26, 52-63.	1.1	2
1403	Immunosenescence and the Ageing Lung. , 2017, , 87-104.		2
1404	Protective effects of bezafibrate against elaidic acid-induced accumulation of lipid droplets in monocytic cells. Current Research in Translational Medicine, 2017, 65, 20-30.	1.2	4
1405	Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay. Brain and Development, 2017, 39, 48-57.	0.6	17
1406	Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice. Nature Microbiology, 2017, 2, 16220.	5.9	47
1407	Targeting Complications of Diabetes with Antioxidants. , 2017, , 397-445.		1
1408	Antiobesity potential of Piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats. Nutrition and Metabolism, 2017, 14, 72.	1.3	37
1410	The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus. Translational Research in Oral Oncology, 2017, 2, 2057178X1773980.	2.3	0
1411	Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPARÎ³-SIRT1 feedback loop. Journal of Cancer, 2017, 8, 2282-2295.	1.2	35
1412	Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Dysfunction. Nutrients, 2017, 9, 540.	1.7	31
1413	Gestational diabetes from A to Z. World Journal of Diabetes, 2017, 8, 489-511.	1.3	136

#	Article	IF	Citations
1414	PPAR-Î³ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Frontiers in Endocrinology, 2017, 8, 31.	1.5	72
1415	Fatty Acids of CLA-Enriched Egg Yolks Can Induce Transcriptional Activation of Peroxisome Proliferator-Activated Receptors in MCF-7 Breast Cancer Cells. PPAR Research, 2017, 2017, 1-12.	1.1	10
1416	Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARÎ´ Regulation in Hyperlipidemic and Hypertensive Conditions. PPAR Research, 2017, 2017, 1-14.	1.1	10
1417	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. PPAR Research, 2017, 2017, 1-15.	1.1	119
1418	Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs. International Journal of Medicinal Chemistry, 2017, 2017, 1-20.	2.2	48
1419	Preclinical Studies and Translational Applications of Intracerebral Hemorrhage. BioMed Research International, 2017, 2017, 1-18.	0.9	15
1420	PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Research, 2017, 2017, 1-8.	1.1	44
1421	Collaborative Power of Nrf2 and PPARÎ³ Activators against Metabolic and Drug-Induced Oxidative Injury. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	1.9	106
1422	Acute Exercise Stimulates Carnitine Biosynthesis and OCTN2 Expression in Mouse Kidney. Kidney and Blood Pressure Research, 2017, 42, 398-405.	0.9	10
1423	Effects of peroxisome proliferator activated receptors (PPAR)-Î³ and -Î± agonists on cochlear protection from oxidative stress. PLoS ONE, 2017, 12, e0188596.	1.1	50
1424	Transcription Factors That Regulate Trophoblast Development and Function. Progress in Molecular Biology and Translational Science, 2017, 145, 39-88.	0.9	50
1425	The Role of Nuclear Hormone Receptors in Cannabinoid Function. Advances in Pharmacology, 2017, 80, 291-328.	1.2	50
1426	Maternal folic acid consumption during gestation and its long-term effects on offspring's liver: a systematic review. Revista Brasileira De Saude Materno Infantil, 2017, 17, 7-15.	0.2	4
1427	Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis. Journal of Stem Cell Research & Therapy, 2017, 07, .	0.3	26
1428	Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances. Annals of Hepatology, 2017, 16, S58-S67.	0.6	21
1429	Peroxisome proliferator-activated receptor-Î³ in induced sputum is correlated with MMP-9/TIMP-1 imbalance and formation of emphysema in COPD patients. Journal of Thoracic Disease, 2017, 9, 3703-3710.	0.6	7
1430	The influence of arachidonic acid metabolites on PPAR and RXR expression in bovine uterine cells. General and Comparative Endocrinology, 2018, 262, 27-35.	0.8	6
1431	The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice. Journal of Physiology and Biochemistry, 2018, 74, 247-260.	1.3	15

#	Article	IF	Citations
1432	Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study. Cytokine, 2018, 105, 73-79.	1.4	13
1433	Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. International Journal of Oncology, 2018, 52, 1198-1208.	1.4	28
1434	Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats. Experimental Neurology, 2018, 300, 188-200.	2.0	47
1435	Interplay Between Metabolic Sensors and Immune Cell Signaling. Experientia Supplementum (2012), 2018, 109, 115-196.	0.5	2
1436	Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARÎ± selective agonists: New leads for oculovascular conditions. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2717-2722.	1.0	7
1437	Bovine embryo elongation is altered due to maternal fatty acid supplementation. Biology of Reproduction, 2018, 99, 600-610.	1.2	13
1438	Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.3	40
1439	Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes. Studies in Natural Products Chemistry, 2018, 55, 111-143.	0.8	21
1440	Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. Heart Failure Reviews, 2018, 23, 389-408.	1.7	13
1441	Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor Î´ Agonist. ACS Omega, 2018, 3, 1970-1976.	1.6	6
1442	GQ-11: A new PPAR agonist improves obesity-induced metabolic alterations in LDLrâ^'/â^' mice. International Journal of Obesity, 2018, 42, 1062-1072.	1.6	15
1443	Effect of dietary n-3 polyunsaturated fatty acid rich fish oil on the endometrial prostaglandin production in the doe (Capra hircus). Prostaglandins and Other Lipid Mediators, 2018, 135, 27-35.	1.0	8
1444	Atherosclerotic Calcification: Wnt Is the Hint. Journal of the American Heart Association, 2018, 7, .	1.6	62
1445	Effects of Chios mastic gum and exercise on physical characteristics, blood lipid markers, insulin resistance, and hepatic function in healthy Japanese men. Food Science and Biotechnology, 2018, 27, 773-780.	1.2	10
1446	Molecular determinants of PPARÎ³ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators. Food and Chemical Toxicology, 2018, 112, 47-59.	1.8	9
1447	In vitro PPARÎ³ agonistic potential of chitin synthesis inhibitors and their energy metabolism-related hepatotoxicity. Science of the Total Environment, 2018, 615, 1126-1132.	3.9	11
1448	Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARÎ³. Scientific Reports, 2018, 8, 31.	1.6	62
1449	Skeletal Muscle Interleukin-6 Regulates Hepatic Cytochrome P450 Expression: Effects of 16-Week High-Fat Diet and Exercise. Toxicological Sciences, 2018, 162, 309-317.	1.4	20

#	Article	IF	Citations
1450	4â€²,6-Dimethoxyisoflavone-7-O-Î²-d-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor Î± (PPARÎ±) agonist in mouse hepatocytes. Molecular and Cellular Biochemistry, 2018, 446, 35-41.	1.4	5
1451	Current anti-diabetic agents and their molecular targets: A review. European Journal of Medicinal Chemistry, 2018, 152, 436-488.	2.6	235
1452	Antitumor Properties of CLA-Enriched Food Products. Nutrition and Cancer, 2018, 70, 529-545.	0.9	14
1453	A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation. Biological and Pharmaceutical Bulletin, 2018, 41, 29-35.	0.6	20
1454	Transcriptional Regulators as Targets for Alcohol Pharmacotherapies. Handbook of Experimental Pharmacology, 2018, 248, 505-533.	0.9	4
1455	Effects of dietary crude oil exposure on molecular and physiological parameters related to lipid homeostasis in polar cod (Boreogadus saida). Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2018, 206-207, 54-64.	1.3	17
1456	Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. Molecular Genetics and Metabolism Reports, 2018, 15, 55-63.	0.4	22
1457	Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2018, 55, 2789-2813.	1.9	32
1458	A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?. Indian Journal of Clinical Biochemistry, 2018, 33, 121-131.	0.9	14
1459	Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study. Clinical Nutrition, 2018, 37, 1340-1347.	2.3	5
1460	Histone methyltransferase G9a modulates hepatic insulin signaling via regulating HMGA1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 338-346.	1.8	25
1461	Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARÎ±Î³ Agonist, in Healthy Adult Subjects. Clinical Drug Investigation, 2018, 38, 57-65.	1.1	11
1462	Antidiabetic plant-derived nutraceuticals: a critical review. European Journal of Nutrition, 2018, 57, 1275-1299.	1.8	55
1463	Peroxisome proliferator-activated receptor Î³ (PPARÎ³): A master gatekeeper in CNS injury and repair. Progress in Neurobiology, 2018, 163-164, 27-58.	2.8	156
1464	Antidiabetic therapies and male reproductive function: where do we stand?. Reproduction, 2018, 155, R13-R37.	1.1	21
1465	Global analysis of gene expression profiles in the submandibular salivary gland of klotho knockout mice. Journal of Cellular Physiology, 2018, 233, 3282-3294.	2.0	7
1466	Symposium review: Lipids as regulators of conceptus development: Implications for metabolic regulation of reproduction in dairy cattle. Journal of Dairy Science, 2018, 101, 3630-3641.	1.4	23
1467	TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARÎ³-SIRT1 feedback loop in human bladder cancer cells. Cancer Letters, 2018, 414, 278-293.	3.2	58

#	Article	IF	Citations
1468	Neuroinflammation produced by heavy alcohol intake is due to loops of interactions between Toll-like 4 and TNF receptors, peroxisome proliferator-activated receptors and the central melanocortin system: A novel hypothesis and new therapeutic avenues. Neuropharmacology, 2018, 128, 401-407.	2.0	22
1469	Hepatic peroxisome proliferatorâ€activated receptor alpha mediates the major metabolic effects of Wyâ€14643. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1138-1145.	1.4	16
1470	Radioiodination and biological evaluation of mesalamine as a tracer for ulcerative colitis imaging. Radiochimica Acta, 2018, 106, 393-400.	0.5	16
1471	Microglia and alcohol meet at the crossroads: Microglia as critical modulators of alcohol neurotoxicity. Toxicology Letters, 2018, 283, 21-31.	0.4	59
1472	C2H2-Type Zinc Finger Proteins: Evolutionarily Old and New Partners of the Nuclear Hormone Receptors. Nuclear Receptor Signaling, 2018, 15, 155076291880107.	1.0	37
1473	Cross-Conjugated Cyclopentenone Prostaglandins. Recent Advances. Russian Journal of Organic Chemistry, 2018, 54, 1585-1629.	0.3	15
1474	Melatonin May Increase Anticancer Potential of Pleiotropic Drugs. International Journal of Molecular Sciences, 2018, 19, 3910.	1.8	13
1475	MicroRNAs in cell cycle progression and proliferation: molecular mechanisms and pathways. Non-coding RNA Investigation, 0, 2, 28-28.	0.6	16
1476	Thiazolidinediones Cause Cardiotoxicity via PPARÎ³- Independent Mechanism. , 0, , .		3
1477	Identification and Molecular Characterization of Peroxisome Proliferator-Activated Receptor Î´ as a Novel Target for Covalent Modification by 15-Deoxy-Î”^{12,14}-prostaglandin J₂. ACS Chemical Biology, 2018, 13, 3269-3278.	1.6	10
1478	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. Mayo Clinic Proceedings, 2018, 93, 1629-1647.	1.4	31
1479	Idi1 and Hmgcs2 Are Affected by Stretch in HL-1 Atrial Myocytes. International Journal of Molecular Sciences, 2018, 19, 4094.	1.8	7
1480	Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle Toxicity. Lipids, 2018, 53, 947-960.	0.7	6
1481	Regulatory Efficacy of Spirulina platensis Protease Hydrolyzate on Lipid Metabolism and Gut Microbiota in High-Fat Diet-Fed Rats. International Journal of Molecular Sciences, 2018, 19, 4023.	1.8	31
1482	Novel glitazones as PPARÎ³ agonists: molecular design, synthesis, glucose uptake activity and 3D QSAR studies. Chemistry Central Journal, 2018, 12, 141.	2.6	19
1483	Genetic Mouse Models for Female Reproductive Toxicology Studies. , 2018, , 470-494.		0
1484	Identification of a Novel PPAR-Î³ Agonist through a Scaffold Tuning Approach. International Journal of Molecular Sciences, 2018, 19, 3032.	1.8	13
1485	The Role of PPARÎ²/Î´ in Melanoma Metastasis. International Journal of Molecular Sciences, 2018, 19, 2860.	1.8	17

#	Article	IF	Citations
1486	Emerging Therapeutic Role of PPARâ€“Î± in Cognition and Emotions. Frontiers in Pharmacology, 2018, 9, 998.	1.6	24
1487	Pioglitazone Represents an Effective Therapeutic Target in Preventing Oxidative/Inflammatory Cochlear Damage Induced by Noise Exposure. Frontiers in Pharmacology, 2018, 9, 1103.	1.6	31
1488	Plasma Concentrations of Perfluoroalkyl Substances and Risk of Type 2 Diabetes: A Prospective Investigation among U.S. Women. Environmental Health Perspectives, 2018, 126, 037001.	2.8	113
1489	Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications. , 2018, , 419-431.		0
1490	Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. PPAR Research, 2018, 2018, 1-10.	1.1	12
1491	Synthesis of a unique dimethyl thiazoline containing intermediate of novel peroxisome proliferator-activated receptors(PPAR)Î´ agonists. Tetrahedron Letters, 2018, 59, 4384-4386.	0.7	3
1492	Hibernation induction in non-hibernating species. Bioscience Horizons, 2018, 11, .	0.6	14
1493	Phytohormone abscisic acid elicits antinociceptive effects in rats through the activation of opioid and peroxisome proliferator-activated receptors Î²/Î´. European Journal of Pharmacology, 2018, 832, 75-80.	1.7	11
1494	Transcriptional regulation of milk lipid synthesis by exogenous C16:0 and C18 fatty acids in bovine mammary epithelial cells. Canadian Journal of Animal Science, 2018, 98, 260-270.	0.7	5
1495	Pharmacokinetic and metabolism studies of bavachinin through ultraâ€highâ€performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Biomedical Chromatography, 2018, 32, e4293.	0.8	7
1496	Beneficial effects of fenofibrate in pulmonary hypertension in rats. Molecular and Cellular Biochemistry, 2018, 449, 185-194.	1.4	9
1497	Plant-Derived Antiinflammatory Steroid Analogs for Neuroprotection. , 2018, , 321-358.		1
1498	Chapter 1 Antioxidant systems in animal body. , 2018, , 19-65.		0
1499	Mechanisms of Action of Dehydroepiandrosterone. Vitamins and Hormones, 2018, 108, 29-73.	0.7	32
1500	Biosynthesis of the Essential Fatty Acid Oxidation Cofactor Carnitine Is Stimulated in Heart and Liver after a Single Bout of Exercise in Mice. Journal of Nutrition and Metabolism, 2018, 2018, 1-7.	0.7	8
1501	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
1502	Toxicant Actions: Mode of Action of Endocrine Disruptors. , 2018, , 567-572.		2
1503	The importance of phospholipids combined with long-chain PUFA in formulated diets for pikeperch (Sander lucioperca) larvae. British Journal of Nutrition, 2018, 120, 628-644.	1.2	21

#	Article	IF	Citations
1504	DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. Physiological Reviews, 2018, 98, 1765-1803.	13.1	64
1505	Anticancer Properties of Fenofibrate: A Repurposing Use. Journal of Cancer, 2018, 9, 1527-1537.	1.2	50
1506	Mechanistic Insights into PFOS-Mediated Sertoli Cell Injury. Trends in Molecular Medicine, 2018, 24, 781-793.	3.5	39
1507	Hypoglycemic activity and constituents analysis of blueberry (<em>Vaccinium) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 627 Therapy, 2018, Volume 11, 357-366.	1.1	15
1508	A pivotal role of BEX1 in liver progenitor cell expansion in mice. Stem Cell Research and Therapy, 2018, 9, 164.	2.4	10
1509	The Activin A-Peroxisome Proliferator-Activated Receptor Gamma Axis Contributes to the Transcriptome of GM-CSF-Conditioned Human Macrophages. Frontiers in Immunology, 2018, 9, 31.	2.2	18
1510	Effect of Eicosapentaenoic Acid and Docosahexaenoic Acid on Myogenesis and Mitochondrial Biosynthesis during Murine Skeletal Muscle Cell Differentiation. Frontiers in Nutrition, 2018, 5, 15.	1.6	34
1511	Metabolic transition of milk triacylglycerol synthesis in response to varying levels of palmitate in porcine mammary epithelial cells. Genes and Nutrition, 2018, 13, 18.	1.2	23
1512	Advances and Challenges in Drug Design of PPARÎ´ Ligands. Current Drug Targets, 2018, 19, 144-154.	1.0	11
1513	Preventive Effects of Resveratrol on Endocannabinoid System and Synaptic Protein Modifications in Rat Cerebral Cortex Challenged by Bilateral Common Carotid Artery Occlusion and Reperfusion. International Journal of Molecular Sciences, 2018, 19, 426.	1.8	11
1514	PPARÎ³ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. Inflammation, 2018, 41, 2079-2089.	1.7	13
1515	Study Design Selection in Early Clinical Antiâ€Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 432-441.	1.3	5
1516	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARÎ³/PTEN/mTOR signaling pathway. BMC Cancer, 2018, 18, 407.	1.1	33
1517	RXRG associated in PPAR signal regulated the differentiation of primordial germ cell. Journal of Cellular Biochemistry, 2018, 119, 6926-6934.	1.2	18
1518	Conserved transcriptional activity and ligand responsiveness of avian PPARs: Potential role in regulating lipid metabolism in mirgratory birds. General and Comparative Endocrinology, 2018, 268, 110-120.	0.8	11
1519	Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: Possible role of PPAR-Î³, Bax/Bcl-2, and caspase-3. Food and Chemical Toxicology, 2018, 121, 95-108.	1.8	63
1520	In Vivo Analysis of miR-34a Regulated Glucose Metabolism Related Genes in Megalobrama amblycephala. International Journal of Molecular Sciences, 2018, 19, 2417.	1.8	7
1521	Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemannâ€“Pick-Disease Type C1. International Journal of Molecular Sciences, 2018, 19, 972.	1.8	16

#	Article	IF	Citations
1522	Troglitazone Inhibits Matrix Metalloproteinase-9 Expression and Invasion of Breast Cancer Cell through a Peroxisome Proliferator-Activated Receptor Î³-Dependent Mechanism. Journal of Breast Cancer, 2018, 21, 28.	0.8	14
1523	Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Psychopharmacology, 2018, 235, 2957-2966.	1.5	13
1524	Phytol: A review of biomedical activities. Food and Chemical Toxicology, 2018, 121, 82-94.	1.8	198
1525	Work in Progress. Clinics in Liver Disease, 2018, 22, 501-515.	1.0	1
1526	Ameliorative effect of Sedum sarmentosum Bunge extract on Tilapia fatty liver via the PPAR and P53 signaling pathway. Scientific Reports, 2018, 8, 8456.	1.6	23
1527	Modulation of Nuclear Receptor Function by Chromatin Modifying Factor TIP60. Endocrinology, 2018, 159, 2199-2215.	1.4	18
1528	Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity. Frontiers in Pharmacology, 2019, 10, 819.	1.6	27
1529	Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey. Molecular Genetics and Metabolism Reports, 2019, 20, 100496.	0.4	7
1530	Transcriptomic study of the mechanism of anoikis resistance in head and neck squamous carcinoma. PeerJ, 2019, 7, e6978.	0.9	6
1531	The pathobiology of perturbed mutant huntingtin proteinâ€“protein interactions in Huntington's disease. Journal of Neurochemistry, 2019, 151, 507-519.	2.1	70
1532	Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARÎ³ phosphorylation. Scientific Reports, 2019, 9, 11168.	1.6	12
1533	Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARÎ±-selective agonist. Bioorganic and Medicinal Chemistry, 2019, 27, 4059-4068.	1.4	9
1534	Diet-Induced Obesity Disturbs Microglial Immunometabolism in a Time-of-Day Manner. Frontiers in Endocrinology, 2019, 10, 424.	1.5	35
1535	PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. Molecules, 2019, 24, 2545.	1.7	132
1536	Molecular and biochemical monitoring of the possible herb-drug interaction between Momordica charantia extract and glibenclamide in diabetic rats. Saudi Pharmaceutical Journal, 2019, 27, 803-816.	1.2	17
1537	Platycodon grandiflorumExtract Reduces High-Fat Diet-Induced Obesity Through Regulation of Adipogenesis and Lipogenesis Pathways in Mice. Journal of Medicinal Food, 2019, 22, 993-999.	0.8	21
1538	Peroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis. Frontiers in Genetics, 2019, 10, 554.	1.1	20
1539	Full Transcriptome Profiling of the Liver of Fat-, Fructose- and Cholesterol-Fed C57Black/6J Mice. Russian Journal of Genetics, 2019, 55, 399-410.	0.2	2

#	Article	IF	Citations
1540	Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease. Mayo Clinic Proceedings, 2019, 94, 1171-1179.	1.4	4
1541	Ketogenic Diet: A New Light Shining on Old but Gold Biochemistry. Nutrients, 2019, 11, 2497.	1.7	62
1542	Evidence from 3-month-old infants shows that a combination of postnatal feeding and exposures in utero shape lipid metabolism. Scientific Reports, 2019, 9, 14321.	1.6	9
1543	Robust Two-Dimensional Spatial-Variant Map-Drift Algorithm for UAV SAR Autofocusing. Remote Sensing, 2019, 11, 340.	1.8	25
1544	Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARÎ³ Agonists as a Promising Tool. Frontiers in Neuroscience, 2019, 13, 907.	1.4	55
1545	LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis. Cell, 2019, 178, 1478-1492.e20.	13.5	122
1546	Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. Nutrients, 2019, 11, 2022.	1.7	173
1547	Extra Virgin Olive Oil: Lesson from Nutrigenomics. Nutrients, 2019, 11, 2085.	1.7	57
1548	Structural Basis for the Regulation of PPARÎ³ Activity by Imatinib. Molecules, 2019, 24, 3562.	1.7	11
1549	Peroxisome Proliferatorâ€“Activated Receptor-Î´ Acts within Peripheral Myeloid Cells to Limit Th Cell Priming during Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2019, 203, 2588-2601.	0.4	10
1550	Regulation of expression and role of peroxisome proliferator-activated receptors (PPARs) in luminal epithelial and stromal cells of the porcine endometrium. Theriogenology, 2019, 127, 88-101.	0.9	14
1551	Endothelial Cellâ€“Targeted Deletion of PPARÎ³Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 514-523.	1.3	2
1552	Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. European Journal of Medicinal Chemistry, 2019, 166, 502-513.	2.6	302
1553	Phytohormone abscisic acid ameliorates cognitive impairments in streptozotocin-induced rat model of Alzheimer's disease through PPARÎ²/Î´ and PKA signaling. International Journal of Neuroscience, 2019, 129, 1053-1065.	0.8	18
1554	Alterations in protein expression patterns of spinal peroxisome proliferator-activated receptors after spinal cord injury. Neurological Research, 2019, 41, 883-892.	0.6	4
1555	The PPARâ€“microbiotaâ€“metabolic organ trilogy to fineâ€tune physiology. FASEB Journal, 2019, 33, 9706-9730.	0.2	46
1556	Polymorphism of the PPARD Gene and Dynamic Balance Performance in Han Chinese Children. Hereditas, 2019, 156, 15.	0.5	3
1557	Gene expression profiling of the canine placenta during normal and antigestagen-induced luteolysis. General and Comparative Endocrinology, 2019, 282, 113194.	0.8	16

#	Article	IF	Citations
1558	Additional fibrate treatment in UDCAâ€refractory PBC patients. Liver International, 2019, 39, 1776-1785.	1.9	24
1559	Importance of the Proximity and Orientation of Ligand-Linkage to the Design of Cinnamate-GW9662 Hybrid Compounds as Covalent PPARÎ³ Agonists. Molecules, 2019, 24, 2019.	1.7	2
1560	Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 981-989.	2.5	11
1561	The effects of shortâ€chain fatty acids on the transcription and secretion of apolipoprotein Aâ€I in human hepatocytes in vitro. Journal of Cellular Biochemistry, 2019, 120, 17219-17227.	1.2	16
1562	A strategy to validate a selection of human effect biomarkers using adverse outcome pathways: Proof of concept for phthalates and reproductive effects. Environmental Research, 2019, 175, 235-256.	3.7	34
1563	Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimerâ€™s Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³) Agonist. Molecular Neurobiology, 2019, 56, 7267-7283.	1.9	25
1564	Bexarotene Exerts Protective Effects Through Modulation of the Cerebral Vascular Smooth Muscle Cell Phenotypic Transformation by Regulating PPARÎ³/FLAP/LTB4 After Subarachnoid Hemorrhage in Rats. Cell Transplantation, 2019, 28, 1161-1172.	1.2	9
1565	Icariin Attenuates M1 Activation of Microglia and AÎ² Plaque Accumulation in the Hippocampus and Prefrontal Cortex by Up-Regulating PPARÎ³ in Restraint/Isolation-Stressed APP/PS1 Mice. Frontiers in Neuroscience, 2019, 13, 291.	1.4	34
1566	Metabolic regulation by the PGC-1Î± and PGC-1Î² coactivators in larval zebrafish (Danio rerio). Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2019, 234, 60-67.	0.8	12
1567	Molecular Modeling Approach to Study the PPARÎ³â€“Ligand Interactions. Methods in Molecular Biology, 2019, 1966, 261-289.	0.4	1
1568	Nuclear Receptors. Methods in Molecular Biology, 2019, , .	0.4	1
1569	PCB52 induces hepatotoxicity in male offspring through aggravating loss of clearance capacity and activating the apoptosis: Sex-biased effects on rats. Chemosphere, 2019, 227, 389-400.	4.2	16
1570	PPARÎ³ promotes diabetesâ€associated centrosome amplification via increasing the expression of SKA1 directly at the transcriptional level. Journal of Cellular Physiology, 2019, 234, 20694-20703.	2.0	2
1571	FermentedCordyceps militarisExtract Ameliorates Hepatosteatosis via Activation of Fatty Acid Oxidation. Journal of Medicinal Food, 2019, 22, 325-336.	0.8	6
1572	Beneficial Effects of Pomegranate Peel Extract and Probiotics on Pre-adipocyte Differentiation. Frontiers in Microbiology, 2019, 10, 660.	1.5	68
1573	REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION. International Research Journal of Pharmacy, 2019, 9, 81-87.	0.0	0
1574	Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer. Medical Hypotheses, 2019, 126, 78-81.	0.8	2
1575	Molecular Cloning and Transient Expression of Recombinant Human PPARÎ³ in HEK293T Cells Under an Inducible Tet-on System. Molecular Biotechnology, 2019, 61, 427-431.	1.3	0

#	Article	IF	Citations
1576	The lipid metabolism alteration of three spirocyclic tetramic acids on zebrafish (Danio rerio) embryos. Environmental Pollution, 2019, 248, 715-725.	3.7	24
1577	Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology, 2019, 76, 526.	4.5	83
1578	Structure-Based Stepwise Screening of PPARÎ³ Antagonists as Potential Competitors with NCOA1 Coactivator Peptide for PPARÎ³ CIS Site. International Journal of Peptide Research and Therapeutics, 2019, 25, 1369-1377.	0.9	7
1579	Possible role of PPAR-Î³ and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma. Medical Hypotheses, 2019, 124, 98-100.	0.8	15
1580	Targeting dysregulation of redox homeostasis in noise-induced hearing loss: Oxidative stress and ROS signaling. Free Radical Biology and Medicine, 2019, 135, 46-59.	1.3	115
1581	In Silico Identification and Experimental Validation of (â˜)-Muqubilin A, a Marine Norterpene Peroxide, as PPARÎ±/Î³-RXRÎ± Agonist and RARÎ± Positive Allosteric Modulator. Marine Drugs, 2019, 17, 110.	2.2	11
1582	Binding partners of NRF2: Functions and regulatory mechanisms. Archives of Biochemistry and Biophysics, 2019, 678, 108184.	1.4	37
1583	Amoxicillin Modulates ApoA-I Transcription and Secretion, Predominantly via PPARÎ± Transactivation Inhibition. International Journal of Molecular Sciences, 2019, 20, 5967.	1.8	6
1584	Neuropeptide Y â€“ Its role in human performance and extreme environments. Reach, 2019, 14-15, 100032.	0.4	4
1585	Meglumine acridone acetate, the ionic salt of CMA and N-methylglucamine, induces apoptosis in human PBMCs via the mitochondrial pathway. Scientific Reports, 2019, 9, 18240.	1.6	6
1586	Autophagy-activating strategies to promote innate defense against mycobacteria. Experimental and Molecular Medicine, 2019, 51, 1-10.	3.2	43
1587	A high-throughput chemicalâ€“genetics screen in murine adipocytes identifies insulin-regulatory pathways. Journal of Biological Chemistry, 2019, 294, 4103-4118.	1.6	9
1588	Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferatorâ€“activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue. Clinical Cancer Research, 2019, 25, 2336-2347.	3.2	18
1589	PPARÎ³ overexpression regulates cholesterol metabolism in human L02 hepatocytes. Journal of Pharmacological Sciences, 2019, 139, 1-8.	1.1	45
1590	Early life adversity blunts responses to pioglitazone in depressed, overweight adults. European Psychiatry, 2019, 55, 4-9.	0.1	5
1591	The association between peroxisome proliferator-activated receptor Î” rs3777744, rs3798343, and rs6922548 and coronary artery disease. Bioscience Reports, 2019, 39, .	1.1	1
1592	Therapeutic potential of selective histone deacetylase 3 inhibition. European Journal of Medicinal Chemistry, 2019, 162, 534-542.	2.6	30
1593	Radiation-induced lung injury: impact on macrophage dysregulation and lipid alteration â€“ a review. Immunopharmacology and Immunotoxicology, 2019, 41, 370-379.	1.1	22

#	Article	IF	Citations
1594	Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. Gastroenterology Research and Practice, 2019, 2019, 1-24.	0.7	20
1595	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. Journal of Neuro-Oncology, 2019, 142, 39-48.	1.4	21
1596	Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells. Toxicology and Applied Pharmacology, 2019, 365, 61-70.	1.3	15
1597	Bezafibrate Upregulates Mitochondrial Biogenesis and Influence Neural Differentiation of Human-Induced Pluripotent Stem Cells. Molecular Neurobiology, 2019, 56, 4346-4363.	1.9	26
1598	(allâ€Ł)â€•and (5Z)â€Łycopene Display Similar Biological Effects on Adipocytes. Molecular Nutrition and Food Research, 2019, 63, e1800788.	1.5	26
1599	Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling. Cell Metabolism, 2019, 29, 91-102.e5.	7.2	33
1600	Enhancement of fear learning in PPARÎ± knockout mice. Behavioural Brain Research, 2019, 359, 664-670.	1.2	8
1601	Is fatty acid composition of human bone marrow significant to bone health?. Bone, 2019, 118, 53-61.	1.4	27
1602	Genetic Variability Among Power Athletes: The Stronger vs. the Faster. Journal of Strength and Conditioning Research, 2019, 33, 1505-1511.	1.0	28
1603	PPAR Receptors Expressed from Vectors Containing CMV Promoter Can Enhance Self-Transcription in the Presence of Fatty Acids from CLA-Enriched Egg Yolksâ€"A Novel Method for Studies of PPAR Ligands. Nutrition and Cancer, 2020, 72, 892-902.	0.9	0
1604	Factors associated with dietary glycemic index and glycemic load in pregnant women and risk for gestational diabetes mellitus. International Journal of Food Sciences and Nutrition, 2020, 71, 516-524.	1.3	14
1605	Analysis of the uterine lumen in fertility-classified heifers: I. Glucose, prostaglandins, and lipidsâ€. Biology of Reproduction, 2020, 102, 456-474.	1.2	19
1606	High Fat Diet Suppresses Peroxisome Proliferator-Activated Receptors and Reduces Dopaminergic Neurons in the Substantia Nigra. International Journal of Molecular Sciences, 2020, 21, 207.	1.8	37
1607	PPARÎ± serves as a new receptor of aspirin for neuroprotection. Journal of Neuroscience Research, 2020, 98, 626-631.	1.3	17
1608	LPS impairs steroidogenesis and ROS metabolism and induces PPAR transcriptional activity to disturb estrogen/androgen receptor expression in testicular cells. Molecular Biology Reports, 2020, 47, 1045-1056.	1.0	12
1609	NPY1R-targeted peptide-mediated delivery of a dual PPARÎ±/Î³ agonist to adipocytes enhances adipogenesis and prevents diabetes progression. Molecular Metabolism, 2020, 31, 163-180.	3.0	17
1610	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2020, 9, 37.	1.8	85
1611	Swimming Physical Training Prevented the Onset of Acute Muscle Pain by a Mechanism Dependent of PPARÎ³ Receptors and CINC-1. Neuroscience, 2020, 427, 64-74.	1.1	6

#	Article	IF	Citations
1612	Natural and synthetic retinoid X receptor ligands and their role in selected nuclear receptor action. Biochimie, 2020, 179, 157-168.	1.3	24
1613	The effects of omega-3 fatty acid supplementation on inflammatory factors in HIV-infected patients: A systematic review and meta-analysis of randomized clinical trials. Cytokine, 2020, 136, 155298.	1.4	12
1614	Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depressionâ€"A Literature Review. International Journal of Molecular Sciences, 2020, 21, 6969.	1.8	18
1615	ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. Heliyon, 2020, 6, e05097.	1.4	4
1616	Antiepileptic Drugâ€"Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferatorâ€"Activated ReceptorÎ±and Peroxisome Proliferatorâ€"Activated ReceptorÎ³Coactivator 1Î±â€"Dependent Gene Expression to Increase Blood Triglyceride Levels. Molecular Pharmacology, 2020, 98, 634-647.	1.0	7
1617	Ecotoxico-lipidomics: An emerging concept to understand chemical-metabolic relationships in comparative fish models. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2020, 36, 100742.	0.4	17
1618	Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors. ACS Chemical Biology, 2020, 15, 325-333.	1.6	18
1619	The skeletal muscles of mice infected with Plasmodium berghei and Plasmodium chabaudi reveal a crosstalk between lipid mediators and gene expression. Malaria Journal, 2020, 19, 254.	0.8	7
1620	PPARÎ³: A turning point for irritable bowel syndrome treatment. Life Sciences, 2020, 257, 118103.	2.0	10
1621	Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies. Life, 2020, 10, 277.	1.1	20
1622	Cytochrome P450 Metabolism of Polyunsaturated Fatty Acids and Neurodegeneration. Nutrients, 2020, 12, 3523.	1.7	26
1623	Differential Effects of Cancer-Associated Mutations Enriched in Helix H3 of PPARÎ³. Cancers, 2020, 12, 3580.	1.7	3
1624	miR-3666 inhibits development of hepatic steatosis by negatively regulating PPARÎ³. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158777.	1.2	6
1625	Microencapsulated Pomegranate Modifies the Composition and Function of High-Density Lipoproteins (HDL) in New Zealand Rabbits. Molecules, 2020, 25, 3297.	1.7	5
1626	Valorisation of stachysetin from cultivated Stachys iva Griseb. as anti-diabetic agent: a multi-spectroscopic and molecular docking approach. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6452-6466.	2.0	12
1627	Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization. International Journal of Molecular Sciences, 2020, 21, 5296.	1.8	14
1628	Synthesis, molecular docking, Î±-glucosidase inhibition, and antioxidant activity studies of novel benzimidazole derivatives. Medicinal Chemistry Research, 2020, 29, 1846-1866.	1.1	8
1629	Ganoderic acid A attenuates high-fat-diet-induced liver injury in rats by regulating the lipid oxidation and liver inflammation. Archives of Pharmacal Research, 2020, 43, 744-754.	2.7	14

#	Article	IF	Citations
1630	Mechanisms of action, chemical characteristics, and model systems of obesogens. BMC Biomedical Engineering, 2020, 2, 6.	1.7	24
1631	Gynura divaricata exerts hypoglycemic effects by regulating the PI3K/AKT signaling pathway and fatty acid metabolism signaling pathway. Nutrition and Diabetes, 2020, 10, 31.	1.5	9
1632	Protective Effects of (E)-Î²-Caryophyllene (BCP) in Chronic Inflammation. Nutrients, 2020, 12, 3273.	1.7	64
1633	Modulation of the mRNA of the Nlrp3 inflammasome by Morin and PUFAs in an obesity model induced by a high-fat diet. Food Research International, 2020, 137, 109706.	2.9	10
1634	Non-hormonal mediators of uterine fibroid growth. Current Opinion in Obstetrics and Gynecology, 2020, 32, 361-370.	0.9	11
1635	Anti-nociceptive effect of Arbutus andrachneÂL. methanolic leaf extract mediated by CB1, TRPV1 and PPARs in mouse pain models. Inflammopharmacology, 2020, 28, 1567-1577.	1.9	4
1636	The Role of PPARÎ³ Ligands in Breast Cancer: From Basic Research to Clinical Studies. Cancers, 2020, 12, 2623.	1.7	36
1637	PPARD May Play a Protective Role against the Development of Schizophrenia. PPAR Research, 2020, 2020, 1-6.	1.1	4
1638	Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia. Frontiers in Cell and Developmental Biology, 2020, 8, 703.	1.8	23
1639	Role of PPARs in Progression of Anxiety: Literature Analysis and Signaling Pathways Reconstruction. PPAR Research, 2020, 2020, 1-15.	1.1	6
1640	Citri Reticulatae Pericarpium protects against isoproterenol-induced chronic heart failure via activation of PPARÎ³. Annals of Translational Medicine, 2020, 8, 1396-1396.	0.7	17
1641	Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. International Journal of Molecular Sciences, 2020, 21, 9251.	1.8	6
1642	PFAS Environmental Pollution and Antioxidant Responses: An Overview of the Impact on Human Field. International Journal of Environmental Research and Public Health, 2020, 17, 8020.	1.2	52
1643	Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-Î³ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. Molecules, 2020, 25, 2076.	1.7	94
1644	COX-2-PGE2-EPs in gynecological cancers. Archives of Gynecology and Obstetrics, 2020, 301, 1365-1375.	0.8	51
1645	Effects of Exercise Training on Renal Carnitine Biosynthesis and Uptake in the High-Fat and High-Sugar-Fed Mouse. Molecules, 2020, 25, 2100.	1.7	2
1646	Telmisartan Protects Auditory Hair Cells from Gentamicin-Induced Toxicity in vitro. Audiology and Neuro-Otology, 2020, 25, 297-308.	0.6	3
1647	Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. Journal of Cellular and Molecular Medicine, 2020, 24, 7201-7213.	1.6	15

#	Article	IF	Citations
1648	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. Cells, 2020, 9, 1196.	1.8	26
1649	The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity. Bioorganic Chemistry, 2020, 100, 103927.	2.0	12
1650	Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2020, 11, 730.	1.6	78
1651	Roles of peroxisome proliferator-activated receptor Î± in the pathogenesis of ethanol-induced liver disease. Chemico-Biological Interactions, 2020, 327, 109176.	1.7	17
1652	Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165727.	1.8	15
1653	Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARÎ´): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2020, 63, 10109-10134.	2.9	14
1654	Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression. Metabolism: Clinical and Experimental, 2020, 110, 154302.	1.5	21
1655	Peroxisome proliferator-activated receptor Î²/Î´ and Î³ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation. Theriogenology, 2020, 152, 36-46.	0.9	6
1656	Synthesis and Biological Activity of Piperine Derivatives as Potential PPARÎ³ Agonists . Drug Design, Development and Therapy, 2020, Volume 14, 2069-2078.	2.0	10
1657	Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-ÎºB/Nrf-2/PPAR-Î³ interplay in mice. Life Sciences, 2020, 256, 117908.	2.0	33
1658	Chaperone-mediated Autophagy Governs Progression of Papillary Thyroid Carcinoma via PPARÎ³-SDF1/CXCR4 Signaling. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3308-3323.	1.8	7
1659	Retinoids Augment Thiazolidinedione PPARÎ³ Activation in Oral Cancer Cells. Anticancer Research, 2020, 40, 3071-3080.	0.5	3
1660	The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma. Frontiers in Immunology, 2020, 11, 1043.	2.2	63
1661	The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. Neurochemical Research, 2020, 45, 972-988.	1.6	161
1662	Lipid Mediated Regulation of Adult Stem Cell Behavior. Frontiers in Cell and Developmental Biology, 2020, 8, 115.	1.8	66
1663	Identification and structural insight of an effective PPARÎ³ modulator with improved therapeutic index for anti-diabetic drug discovery. Chemical Science, 2020, 11, 2260-2268.	3.7	15
1664	A Systematic Review on Anti-diabetic and Cardioprotective Potential of Gallic Acid: A Widespread Dietary Phytoconstituent. Food Reviews International, 2022, 38, 420-439.	4.3	8
1665	The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis. Scientific Reports, 2020, 10, 5140.	1.6	7

#	Article	IF	Citations
1666	Adenosine Receptor A1-A2a Heteromers Regulate EAAT2 Expression and Glutamate Uptake via YY1-Induced Repression of PPARÎ³ Transcription. PPAR Research, 2020, 2020, 1-11.	1.1	16
1667	Signaling pathways of oxidative stress in aquatic organisms exposed to xenobiotics. Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, 2020, 333, 436-448.	0.9	30
1668	Developmental exposure to Î”9-tetrahydrocannabinol (THC) causes biphasic effects on longevity, inflammation, and reproduction in aged zebrafish (Danio rerio). GeroScience, 2020, 42, 923-936.	2.1	12
1669	Regulation of the germinal center response by nuclear receptors and implications for autoimmune diseases. FEBS Journal, 2020, 287, 2866-2890.	2.2	5
1670	Lycopene supplementation regulates the gene expression profile and fat metabolism of breeding hens. Journal of Animal Physiology and Animal Nutrition, 2020, 104, 936-945.	1.0	8
1671	The Peroxisome Proliferator-Activated Receptor Î³ Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase. Cardiology Research and Practice, 2020, 2020, 1-9.	0.5	6
1672	Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARÎ³ Agonist via a Combined Computational and Functional Study. Molecules, 2020, 25, 1119.	1.7	20
1673	Nutritional programming in early life: the role of dietary lipid quality for future health. OCL - Oilseeds and Fats, Crops and Lipids, 2020, 27, 15.	0.6	5
1674	Investigating the Role of PPARÎ²/Î´ in Retinal Vascular Remodeling Using PparÎ²/Î´-Deficient Mice. International Journal of Molecular Sciences, 2020, 21, 4403.	1.8	6
1675	PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma. PPAR Research, 2020, 2020, 1-9.	1.1	16
1676	Discovery of Novel Peroxisome Proliferator-Activated Receptor Î± (PPARÎ±) Agonists by Virtual Screening and Biological Evaluation. Journal of Chemical Information and Modeling, 2020, 60, 1717-1727.	2.5	7
1677	Targeting Abdominal Obesity and Its Complications with Dietary Phytoestrogens. Nutrients, 2020, 12, 582.	1.7	27
1678	Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARÎ± Agonists as Leads for Retinal Disorders. Journal of Medicinal Chemistry, 2020, 63, 2854-2876.	2.9	7
1679	Development of AOP relevant to microplastics based on toxicity mechanisms of chemical additives using ToxCastâ„¢ and deep learning models combined approach. Environment International, 2020, 137, 105557.	4.8	59
1680	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. Gastroenterology Clinics of North America, 2020, 49, 105-121.	1.0	4
1681	Shared PPARÎ±/Î³ Target Genes Regulate Brown Adipocyte Thermogenic Function. Cell Reports, 2020, 30, 3079-3091.e5.	2.9	26
1682	Neuroendocrinology and neurobiology of sebaceous glands. Biological Reviews, 2020, 95, 592-624.	4.7	48
1683	Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells. Frontiers in Immunology, 2019, 10, 2927.	2.2	44

#	Article	IF	Citations
1684	Hepatic Lipid Catabolism via PPARÎ±-Lysosomal Crosstalk. International Journal of Molecular Sciences, 2020, 21, 2391.	1.8	28
1685	Divergent effects of myogenic differentiation and diabetes on the capacity for muscle precursor cell adipogenic differentiation in a fibrin matrix. Biochemical and Biophysical Research Communications, 2020, 526, 21-28.	1.0	7
1686	Isolation of lactic acid bacteria from kimchi and screening of Lactobacillus sakei ADM14 with anti-adipogenic effect and potential probiotic properties. LWT - Food Science and Technology, 2020, 126, 109296.	2.5	43
1687	Metabolic Checkpoints in Rheumatoid Arthritis. Frontiers in Physiology, 2020, 11, 347.	1.3	41
1688	The role and function of PPARÎ³ in bladder cancer. Journal of Cancer, 2020, 11, 3965-3975.	1.2	17
1689	The impact of single and combined PPAR-Î± and PPAR-Î³ activation on the neurological outcomes following cerebral ischemia reperfusion. Life Sciences, 2020, 252, 117679.	2.0	18
1690	Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist. Bioorganic Chemistry, 2020, 100, 103867.	2.0	20
1691	MicroRNA-409-5p promotes retinal neovascularization in diabetic retinopathy. Cell Cycle, 2020, 19, 1314-1325.	1.3	14
1692	Fatty acid metabolism and brain mitochondrial performance of juvenile Nile tilapia (Oreochromis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 Environmental Safety, 2020, 197, 110624.	2.9	1
1693	Insights into PPARÎ³ Phosphorylation and Its Inhibition Mechanism. Journal of Medicinal Chemistry, 2020, 63, 4811-4823.	2.9	21
1694	Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARÎ´-AMPK-PGC-1Î±Pathway in Dyslipidemic Conditions. BioMed Research International, 2020, 2020, 1-17.	0.9	20
1695	Coronary Disease Surveillance in the Community: Angiography and Revascularization. Journal of the American Heart Association, 2020, 9, e015231.	1.6	14
1696	Unbiased approach for the identification of molecular mechanisms sensitive to chemical exposures. Chemosphere, 2021, 262, 128362.	4.2	15
1697	Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice. Biomedicine and Pharmacotherapy, 2021, 133, 110966.	2.5	12
1698	Oral administration of curcumin ameliorates pulmonary fibrosis in mice through 15d-PGJ2-mediated induction of hepatocyte growth factor in the colon. Acta Pharmacologica Sinica, 2021, 42, 422-435.	2.8	8
1699	The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism: Clinical and Experimental, 2021, 114, 154338.	1.5	229
1700	Advances in novel molecular targets for antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110041.	2.5	11
1701	Detrimental Effects of Bisphenol Compounds on Physiology and Reproduction in Fish: A Literature Review. Environmental Toxicology and Pharmacology, 2021, 81, 103497.	2.0	41

#	Article	IF	Citations
1702	Targeting peroxisome proliferator-activated receptors: A new strategy for the treatment of cardiac fibrosis. , 2021, 219, 107702.		8
1703	Phthalate inhibits Leydig cell differentiation and promotes adipocyte differentiation. Chemosphere, 2021, 262, 127855.	4.2	9
1704	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. European Journal of Pharmacology, 2021, 890, 173620.	1.7	24
1705	Taxifolin ameliorate high-fat-diet feeding plus acute ethanol binge-induced steatohepatitis through inhibiting inflammatory caspase-1-dependent pyroptosis. Food and Function, 2021, 12, 362-372.	2.1	35
1706	Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 664-673.	2.2	76
1707	Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. , 2021, 222, 107791.		37
1708	Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression. Molecular Biology Reports, 2021, 48, 195-202.	1.0	13
1709	Pregnane X receptor (PXR) protects against cisplatin-induced acute kidney injury in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165996.	1.8	15
1710	Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency. Brain and Development, 2021, 43, 214-219.	0.6	5
1711	An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT). Current Medical Research and Opinion, 2021, 37, 185-193.	0.9	2
1712	Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-Î³ agonists as anti-diabetic drugs. Journal of Biomolecular Structure and Dynamics, 2021, 39, 728-742.	2.0	21
1713	Contribution of RAGE axis activation to the association between metabolic syndrome and cancer. Molecular and Cellular Biochemistry, 2021, 476, 1555-1573.	1.4	16
1714	Carnitine palmitoyltransferase 1 (CPT1) alleviates oxidative stress and apoptosis of hippocampal neuron in response to beta-Amyloid peptide fragment AÎ² ₂₅₋₃₅. Bioengineered, 2021, 12, 5440-5449.	1.4	11
1715	Uteroplacental Insufficiency with Hypoxia Upregulates Placental PPARÎ³-KMT5A Axis in the Rat. Reproductive Sciences, 2021, 28, 1476-1488.	1.1	3
1716	Normothermic Ex-vivo Kidney Perfusion in a Porcine Auto-Transplantation Model Preserves the Expression of Key Mitochondrial Proteins: An Unbiased Proteomics Analysis. Molecular and Cellular Proteomics, 2021, 20, 100101.	2.5	6
1717	Fenofibrate Protects Cardiomyocytes from Hypoxia/Reperfusion- and High Glucose-Induced Detrimental Effects. PPAR Research, 2021, 2021, 1-15.	1.1	8
1718	Endotoxemia by Porphyromonas gingivalis Alters Endocrine Functions in Brown Adipose Tissue. Frontiers in Cellular and Infection Microbiology, 2020, 10, 580577.	1.8	11
1719	Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. International Journal of Molecular Sciences, 2021, 22, 1001.	1.8	23

#	Article	IF	Citations
1720	Genome-wide association study between copy number variation regions and carcass- and meat-quality traits in Nellore cattle. Animal Production Science, 2021, 61, 731.	0.6	2
1722	Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARÎ³/ NF-Î²B signaling pathway in C6 glioma cells. Medical Oncology, 2021, 38, 31.	1.2	19
1724	Ligand and structure-based computational designing of multi-target molecules directing FFAR-1, FFAR-4 and PPAR-G as modulators of insulin receptor activity. Journal of Biomolecular Structure and Dynamics, 2022, 40, 6974-6988.	2.0	1
1725	INPP4B protects from metabolicÂsyndrome and associated disorders. Communications Biology, 2021, 4, 416.	2.0	10
1726	Oxidative stress in bladder cancer: an ally or an enemy?. Molecular Biology Reports, 2021, 48, 2791-2802.	1.0	9
1727	Cell signaling pathways as molecular targets to eliminate AML stem cells. Critical Reviews in Oncology/Hematology, 2021, 160, 103277.	2.0	20
1728	ELÄ°T KAYAKLI KOÅžUCULARDA PPAR-A'NIN (RS4253778) SERUM LÄ°PÄ°TLERÄ° ÃœZERÄ°NDEKÄ° ETKÄ°SÄ°NÄ°N Ä°NCELENMESÄ°. Spor Performans AraÅŸtÄ±rmalarÄ± Dergisi, 2021, 12, 72-79.	0.1	0
1729	Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG. American Journal of Physiology - Cell Physiology, 2021, 320, C577-C590.	2.1	29
1730	Fenofibrate (a PPAR-Î± Agonist) Administered During Ethanol Withdrawal Reverts Ethanol-Induced Astrogliosis and Restores the Levels of Glutamate Transporter in Ethanol-Administered Adolescent Rats. Frontiers in Pharmacology, 2021, 12, 653175.	1.6	7
1731	mRNA Expressions of Candidate Genes in Gestational Day 16 Conceptus and Corresponding Endometrium in Repeat Breeder Dairy Cows with Suboptimal Uterine Environment Following Transfer of Different Quality Day 7 Embryos. Animals, 2021, 11, 1092.	1.0	5
1732	PPARÎ³ and Diabetes: Beyond the Genome and Towards Personalized Medicine. Current Diabetes Reports, 2021, 21, 18.	1.7	23
1733	Regulation of long-chain polyunsaturated fatty acid biosynthesis in teleost fish. Progress in Lipid Research, 2021, 82, 101095.	5.3	66
1734	Type II nuclear receptors with potential role in Alzheimer disease. Molecular Aspects of Medicine, 2021, 78, 100940.	2.7	5
1735	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes, 2021, 12, 645.	1.0	41
1736	SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways. Scientific Reports, 2021, 11, 8177.	1.6	77
1737	Cellular Responses to the Efferocytosis of Apoptotic Cells. Frontiers in Immunology, 2021, 12, 631714.	2.2	39
1738	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. International Journal of Molecular Sciences, 2021, 22, 4495.	1.8	56
1739	Visible light induced nano copper catalyzed one pot synthesis of novel quinoline bejeweled thiobarbiturates as potential hypoglycemic agents. Journal of Heterocyclic Chemistry, 2021, 58, 1446-1460.	1.4	2

#	Article	IF	Citations
1740	Uncoupling Protein 2 as a Pathogenic Determinant and Therapeutic Target in Cardiovascular and Metabolic Diseases. Current Neuropharmacology, 2022, 20, 662-674.	1.4	6
1741	Selection and Characterization of Probiotic Bacteria Exhibiting Antiadipogenic Potential in 3T3-L1 Preadipocytes. Probiotics and Antimicrobial Proteins, 2022, 14, 72-86.	1.9	8
1742	Biomimetic Total Syntheses of Amorfrutins A, B, (S)â€Ð and (R)â€Ð and Formal Synthesis of Amorfrutin C. European Journal of Organic Chemistry, 2021, 2021, 2540-2548.	1.2	2
1743	Impact of endocrine-disrupting chemicals on steroidogenesis and consequences on testicular function. Molecular and Cellular Endocrinology, 2021, 527, 111215.	1.6	27
1744	Natural Compound 3Î²,7Î²,25-trihydroxycucurbita-5,23(E)-dien-19-al from Momordica charantia Acts as PPARÎ³ Ligand. Molecules, 2021, 26, 2682.	1.7	7
1745	Identification of miRNAs that regulate human CYP2B6 expression. Drug Metabolism and Pharmacokinetics, 2021, 38, 100388.	1.1	4
1746	Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166100.	1.8	5
1747	Species Differences between Mouse and Human PPARÎ± in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARÎ± Agonist in Mice. Toxicological Sciences, 2021, 183, 81-92.	1.4	12
1748	A Chinese hamster transcription start site atlas that enables targeted editing of CHO cells. NAR Genomics and Bioinformatics, 2021, 3, lqab061.	1.5	7
1749	Integrated metabolomics analysis of the effect of PPARÎ´ agonist GW501516 on catabolism of BCAAs and carboxylic acids in diabetic mice. Chinese Chemical Letters, 2021, 32, 2197-2202.	4.8	10
1750	Tetrazoles as PPARÎ³ ligands: A structural and computational investigation. Journal of Molecular Graphics and Modelling, 2021, 106, 107932.	1.3	1
1751	The Gutâ€“Brain Axis and Peroxisome Proliferator-Activated Receptors in the Regulation of Epileptogenesis. Journal of Evolutionary Biochemistry and Physiology, 2021, 57, 743-760.	0.2	2
1752	Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-Î±/Î³) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. PPAR Research, 2021, 2021, 1-12.	1.1	12
1753	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. Infectious Diseases and Therapy, 2021, 10, 1907-1931.	1.8	38
1754	Radiosynthesis and in silico bioevaluation of ¹³¹Iâ€Sulfasalazine as a highly selective radiotracer for imaging of ulcerative colitis. Chemical Biology and Drug Design, 2021, 98, 751-761.	1.5	13
1755	Hypothyroidism Intensifies Both Canonic and the De Novo Pathway of Peroxisomal Biogenesis in Rat Brown Adipocytes in a Time-Dependent Manner. Cells, 2021, 10, 2248.	1.8	2
1756	Effects of Subacute Exposure of Dibutyl Phthalate on the Homeostatic Model Assessment, Thyroid Function, and Redox Status in Rats. BioMed Research International, 2021, 2021, 1-8.	0.9	4
1758	DNMT1-mediated PPARÎ± methylation aggravates damage of retinal tissues in diabetic retinopathy mice. Biological Research, 2021, 54, 25.	1.5	19

#	Article	IF	Citations
1759	Elastin-Derived Peptides in the Central Nervous System: Friend or Foe. Cellular and Molecular Neurobiology, 2022, 42, 2473-2487.	1.7	18
1760	Exposure, health effects, sensing, and remediation of the emerging PFAS contaminants â€“ Scientific challenges and potential research directions. Science of the Total Environment, 2021, 780, 146399.	3.9	42
1761	Identification of an allosteric hotspot for additive activation of PPARÎ³ in antidiabetic effects. Science Bulletin, 2021, 66, 1559-1570.	4.3	18
1762	PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. International Journal of Molecular Sciences, 2021, 22, 8298.	1.8	29
1763	Effects of Fatty Acid Oxidation and Its Regulation on Dendritic Cell-Mediated Immune Responses in Allergies: An Immunometabolism Perspective. Journal of Immunology Research, 2021, 2021, 1-10.	0.9	4
1764	Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPARÎ³ and PGC1Î±. PPAR Research, 2021, 2021, 1-17.	1.1	10
1765	The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. Journal of Nutritional Biochemistry, 2021, 95, 108633.	1.9	17
1766	In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels. Metabolites, 2021, 11, 657.	1.3	10
1767	Simvastatin-romidepsin combination kills bladder cancer cells synergistically. Translational Oncology, 2021, 14, 101154.	1.7	5
1768	Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. Inflammation, 2022, 45, 156-171.	1.7	10
1769	MicroRNA-126b-5p Exacerbates Development of Adipose Tissue and Diet-Induced Obesity. International Journal of Molecular Sciences, 2021, 22, 10261.	1.8	9
1770	PPARÎ± at the crossroad of metabolicâ€“immune regulation in cancer. FEBS Journal, 2022, 289, 7726-7739.	2.2	18
1771	Cyclooxygenase-2 Inhibitor Parecoxib Was Disclosed as a PPAR-Î³ Agonist by In Silico and In Vitro Assay. Biomolecules and Therapeutics, 2021, 29, 519-526.	1.1	1
1772	Accelerated Barrier Repair in Human Skin Explants Induced with a Plant-Derived PPAR-Î± Activating Complex via Cooperative Interactions. Clinical, Cosmetic and Investigational Dermatology, 2021, Volume 14, 1271-1293.	0.8	5
1773	Regulation of cholesterol biosynthesis and lipid metabolism: A microRNA management perspective. Steroids, 2021, 173, 108878.	0.8	22
1774	Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor Î³ toward Potential Pharmacological Applications. Biological and Pharmaceutical Bulletin, 2021, 44, 1185-1195.	0.6	7
1775	PPAR-Î± Hypermethylation in the Hippocampus of Mice Exposed to Social Isolation Stress Is Associated with Enhanced Neuroinflammation and Aggressive Behavior. International Journal of Molecular Sciences, 2021, 22, 10678.	1.8	23
1776	Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-Î³/ Nrf-2 crosstalk in mice. International Immunopharmacology, 2021, 99, 107963.	1.7	17

#	Article	IF	Citations
1777	Circadian clock core component Bmal1 dictates cell cycle rhythm of proliferating hepatocytes during liver regeneration. American Journal of Physiology - Renal Physiology, 2021, 321, G389-G399.	1.6	4
1779	Immune treatments for alcohol use disorder: A translational framework. Brain, Behavior, and Immunity, 2021, 97, 349-364.	2.0	30
1780	Simvastatin affects the PPARÎ± signaling pathway and causes oxidative stress and embryonic development interference in Mugilogobius abei. Aquatic Toxicology, 2021, 239, 105951.	1.9	3
1781	Ultrasound promoted montmorillonite K-10 catalyzed synthesis, characterization, molecular modelling, SAR and hypoglycemic studies of new rhodanine bejeweled acridine analogues. Journal of Molecular Structure, 2021, 1242, 130828.	1.8	6
1782	Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents. Bioorganic Chemistry, 2021, 115, 105162.	2.0	13
1783	Sex differences feed into nuclear receptor signaling along the digestive tract. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166211.	1.8	3
1784	Probiotic supplementation mitigates the developmental toxicity of perfluorobutanesulfonate in zebrafish larvae. Science of the Total Environment, 2021, 799, 149458.	3.9	17
1785	Nuclear receptors in liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166235.	1.8	23
1786	Disruption of Other Receptor Systems. , 2022, , 127-140.		1
1787	Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities. Environmental Research, 2022, 204, 111904.	3.7	25
1788	Polar fraction from Parkinsonia aculeata aerial parts extract improves imbalanced metabolic profile and reduces proinflammatory interleukin levels in white adipose tissue in obese rats induced by western diet. Journal of Ethnopharmacology, 2022, 282, 114557.	2.0	1
1789	Metabolic Transition of Milk Triacylglycerol Synthesis in Response to Varying Levels of Three 18-Carbon Fatty Acids in Porcine Mammary Epithelial Cells. International Journal of Molecular Sciences, 2021, 22, 1294.	1.8	4
1790	The biology of nutrients: genetic and molecular principles. , 2021, , 273-288.		0
1791	Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPARÎ³. International Journal of Molecular Sciences, 2021, 22, 985.	1.8	25
1792	Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing. Pharmaceuticals, 2021, 14, 88.	1.7	5
1793	Herbal therapy as a promising approach for regulation on lipid profiles: A review of molecular aspects. Journal of Cellular Physiology, 2021, 236, 5533-5546.	2.0	7
1795	Mammalian Hibernation. Advances in Experimental Medicine and Biology, 2003, , 21-38.	0.8	96
1796	Peroxisome Proliferator-Activated Receptors and Inflammation. , 2013, , 221-233.		2

#	Article	IF	Citations
1797	The Role of PPARÎ³ in Stroke. , 2014, , 301-320.		2
1798	Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies. , 2005, , 57-68.		2
1799	Genomics of Aerobic Capacity and Endurance Performance: Clinical Implications. , 2011, , 179-229.		3
1800	Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders. Emerging Contaminants and Associated Treatment Technologies, 2021, , 301-322.	0.4	1
1801	Roles of N-Acylethanolamines in Brain Functions and Neuropsychiatric Diseases. , 2017, , 319-346.		3
1802	Possible Mechanisms of Ï‰-3 PUFA Anti-tumour Action. , 2010, , 3-38.		7
1803	PPARÎ³ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study. Psychopharmacology, 2020, 237, 2367-2380.	1.5	14
1804	Cerebral Vascular Dysfunction with Aging. , 2011, , 405-419.		8
1805	NURA: A curated dataset of nuclear receptor modulators. Toxicology and Applied Pharmacology, 2020, 407, 115244.	1.3	17
1806	Edible flowers as a health promoter: An evidence-based review. Trends in Food Science and Technology, 2021, 117, 46-59.	7.8	27
1807	Comprehensive analysis of long noncoding RNA and mRNA in five colorectal cancer tissues and five normal tissues. Bioscience Reports, 2020, 40, .	1.1	4
1808	Epigenetic modification and therapeutic targets of diabetes mellitus. Bioscience Reports, 2020, 40, .	1.1	38
1809	Genetic Predictors of Obesity. , 2008, , 437-460.		5
1810	The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARÎ± and PPARÎ³ Activation. Journal of Cardiovascular Pharmacology, 2020, 76, 514-526.	0.8	14
1813	Peroxisome Proliferator-Activated Receptors Features, Functions, and Future. Nuclear Receptor Research, 2015, 2, .	2.5	10
1814	The Myofibroblast: TGFÎ²-1, A Conductor which Plays a Key Role in Fibrosis by Regulating the Balance between PPARÎ³ and the Canonical WNT Pathway. Nuclear Receptor Research, 2017, 4, .	2.5	15
1815	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Nuclear Receptor Research, 2017, 4, .	2.5	12
1816	PPARÎ³ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	3.9	257

#	Article	IF	Citations
1817	PPARÎ³ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	3.9	185
1818	Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1â€“deficient mice. Journal of Clinical Investigation, 2004, 113, 96-105.	3.9	131
1819	Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1â€“deficient mice. Journal of Clinical Investigation, 2004, 113, 96-105.	3.9	200
1820	Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARÎ³. Journal of Clinical Investigation, 2004, 114, 240-249.	3.9	125
1821	Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRÎ± phosphorylation. Journal of Clinical Investigation, 2005, 115, 2924-2933.	3.9	40
1822	MicroRNA-223 is a crucial mediator of PPARÎ³-regulated alternative macrophage activation. Journal of Clinical Investigation, 2015, 125, 4149-4159.	3.9	115
1823	Signaling and other functions of lipids in autophagy: a review. Lipids in Health and Disease, 2020, 19, 214.	1.2	32
1824	Assessment of Hepatotoxicity. , 2009, , 37-66.		1
1825	Carnitine Enigma: From Antioxidant Action to Vitagene Regulation. Part 2. Transcription Factors and Practical Applications. Journal of Veterinary Science & Medicine, 2015, 3, .	1.0	15
1826	PPARÎ± Deficiency in Inflammatory Cells Suppresses Tumor Growth. PLoS ONE, 2007, 2, e260.	1.1	87
1827	Lysophosphatidic Acid Activates Peroxisome Proliferator Activated Receptor-Î³ in CHO Cells That Over-Express Glycerol 3-Phosphate Acyltransferase-1. PLoS ONE, 2011, 6, e18932.	1.1	41
1828	Scaffold-Based Pan-Agonist Design for the PPARÎ±, PPARÎ² and PPARÎ³ Receptors. PLoS ONE, 2012, 7, e48453.	1.1	13
1829	Identification of PPARgamma Partial Agonists of Natural Origin (II): In Silico Prediction in Natural Extracts with Known Antidiabetic Activity. PLoS ONE, 2013, 8, e55889.	1.1	25
1830	Possible Role of Intestinal Fatty Acid Oxidation in the Eating-Inhibitory Effect of the PPAR-Î± Agonist Wy-14643 in High-Fat Diet Fed Rats. PLoS ONE, 2013, 8, e74869.	1.1	46
1831	Antidiabetic Effects of Chamomile Flowers Extract in Obese Mice through Transcriptional Stimulation of Nutrient Sensors of the Peroxisome Proliferator-Activated Receptor (PPAR) Family. PLoS ONE, 2013, 8, e80335.	1.1	46
1832	Modulation of Membrane Lipid Composition and Homeostasis in Salmon Hepatocytes Exposed to Hypoxia and Perfluorooctane Sulfonamide, Given Singly or in Combination. PLoS ONE, 2014, 9, e102485.	1.1	17
1833	Influence of Fenofibrate Treatment on Triacylglycerides, Diacylglycerides and Fatty Acids in Fructose Fed Rats. PLoS ONE, 2014, 9, e106849.	1.1	19
1834	Metabolic Profiling of Chicken Embryos Exposed to Perfluorooctanoic Acid (PFOA) and Agonists to Peroxisome Proliferator-Activated Receptors. PLoS ONE, 2015, 10, e0143780.	1.1	14

#	Article	IF	Citations
1835	Transcriptome Profiling of Caco-2 Cancer Cell Line following Treatment with Extracts from Iodine-Biofortified Lettuce (Lactuca sativa L.). PLoS ONE, 2016, 11, e0147336.	1.1	14
1836	Depot-Specific Changes in Fat Metabolism with Aging in a Type 2 Diabetic Animal Model. PLoS ONE, 2016, 11, e0148141.	1.1	11
1837	Effects of Peroxisome Proliferator-Activated Receptor-Î´ Agonist on Cardiac Healing after Myocardial Infarction. PLoS ONE, 2016, 11, e0148510.	1.1	13
1838	Mid-gestation serum lipidomic profile associations with spontaneous preterm birth are influenced by body mass index. PLoS ONE, 2020, 15, e0239115.	1.1	15
1839	Differential Interactions of the Flame Retardant Triphenyl Phosphate within the PPAR Signaling Network. MOJ Toxicology, 2016, 2, .	0.2	1
1840	Nutrition Solutions to Counter Health Impact of Air Pollution: Scientific Evidence of Marine Omega-3 Fatty Acids and Vitamins Alleviating Some Harmful Effects of PM2.5. International Journal of Food and Nutritional Science, 2015, 2, 1-6.	0.4	1
1841	Fatty acids â€“ from energy substrates to key regulators of cell survival, proliferation and effector function. Cell Stress, 2020, 4, 9-23.	1.4	34
1843	Critical Review: Essential Fatty Acids on Shrimp Feeding. Scientia Agraria Paranaensis, 2016, 15, 236-243.	0.1	1
1844	Synthesis, Computational & Docking Studies Of Bis-(4-Hydroxycoumarin-3-Yl) Methanes As Potential Inhibitor For Carbonic Anhydrase, Glyceraldehyde-3-Phosphate Dehydrogenase. Journal of Pharmaceutical and Applied Chemistry, 2016, 2, 81-101.	0.2	7
1845	Lipid-lowering fibrates extend C. elegans lifespan in a NHR-49/PPARalpha-dependent manner. Aging, 2013, 5, 270-275.	1.4	26
1846	Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway. Aging, 2016, 8, 2777-2789.	1.4	42
1847	AMPKÎ± pathway involved in hepatic triglyceride metabolism disorder in diet-induced obesity mice following Escherichia coli Infection. Aging, 2018, 10, 3161-3172.	1.4	6
1848	PPARÎ±, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop. Oncotarget, 2016, 7, 84623-84633.	0.8	21
1849	Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013). Oncotarget, 2017, 8, 16912-16924.	0.8	11
1850	Induction of apoptosis in prostate cancer by ginsenoside Rh2. Oncotarget, 2018, 9, 11109-11118.	0.8	24
1851	Adipose triglyceride lipase decrement affects skeletal muscle homeostasis during aging through FAs-PPARÎ±-PGC-1Î± antioxidant response. Oncotarget, 2016, 7, 23019-23032.	0.8	30
1852	Physiological and cellular requirements for successful elongation of the preimplantation conceptus and the implications for fertility in lactating dairy cows. Animal Reproduction, 2018, 15, 765-783.	0.4	4
1853	Insulin Resistance Syndrome in Children. , 2003, 5, 291.		1

#	Article	IF	Citations
1854	Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment. Current Medicinal Chemistry, 2013, 20, 3370-3396.	1.2	71
1855	Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics. Current Medicinal Chemistry, 2019, 26, 1185-1223.	1.2	15
1856	Mitochondria: Prospective Targets for Neuroprotection in Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2014, 20, 5558-5573.	0.9	22
1857	Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets. Current Pharmaceutical Design, 2015, 21, 3654-3664.	0.9	92
1858	The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. Current Pharmaceutical Design, 2019, 25, 2540-2554.	0.9	21
1859	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	0.9	10
1860	Roles of Perilipins in Diseases and Cancers. Current Genomics, 2018, 19, 247-257.	0.7	24
1861	Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence. Current Drug Targets, 2013, 14, 768-776.	1.0	65
1862	Discovery of Novel Anti-Diabetic Drugs by Targeting Lipid Metabolism. Current Drug Targets, 2015, 16, 1372-1380.	1.0	12
1863	Novel Cinnamic Acid Derivatives as Potential PPARÎ´ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies. Current Drug Discovery Technologies, 2020, 17, 338-347.	0.6	3
1864	Inhibition of PPARÎ³ by Natural Compounds as a Promising Strategy in Obesity and Diabetes. Open Medicinal Chemistry Journal, 2019, 13, 7-15.	0.9	11
1865	Effects of Glycyrrhetic Acid (GE) on Some Gluconeogenic Enzymes, Lipoprotein Lipase and Peroxisome Proliferator-Activated Receptors Alpha and Gamma. The Open Bioactive Compounds Journal, 2013, 4, 14-24.	0.8	4
1866	Peroxisome proliferator-activated receptor gamma as modulator of inflammation in pulmonary sarcoidosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 705-709.	0.1	6
1868	Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Bioscience - Landmark, 2008, 13, 1813.	3.0	356
1869	In silico molecular docking studies of some phytochemicals against peroxisome-proliferator activated receptor gamma (PPAR-Î³). GSC Biological and Pharmaceutical Sciences, 2018, 5, 001-005.	0.1	5
1870	CP-MLR derived QSAR rationales for the PPARγ agonistic activity of the pyridyloxybenzene-acylsulfonamide derivatives. GSC Biological and Pharmaceutical Sciences, 2020, 12, 273-285.	0.1	1
1871	Acne and Its Therapy. , 0, , .		4
1872	Treating Acne with Octadecenedioic Acid: Mechanism of Action, Skin Delivery, and Clinical Results. Basic and Clinical Dermatology, 2007, , 137-154.	0.1	5

#	Article	IF	Citations
1873	Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Medica, 2020, 63, 188-197.	0.3	15
1874	Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology, 2020, 11, 595498.	1.6	68
1875	Anti-obesity Effects of African Mango (Irvingia gabonesis, IGOB 131^{TM}) Extract in Leptin-deficient Obese Mice. Journal of the Korean Society of Food Science and Nutrition, 2014, 43, 1477-1483.	0.2	4
1876	Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis. World Journal of Gastroenterology, 2005, 11, 6322.	1.4	29
1877	Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. World Journal of Gastroenterology, 2007, 13, 1983.	1.4	19
1878	Obstructive sleep apnea syndrome and fatty liver: Association or causal link?. World Journal of Gastroenterology, 2010, 16, 4243.	1.4	55
1879	Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor Î±-mediated superoxide dismutase induction in HeLa cells. Radiation Oncology Journal, 2012, 30, 88.	0.7	21
1880	Lowering Lipid Mechanism of the Ethanol Extracts from Maggot of Musca domestica in Rats Fed a High-Cholesterol Diet. International Journal of Pharmacology, 2014, 11, 1-9.	0.1	2
1881	Role of PPARÎ± and PPARÎ³ in Mediating the Analgesic Properties of Ibuprofen in vivo and the Effects of Dual PPARÎ±/Î³ Activation in Inflammatory Pain Model in the Rat. International Journal of Pharmacology, 2016, 12, 812-820.	0.1	7
1882	Anti-Inflammatory and PPAR Transactivational Effects of Oleanane-Type Triterpenoid Saponins from the Roots of Pulsatilla koreana. Biomolecules and Therapeutics, 2014, 22, 334-340.	1.1	16
1883	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes and Metabolism Journal, 2020, 44, 213.	1.8	43
1884	Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes and Metabolism Journal, 2020, 44, 640-657.	1.8	16
1885	Significant correlation between BMI/BW with insulin resistance by McAuley, HOMA and QUICKI indices after 3 months of pioglitazone in diabetic population. International Journal of Diabetes in Developing Countries, 2007, 27, 87.	0.3	1
1886	Beneficial effects of green coffee and green tea extract combination on metabolic syndrome improvement by affecting AMPK And PPAR-Î± gene expression. Journal of Advanced Pharmaceutical Technology and Research, 2020, 11, 81.	0.4	14
1887	Changes in N-acylethanolamine Pathway Related Metabolites in a Rat Model of Cerebral Ischemia/Reperfusion. Journal of Glycomics & Lipidomics, 2011, 01, .	0.4	10
1888	Potential of Resveratrol in Inhibiting Cancer and Slowing Aging. Journal of Nutrition & Food Sciences, 0, s5, .	1.0	9
1889	UP780, a Chromone-Enriched <i>Aloe</i> Composition, Enhances Adipose Insulin Receptor Signaling and Decreases Liver Lipid Biosynthesis. Open Journal of Genetics, 2013, 03, 9-86.	0.1	3
1890	Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World Journal of Hepatology, 2016, 8, 211.	0.8	15

#	Article	IF	Citations
1891	Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6, 120.	0.6	7
1892	Anti-inflammatory and PPAR Subtypes Transactivational Activities of Phenolics and Lignans from the Stem Bark of Kalopanax pictus. Bulletin of the Korean Chemical Society, 2011, 32, 4049-4054.	1.0	4
1893	Biapigenin, Candidate of an Agonist of Human Peroxisome Proliferator-Activated Receptor Î³ with Anticancer Activity. Bulletin of the Korean Chemical Society, 2011, 32, 2717-2721.	1.0	2
1894	Binding Model of Amentoflavone to Peroxisome Proliferator-Activated Receptor γ. Bulletin of the Korean Chemical Society, 2012, 33, 1475-1479.	1.0	3
1895	Design and Synthesis of Oxime Ethers of Î²-Oxo-Î³-phenylbutanoic Acids as PPAR Î± and -Î³ Dual Agonists. Bulletin of the Korean Chemical Society, 2012, 33, 1979-1982.	1.0	3
1896	Cytotoxic Activities of Amentoflavone against Human Breast and Cervical Cancers are Mediated by Increasing of PTEN Expression Levels due to Peroxisome Proliferator-Activated Receptor Î³ Activation. Bulletin of the Korean Chemical Society, 2012, 33, 2219-2223.	1.0	13
1897	NF-ÎºB Inhibition and PPAR Activation by Phenolic Compounds from Hypericum perforatum L. Adventitious Root. Bulletin of the Korean Chemical Society, 2013, 34, 1407-1413.	1.0	11
1898	NF-ÎºB Activation and PPAR Transactivational Effects of a New Aliphatic Acid Amide from Pericarps of Zanthoxylum piperitum. Bulletin of the Korean Chemical Society, 2014, 35, 2361-2366.	1.0	17
1899	A pilot study of circulating PPAR-Î³ receptor protein in elderly patients with atrial fibrillation. Archives of Medical Science, 2012, 8, 471-6.	0.4	11
1900	Genetic variants in the PPARD-PPARGC1A-NRF-TFAM mitochondriogenesis pathway are neither associated with muscle characteristics nor physical performance in elderly. [Variaciones genÃ©ticas en la vÃa de la mitocondriogÃ©nesis PPARD-PPARGC1A-NRF-TFAM no estÃ¡n asociadas ni con caracterÃsticas musculares ni con rendimiento fÃsico en personas mayores].. RICYDE Revista Internacional De Ciencias Del Deporte, 2015, 11, 196-208.	0.1	1
1901	Molecular Characterization and Expression Analysis of the Peroxisome Proliferator Activated Receptor Delta (<i>PPARÎ´</i>) Gene before and after Exercise in Horse. Asian-Australasian Journal of Animal Sciences, 2015, 28, 697-702.	2.4	11
1902	Effect of dietary n-6 to n-3 polyunsaturated fatty acid ratio on prostaglandin plasma levels and genes expression peroxisome proliferator-activated receptor (PPAR) in pregnant Sprague Dawley rats. African Journal of Biotechnology, 2011, 10, 8703-8708.	0.3	9
1903	Delayed-Onset Heparin-Induced Thrombocytopenia. Annals of Internal Medicine, 2003, 139, 790.	2.0	1
1904	Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite. ELife, 2014, 3, .	2.8	72
1905	Prostaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney development. ELife, 2016, 5, .	2.8	44
1906	LRP1 regulates peroxisome biogenesis and cholesterol homeostasis in oligodendrocytes and is required for proper CNS myelin development and repair. ELife, 2017, 6, .	2.8	54
1907	The Actions of PPARÎ³ Agonists on the Various Target Organs. The Korean Journal of Obesity, 2011, 20, 161.	0.2	4
1908	PPAR GAMMA AGONISTS: AN EFFECTIVE STRATEGY FOR CANCER TREATMENT. Journal of Pharmaceutical and Scientific Innovation, 2013, 2, 1-3.	0.1	3

#	Article	IF	Citations
1909	Curcumin Derivative MTH-3 Regulates Palmitate-induced Insulin Resistance in Mouse Myoblast C₂C₁₂Cells. In Vivo, 2021, 35, 3181-3191.	0.6	1
1910	Coffee Bioactive N-Methylpyridinium Attenuates Tumor Necrosis Factor (TNF)-Î±-Mediated Insulin Resistance and Inflammation in Human Adipocytes. Biomolecules, 2021, 11, 1545.	1.8	4
1911	Moderating effect of ppar-Î³ on the association of c-reactive protein and ischemic stroke in patients younger than 60. Gene, 2022, 809, 146029.	1.0	2
1912	Histone H4 lysine 16 acetylation controls central carbon metabolism and diet-induced obesity in mice. Nature Communications, 2021, 12, 6212.	5.8	16
1913	The Role of PPAR-Î³ in Allergic Disease. Current Allergy and Asthma Reports, 2021, 21, 45.	2.4	27
1914	Cornelian Cherry (Cornus mas L.) Iridoid and Anthocyanin Extract Enhances PPAR-Î±, PPAR-Î³ Expression and Reduces I/M Ratio in Aorta, Increases LXR-Î± Expression and Alters Adipokines and Triglycerides Levels in Cholesterol-Rich Diet Rabbit Model. Nutrients, 2021, 13, 3621.	1.7	18
1915	Healthy ageing and Mediterranean diet: A focus on hormetic phytochemicals. Mechanisms of Ageing and Development, 2021, 200, 111592.	2.2	13
1916	GYY4137 Regulates Extracellular Matrix Turnover in the Diabetic Kidney by Modulating Retinoid X Receptor Signaling. Biomolecules, 2021, 11, 1477.	1.8	9
1917	Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. Pharmaceuticals, 2021, 14, 1025.	1.7	13
1918	Endocrine Regulation of Leptin Production. , 2003, , 39-51.		1
1919	The Macrophage as a Validated Pharmaceutical Target. Handbook of Experimental Pharmacology, 2003, , 3-10.	0.9	0
1920	æ¸å†…å•†å®¹ä½“PPARã•è„‚è³ªä»£è¬èª¿ç¯€. Journal of Lipid Nutrition, 2003, 12, 65-74.	0.1	0
1921	Fatty Acid Receptors. , 2004, , 95-98.		0
1922	Lipid-Lowering Responses Modified by Genetic Variation. Handbook of Experimental Pharmacology, 2004, , 107-147.	0.9	1
1923	Retinoids and Carotenoids as Cancer Chemopreventive Agents. , 2005, , .		0
1924	Fatty Acids, Gene Expression, and Coronary Heart Disease (CHD). Oxidative Stress and Disease, 2005, , 181-200.	0.3	0
1925	Anti-Inflammatory Agents in Cancer Cachexia. , 2005, , 369-391.		0
1927	Modulatory Properties of Conjugated Linoleic Acid on Inflammation and Immune Function. , 2006, , 153-170.		0

#	Article	IF	Citations
1928	Nuclear Hormone Receptors. , 2007, , 1-3.		0
1929	Regulation of Fatty Acid Oxidation of the Heart. , 2007, , 27-62.		0
1930	Regulation of Mitochondrial Fuel Handling by the Peroxisome Proliferator-Activated Receptors. , 2007, , 63-95.		0
1931	Intracellular Signaling Pathways and Peroxisome Proliferator-Activated Receptors in Vascular Health in Hypertension and in Diabetes. Oxidative Stress and Disease, 2007, , 195-210.	0.3	0
1932	AETIOLOGY, PATHOLOGY AND MEDICAL ASPECTS OF ULCERATIVE COLITIS. , 2008, , 1427-1475.		0
1933	Modulation of Gene Expression by Dietary Carotenoids and Retinoids. Oxidative Stress and Disease, 2008, , .	0.3	0
1934	Correlation between BMI and insulin resistance in type 2 diabetes mellitus patients on pioglitazone treatment. Galle Medical Journal, 2009, 12, 18.	0.1	0
1935	Combination of nateglinide with thiazolidinediones in Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2009, 4, 537-552.	1.2	1
1936	Gut Hormones and Energy Balance, The Future for Obesity Therapy?. Indonesian Biomedical Journal, 2009, 1, 33.	0.2	56
1937	ThÃ©rapeutique des dÃ©sordres glycÃ©miques. , 2010, , 119-174.		0
1940	Nutritional Genomics. , 2011, , 77-138.		2
1941	Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction. , 2013, , 235-260.		2
1942	Effects of FXR Deficiency and Pioglitazone on Atherosclerosis in ApoE-Knockout Mice. Korean Journal of Medicine, 2013, 84, 238.	0.1	0
1943	Genetic Modification of MSCs for Pharmacological Screening. , 2013, , 127-138.		0
1944	Lipids | Fatty Acid Structure and Synthesis. , 2013, , 478-482.		0
1945	Combination of PPAR-Î± Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	1
1946	Effect of Hepatic Steatosis on Bioenergetic Function During Hepatic Ischemia-reperfusion: A Systematic Review. The Open Transplantation Journal, 2013, 7, 10-32.	0.1	0
1947	Emerging Acne Treatments. , 2014, , 441-447.		0

#	Article	IF	Citations
1948	PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanish cohort. Journal of Genetics Study, 2014, 2, 1.	0.0	2
1949	Molecular Complex Coordinating Peroxisome Morphogenesis in Mammalian Cells. , 2014, , 391-401.		2
1950	Peroxisome Proliferator-Activated Receptor (PPAR) Î±/Î³ Agonist. Korean Journal of Medicine, 2014, 87, 19.	0.1	2
1951	Fine-Tuning of Adipogenesis is a Potential Mechanism for Improved Insulin Sensitivity in Human Adipose Tissue with Rosiglitazone Therapy. Journal of Bangladesh Society of Physiologists, 2010, 4, 34-43.	0.0	0
1952	14. Modulation of lipids, lipoproteins, and other biomarkers with egg consumption and exercise. Human Health Handbooks, 2015, , 231-252.	0.1	1
1953	Allium hookeri Extract Improves Type 2 Diabetes Mellitus in C57BL/KSJ Db/db Obese Mouse via Regulation of Hepatic Lipogenesis and Glucose Metabolism. Journal of Life Science, 2015, 25, 1081-1090.	0.2	6
1954	Non-alcoholic Fatty Liver Disease in Obesity. , 2016, , 159-179.		0
1955	Alzheimerâ€™s Disease Management: Current Therapy and Recent Drug Development. International Neuropsychiatric Disease Journal, 2016, 7, 1-19.	0.1	0
1956	Transcription Modulation of Mitochondrial Function and Related Pathways as a Therapeutic Opportunity in Parkinsonâ€™s Disease. , 2016, , 231-253.		1
1959	Emerging Therapeutic Targets for Diabetes. , 2016, , 53-72.		0
1960	Anti-Obesity Effect of Pine Cone (Pinus koraiensis) Supercritical Extract in High-Fat Diet-Induced Obese Mice. Journal of the Korean Society of Food Science and Nutrition, 2016, 45, 1701-1707.	0.2	1
1961	Identifying Changes in Punitive Transcriptional Factor Binding Sites Created by PPAR<i>Î±/Î³</i> SNPs Associated with Disease. Journal of Biosciences and Medicines, 2017, 05, 81-100.	0.1	0
1962	Genetik der LeistungsfÃhigkeit und Trainierbarkeit. , 2018, , 419-445.		0
1963	Insights into the PPARR Phosphorylation and Its Inhibition Through Direct and Allosteric Mechanisms. SSRN Electronic Journal, 0, , .	0.4	0
1964	Classic ketogenic diet (and its modifications) - the therapy for epileptiform conditions caused by some defects of carbohydrate and fat metabolism. Part I. Ketogenic diet mechanisms of action. PsihiÄeskoe ZdorovÊ¹e, 2018, , 66-83.	0.0	0
1966	ThÃ©rapeutique des dÃ©sordres glycÃ©miques. , 2019, , 141-252.		0
1967	Thiazolidinediones and ischemic stroke (literature review and reasoning for the new potential) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	0.0	0
1969	Valsartan inhibits RhoAâ€“ROCK2â€“MYL pathway in rat model of alcoholic cardiomyopathy. Experimental and Therapeutic Medicine, 2019, 18, 4313-4321.	0.8	1

#	Article	IF	Citations
1972	Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders. Systemic Hypertension, 2021, 18, 130-139.	0.1	2
1973	DHA-enriched phosphatidylcholine suppressed angiogenesis by activating PPARÎ³ and modulating the VEGFR2/Ras/ERK pathway in human umbilical vein endothelial cells. Food Science and Biotechnology, 2021, 30, 1543-1553.	1.2	7
1974	PPARÎ³/LXRÎ± axis mediated phenotypic plasticity of lung fibroblasts in silica-induced experimental silicosis. Environmental Pollution, 2021, 292, 118272.	3.7	4
1975	Review on Amorfrutin of Licorice for Type2 Diabetes Mellitus. The Journal of Internal Korean Medicine, 2020, 41, 1078-1088.	0.0	3
1976	Endocannabinoid-Like Lipid Neuromodulators in the Regulation of Dopamine Signaling: Relevance for Drug Addiction. Frontiers in Synaptic Neuroscience, 2020, 12, 588660.	1.3	10
1977	The lipids. , 2022, , 303-467.		18
1978	Neurotoxicity as a side effect of taxanes in cancer patients. Russian Journal of Pain, 2020, 18, 48.	0.2	2
1979	The role of periostin in kidney diseases. Central-European Journal of Immunology, 2021, 46, 494-501.	0.4	7
1981	Role of genes related to performance and reproduction of Thoroughbreds in training and breeding â€“ A review. Acta Veterinaria Hungarica, 2021, 69, 315-323.	0.2	0
1982	Variants and expression changes in PPAR-encoding genes display no significant association with schizophrenia. Bioscience Reports, 2020, 40, .	1.1	3
1984	Actions of Nuclear Receptors. , 2006, , 273-292.		0
1985	Insulin Resistance, Chronic Inflammation and the Link with Immunosenescence. , 2009, , 1247-1272.		0
1986	Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARÎ³. Journal of Clinical Investigation, 2004, 114, 240-249.	3.9	89
1987	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clinical Biochemist Reviews, 2004, 25, 31-48.	3.3	7
1988	Curcumin is not a ligand for peroxisome proliferator-activated receptor-Î³. Gene Therapy and Molecular Biology, 2009, 13, 20-25.	1.3	19
1990	Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension. International Journal of Physiology, Pathophysiology and Pharmacology, 2010, 2, 104-110.	0.8	2
1991	Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-Î³) polymorphism (Pro12Ala) in Iranian population. Journal of Research in Medical Sciences, 2011, 16, 291-6.	0.4	6
1993	Characterization and Functional Assessment of Mouse PPARÎ³1 Promoter. Avicenna Journal of Medical Biotechnology, 2012, 4, 160-9.	0.2	3

#	Article	IF	Citations
1995	Peroxisome proliferator-activated receptor-Î³ (PPARÎ³) Pro12Ala polymorphism and colorectal cancer (CRC) risk. International Journal of Clinical and Experimental Medicine, 2015, 8, 4066-72.	1.3	8
1996	Changes in N-acylethanolamine Pathway Related Metabolites in a Rat Model of Cerebral Ischemia/Reperfusion. Journal of Glycomics & Lipidomics, 2011, 1, .	0.4	6
1997	Effects of PPARÎ³ agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo. International Journal of Clinical and Experimental Pathology, 2015, 8, 12549-56.	0.5	4
1998	Over-expression of HSPA12B protects mice against myocardium ischemic/reperfusion injury through a PPARÎ³-dependent PI3K/Akt/eNOS pathway. American Journal of Translational Research (discontinued), 2015, 7, 2724-37.	0.0	6
1999	Role of peroxisome proliferator-activated receptor alpha and gamma in antiangiogenic effect of pomegranate peel extract. Iranian Journal of Basic Medical Sciences, 2016, 19, 106-10.	1.0	7
2000	Peroxisome proliferator-activated receptor-Î³ agonist inhibits collagen synthesis in human keloid fibroblasts by suppression of early growth response-1 expression through upregulation of miR-543 expression. American Journal of Cancer Research, 2016, 6, 1358-70.	1.4	6
2001	Toxicological evaluation of subchronic use of pioglitazone in mice. Iranian Journal of Basic Medical Sciences, 2016, 19, 712-9.	1.0	3
2002	Standardized Pericarp Extract, Suppresses Tumor Proliferation and Angiogenesis in a Mouse Model of Melanoma: Possible Involvement of PPARÎ± and PPARÎ³ Pathways. Iranian Journal of Pharmaceutical Research, 2019, 18, 348-357.	0.3	4
2004	Nutrigenetics and nutrigenomicsâ€"A personalized approach to nutrition. Advances in Genetics, 2021, 108, 277-340.	0.8	5
2005	Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration. Current Neuropharmacology, 2022, 20, 893-915.	1.4	2
2006	Nuclear Receptors in Myocardial and Cerebral Ischemiaâ€"Mechanisms of Action and Therapeutic Strategies. International Journal of Molecular Sciences, 2021, 22, 12326.	1.8	8
2007	Biocatalytic one pot three component approach: Facile synthesis, characterization, molecular modelling and hypoglycemic studies of new thiazolidinedione festooned quinoline analogues catalyzed by alkaline protease from Aspergillus niger. Bioorganic Chemistry, 2022, 119, 105533.	2.0	7
2008	A promising in silico protocol to develop novel PPARÎ³ antagonists as potential anticancer agents: Design, synthesis and experimental validation via PPARÎ³ protein activity and competitive binding assay. Computational Biology and Chemistry, 2021, 95, 107600.	1.1	4
2009	Role of Actionable Genes in Pursuing a True Approach of Precision Medicine in Monogenic Diabetes. Genes, 2022, 13, 117.	1.0	10
2010	A new insight into the treatment of diabetes by means of pan PPAR agonists. Chemical Biology and Drug Design, 2022, 100, 947-967.	1.5	13
2011	Hypothalamic Microinflammation: New Paradigm In Obesity And Metabolic Disease. Indonesian Biomedical Journal, 2020, 12, 201-13.	0.2	0
2012	EMERGENCE OF BENZOTHIAZOLE AND ITS DERIVATIVES AS A POTENTIAL ANTIDIABETIC PROBE. Indian Drugs, 2020, 57, 7-18.	0.1	2
2014	PXR Suppresses PPARÎ±-Dependent HMGCS2 Gene Transcription by Inhibiting the Interaction between PPARÎ± and PGC1Î±. Cells, 2021, 10, 3550.	1.8	5

#	Article	IF	Citations
2015	The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models. Molecules, 2022, 27, 607.	1.7	9
2016	The COVID-19-diabetes mellitus molecular tetrahedron. Molecular Biology Reports, 2022, 49, 4013-4024.	1.0	6
2017	NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. International Journal of Molecular Sciences, 2022, 23, 1432.	1.8	38
2018	Chewing the Fat with Microbes: Lipid Crosstalk in the Gut. Nutrients, 2022, 14, 573.	1.7	4
2019	Scutellariae Radix and Citri Reticulatae Pericarpium Mixture Regulate PPARÎ³/RXR Signaling in Reflux Esophagitis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	2
2020	Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases. Journal of Medicinal Chemistry, 2022, 65, 1961-1978.	2.9	6
2021	The Key Role of Peroxisomes in Follicular Growth, Oocyte Maturation, Ovulation, and Steroid Biosynthesis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	1.9	3
2022	Network-Based Approach to Repurpose Approved Drugs for COVID-19 by Integrating GWAS and Text Mining Data. Processes, 2022, 10, 326.	1.3	1
2023	Effects of a yeast cell wall product on the performance of broiler chickens and PGC-1Î±, TLR4, IL-10 and PPARÎ³ genes expression. Italian Journal of Animal Science, 2022, 21, 263-278.	0.8	5
2024	In-silico studies for targeting PPARÎ³ for the Type II Diabetes Mellitus. Materials Today: Proceedings, 2022, , .	0.9	4
2025	The polysaccharideâ€“peptide complex from mushroom Cordyceps militaris ameliorates atherosclerosis by modulating the lncRNAâ€“miRNAâ€“mRNA axis. Food and Function, 2022, 13, 3185-3197.	2.1	11
2027	Systemic Response to Infection Induces Long-Term Cognitive Decline: Neuroinflammation and Oxidative Stress as Therapeutical Targets. Frontiers in Neuroscience, 2021, 15, 742158.	1.4	11
2028	A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 479.	1.4	8
2029	Role of Plant-Derived Products Through Exhilarating Peroxisome Proliferator-Activated Receptor-Î³ (ppar-Î³) in the Amelioration of Obesity Induced Insulin Resistance. Current Nutrition and Food Science, 2022, 18, 549-558.	0.3	1
2030	The Symbiotic Effect of a New Nutraceutical with Yeast Î²-Glucan, Prebiotics, Minerals, and Silybum marianum (Silymarin) for Recovering Metabolic Homeostasis via Pgc-1Î±, Il-6, and Il-10 Gene Expression in a Type-2 Diabetes Obesity Model. Antioxidants, 2022, 11, 447.	2.2	4
2031	Association between recurrent breast cancer and phthalate exposure modified by hormone receptors and body mass index. Scientific Reports, 2022, 12, 2858.	1.6	5
2032	The Role of the Intestine in the Development of Hyperuricemia. Frontiers in Immunology, 2022, 13, 845684.	2.2	31
2033	Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes, Obesity and Metabolism, 2022, 24, 1150-1158.	2.2	13

#	Article	IF	Citations
2034	Septoclasts expressing epidermal fatty acid-binding protein (E-FABP, FABP5) in endochondral ossification. Journal of Oral Biosciences, 2022, 64, 18-25.	0.8	4
2035	The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases. Frontiers in Pharmacology, 2022, 13, 832732.	1.6	16
2036	Citri Reticulatae Pericarpium alleviates postmyocardial infarction heart failure by upregulating <scp>PPARÎ³</scp> expression. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 661-673.	0.9	5
2037	A review on Black Pepper as Antidiabetic agent: Black- Not always bad. Research Journal of Pharmacognosy and Phytochemistry, 2022, , 26-28.	0.1	2
2038	The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review. Translational Lung Cancer Research, 2022, 11, 472-496.	1.3	8
2040	BPA disrupted the testis testosterone levels by interfering ER enrichments within StAR 5â€² flanking region in rare minnow Gobiocypris rarus. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2022, 257, 109338.	1.3	2
2041	Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation. IScience, 2022, 25, 104196.	1.9	15
2042	Evaluation of PPAR-Î³ with lipid profiles and blood glucose in obese persons with DM type 2 and obese persons without DM type 2. International Journal of Health Sciences, 0, , 778-785.	0.0	0
2043	Leveraging ToxCast Data and Protein Sequence Conservation to Complement Aquatic Life Criteria Derivation. Integrated Environmental Assessment and Management, 2022, , .	1.6	1
2044	Molecular characterization, expression and functional analysis of large yellow croaker (Larimichthys crocea) peroxisome proliferator-activated receptor gamma. Fish and Shellfish Immunology, 2022, 123, 50-60.	1.6	1
2045	D-Mannose Regulates Hepatocyte Lipid Metabolism via PI3K/Akt/mTOR Signaling Pathway and Ameliorates Hepatic Steatosis in Alcoholic Liver Disease. Frontiers in Immunology, 2022, 13, 877650.	2.2	10
2046	Organotin(IV) complexes with epigenetic modulator ligands: New promising candidates in cancer therapy. Inorganica Chimica Acta, 2022, 536, 120901.	1.2	3
2047	Molecular docking analysis of PARÎ³ with compounds from Ocimum tenuiflorum. Bioinformation, 2021, 17, 928-931.	0.2	1
2048	Impact of polyunsaturated fatty acid supplementation on assisted reproductive technology outcomes: a systematic review. Human Fertility, 2021, , 1-9.	0.7	0
2049	The potential of micronutrient support with omega-3 and omega-6 fatty acids in the prevention of human reproductive disorders. Journal of Obstetrics and Women's Diseases, 2021, 70, 91-104.	0.0	2
2050	Hepatic transcriptome analysis identifies genes, polymorphisms and pathways involved in the fatty acids metabolism in sheep. PLoS ONE, 2021, 16, e0260514.	1.1	11
2051	Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. Diagnostics, 2021, 11, 2316.	1.3	8
2052	Overcompensation of CoA Trapping by Di(2-ethylhexyl) Phthalate (DEHP) Metabolites in Livers of Wistar Rats. International Journal of Molecular Sciences, 2021, 22, 13489.	1.8	2

#	Article	IF	Citations
2053	The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARÎ³ Receptors. Neurotherapeutics, 2022, 19, 434-449.	2.1	11
2054	Nitro Fatty Acids (NO2-FAs): An Emerging Class of Bioactive Fatty Acids. Molecules, 2021, 26, 7536.	1.7	9
2055	PPAR-Î± Agonist GW7647 Protects Against Oxidative Stress and Iron Deposit via GPx4 in a Transgenic Mouse Model of Alzheimerâ€™s Diseases. ACS Chemical Neuroscience, 2022, 13, 207-216.	1.7	17
2056	Parsing the Role of PPARs in Macrophage Processes. Frontiers in Immunology, 2021, 12, 783780.	2.2	32
2057	Preparation and in-vitro, in-vivo characterisation of pioglitazone loaded chitosan/PEG blended PLGA biocompatible nanoparticles. Journal of Biomaterials Science, Polymer Edition, 2022, 33, 1623-1643.	1.9	2
2058	Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions. Molecular Neurobiology, 2022, 59, 3888-3912.	1.9	15
2059	Pregnancy urinary concentrations of bisphenol A, parabens and other phenols in relation to serum levels of lipid biomarkers: Results from the EARTH study. Science of the Total Environment, 2022, 833, 155191.	3.9	2
2084	PPARs in Atherosclerosis. , 0, , 337-349.		0
2086	Peroxisome Proliferatorâ€“Activated Receptor-Î±: A Pivotal Regulator of the Gastrointestinal Tract. Frontiers in Molecular Biosciences, 2022, 9, 864039.	1.6	0
2087	Quercetin Inhibits Adipocyte Differentiation via Matrix Metalloproteinases in 3T3-L1 Preadipocytes. Journal of the Korean Society of Food Science and Nutrition, 2022, 51, 311-321.	0.2	1
2088	microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection. Journal of Biological Chemistry, 2022, 298, 101983.	1.6	6
2089	PPARÎ³ phase separates with RXRÎ± at PPREs to regulate target gene expression. Cell Discovery, 2022, 8, 37.	3.1	9
2090	Screening of Bovine Tissue-Specific Expressed Genes and Identification of Genetic Variation Within an Adipose Tissue-Specific lncRNA Gene. Frontiers in Veterinary Science, 2022, 9, .	0.9	3
2091	rhEPO Upregulates the PPARÎ³ Pathway in Long-term Cultured Primary Nerve Cells via PI3K/Akt to Delay Cell Senescence. Journal of Molecular Neuroscience, 2022, , 1.	1.1	0
2092	Peroxisomal Modulation as Therapeutic Alternative for Tackling Multiple Cancers. Physiology, 0, , .	4.0	0
2093	Lipid Metabolism and Cancer. Life, 2022, 12, 784.	1.1	14
2094	Impact of concomitant fibrates on immunotherapy outcomes for advanced <scp>nonâ€small</scp> cell lung cancer. Cancer Medicine, 2023, 12, 358-367.	1.3	5
2095	Nuclear hormone receptors in demyelinating diseases. Journal of Neuroendocrinology, 2022, 34, .	1.2	6

#	Article	IF	Citations
2096	Hypoglycemic effects of naturally processed Polygonum multiflorum extract in KK CgAy/J mice and its mechanism of action. Food Science and Human Wellness, 2022, 11, 1177-1182.	2.2	1
2097	Novel derivatives of eugenol as potent anti-inflammatory agents via PPARÎ³ agonism: rational design, synthesis, analysis, PPARÎ³ protein binding assay and computational studies. RSC Advances, 2022, 12, 16966-16978.	1.7	7
2098	Exploring Fenofibrate Formulations for the Treatment of Lipid Disorders: Past, Present, and Future. Cardiometabolic Syndrome Journal, 0, 2, .	1.0	2
2099	Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities. Progress in Medicinal Chemistry, 2022, , 1-91.	4.1	7
2100	Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder. Frontiers in Psychiatry, 0, 13, .	1.3	27
2101	Î±â€lipoic acid inhibits cerulein/resistinâ€induced expression of interleukinâ€6 by activating peroxisome proliferatorâ€activated receptorâ€Î³ in pancreatic acinar cells. Molecular Medicine Reports, 2022, 26, .	1.1	2
2102	The Correlation Between Peroxisome Proliferator-Activated Receptor Alpha and Gamma Polymorphisms and Acute Coronary Syndrome. Cureus, 2022, , .	0.2	0
2103	PPARÎ³ Mediates Protective Effect against Hepatic Ischemia/Reperfusion Injury via NF-ÎºB Pathway. Journal of Investigative Surgery, 2022, 35, 1648-1659.	0.6	3
2104	Nuclear Receptors (PPARs, REV-ERBs, RORs) and Clock Gene Rhythms in Goldfish (Carassius auratus) Are Differently Regulated in Hypothalamus and Liver. Frontiers in Physiology, 0, 13, .	1.3	4
2105	Imeglimin: features of the mechanism of action and potential benefits. Problemy Endokrinologii, 2022, 68, 57-66.	0.2	1
2106	Cross-Talk between Obesity and Diabetes: Introducing Polyphenols as an Effective Phytomedicine to Combat the Dual Sword Diabesity. Current Pharmaceutical Design, 2022, 28, 1523-1542.	0.9	6
2107	Eicosanoid-Activated PPARÎ± Inhibits NFÎºB-Dependent Bacterial Clearance During Post-Influenza Superinfection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7
2108	4,5-diazafenylfluorene-rhodanine conjugates promote anoikis in A375 cells via inhibiting PPAR-Î³ expression. Medicinal Chemistry Research, 0, , .	1.1	0
2109	Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Molecular Cancer Therapeutics, 2004, 3, 993-1001.	1.9	26
2110	Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle, 2022, 21, 2365-2378.	1.3	16
2111	Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway. Pharmacological Research, 2022, 183, 106365.	3.1	44
2112	Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals. Frontiers in Aging Neuroscience, 0, 14, .	1.7	11
2114	Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility. Cells, 2022, 11, 2569.	1.8	9

#	Article	IF	Citations
2115	Camellia oil improves AÎ²25-35-induced memory impairment by regulating the composition of the gut microbiota and lipid metabolism in mice. Journal of Functional Foods, 2022, 96, 105214.	1.6	3
2116	Japanese soup stocks (katsuo-dashi and kombu-dashi) modulate food factor sensing-related gene expression in mice. International Journal of Gastronomy and Food Science, 2022, 29, 100573.	1.3	0
2117	Transcriptional regulation of milk fat synthesis in dairy cattle. Journal of Functional Foods, 2022, 96, 105208.	1.6	5
2118	Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer. International Journal of Molecular Sciences, 2022, 23, 10952.	1.8	5
2119	Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response. , 2022, 238, 108274.		0
2120	Immunomodulatory efficacy of Cousinia thomsonii C.B. Clarke in ameliorating inflammatory cascade expressions. Journal of Ethnopharmacology, 2023, 300, 115727.	2.0	0
2121	How the Structure of Per- and Polyfluoroalkyl Substances (Pfas) Influences Their Binding Potency to the Peroxisome Proliferator-Activated and Thyroid Hormone Receptors â€“ an in Silico Screening Study. SSRN Electronic Journal, 0, , .	0.4	0
2122	Immunomodulatory Efficacy of Cousinia Thomsonii C.B. Clarke in Ameliorating iNOS, COX-2, PPAR-Î³, Rel-A, and CRP Expression and Molecular Docking Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2124	Immunometabolism Dysfunction in the Pathophysiology and Treatment of Rheumatoid Arthritis. Current Medicinal Chemistry, 2023, 30, 3119-3136.	1.2	1
2125	Microsecond MD Simulations to Explore the Structural and Energetic Differences between the Human RXRÎ±-PPARÎ³ vs. RXRÎ±-PPARÎ³-DNA. Molecules, 2022, 27, 5778.	1.7	1
2126	Food groups and nutrients consumption and risk of endometriosis: a systematic review and meta-analysis of observational studies. Nutrition Journal, 2022, 21, .	1.5	12
2127	Bioinformatics analysis reveals the changes of peroxisome proliferator-activated receptor (PPAR) pathway in the development of Marjolin ulcers. International Journal of Transgender Health, 2022, 15, 960-969.	1.1	0
2129	Natural Product Ligands of the Peroxisome Proliferator-Activated Receptor Gamma as Anti-Inflammatory Mediators. Natural Products Journal, 2023, 13, .	0.1	1
2131	Role of Transcription Factors in the Management of Preterm Birth: Impact on Future Treatment Strategies. Reproductive Sciences, 0, , .	1.1	0
2132	Obesity, Diabetes Mellitus, and Vascular Impediment as Consequences of Excess Processed Food Consumption. Cureus, 2022, , .	0.2	0
2133	Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Cofactor Recruitment Assay for PPARÎ± and PPARÎ³. Methods in Molecular Biology, 2023, , 155-169.	0.4	1
2134	Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARÎ±, PPARÎ³, and PPARÎ´ Receptors. Methods in Molecular Biology, 2023, , 145-153.	0.4	0
2135	Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents. ChemMedChem, 2022, 17, .	1.6	1

#	Article	IF	Citations
2136	The effects of breastfeeding and formula feeding on the metabolic factors and the expression level of obesity and diabetesâ€predisposing genes in healthy infants. Physiological Reports, 2022, 10, .	0.7	6
2137	Skeletal muscle mitochondrial remodeling in heart failure: An update on mechanisms and therapeutic opportunities. Biomedicine and Pharmacotherapy, 2022, 155, 113833.	2.5	13
2138	Flavonoids as Antidiabetic and Anti-Inflammatory Agents: A Review on Structural Activity Relationship-Based Studies and Meta-Analysis. International Journal of Molecular Sciences, 2022, 23, 12605.	1.8	46
2139	Pharmacological Treatment for Neuroinflammation in Stress-Related Disorder. Biomedicines, 2022, 10, 2518.	1.4	5
2140	Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents. Molecules, 2022, 27, 6763.	1.7	14
2141	The downstream PPARÎ³ target LRRC1 participates in early stage adipocytic differentiation. Molecular and Cellular Biochemistry, 2023, 478, 1465-1473.	1.4	3
2142	Hydroethanolic Extract of MorusÂnigra L. Leaves: A Dual PPAR-Î±/Î³ Agonist with Anti-Inflammatory Properties in Lipopolysaccharide-Stimulated RAW 264.7. Plants, 2022, 11, 3147.	1.6	3
2145	Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives. , 2023, 241, 108316.		4
2146	Myelin lipid metabolism and its role in myelination and myelin maintenance. Innovation(China), 2023, 4, 100360.	5.2	7
2147	Role of potential bioactive metabolites from traditional Chinese medicine for type 2 diabetes mellitus: An overview. Frontiers in Pharmacology, 0, 13, .	1.6	3
2148	Genome-wide identification and expression of the peroxisome proliferator-activated receptor gene family in the Tibetan highland fish Gymnocypris przewalskii. Fish Physiology and Biochemistry, 2022, 48, 1685-1699.	0.9	1
2149	A Screening System for the Identification of Fragment Molecules toward the Creation of Nuclear Receptor Ligands. Yakugaku Zasshi, 2022, 142, 1345-1351.	0.0	0
2150	Nutraceuticals and the Network of Obesity Modulators. Nutrients, 2022, 14, 5099.	1.7	8
2151	Artesunate Reverses Clozapine-induced Lipid Metabolism Disorder in BRL-3A Cells by Effecting AMPK Pathway. Current Chinese Science, 2023, 3, 194-203.	0.2	0
2152	The Influence of the Differentiation of Genes Encoding Peroxisome Proliferator-Activated Receptors and Their Coactivators on Nutrient and Energy Metabolism. Nutrients, 2022, 14, 5378.	1.7	6
2153	Therapeutic modulation of JAK-STAT, mTOR, and PPAR-Î³ signaling in neurological dysfunctions. Journal of Molecular Medicine, 2023, 101, 9-49.	1.7	9
2154	Kinetics changes in total cholesterol predict <scp>HBeAg</scp> seroconversion in chronic hepatitis B patients treated with pegylated interferonâ€alfa. Journal of Viral Hepatitis, 0, , .	1.0	0
2155	The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review. Diagnostics, 2022, 12, 3107.	1.3	11

#	Article	IF	Citations
2156	How the Structure of Per- and Polyfluoroalkyl Substances (PFAS) Influences Their Binding Potency to the Peroxisome Proliferator-Activated and Thyroid Hormone Receptorsâ€"An In Silico Screening Study. Molecules, 2023, 28, 479.	1.7	9
2158	Current Understanding on the Role of Lipids in Macrophages and Associated Diseases. International Journal of Molecular Sciences, 2023, 24, 589.	1.8	7
2159	The Role of PPARs in Breast Cancer. Cells, 2023, 12, 130.	1.8	16
2160	Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatology International, 2023, 17, 606-614.	1.9	8
2161	Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology, 2023, 78, 1625-1653.	3.6	2
2162	Protective Effects of Resveratrol on Brain Edema and Microstructural Changes in Human Brain After Acute Alcohol Intake: Assessment by Diffusion Weighted Kurtosis Imaging. Lecture Notes in Computer Science, 2023, , 169-179.	1.0	0
2163	The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders. Advances in Experimental Medicine and Biology, 2023, , 513-535.	0.8	0
2164	Molecular Toxicity Mechanism of Plasticizers in the Reservoir. , 2023, , 183-195.		0
2165	Hepatic Transcriptome Analysis Reveals Genes, Polymorphisms, and Molecules Related to Lamb Tenderness. Animals, 2023, 13, 674.	1.0	2
2166	Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors. PPAR Research, 2023, 2023, 1-15.	1.1	1
2167	The emerging role of PPAR-alpha in breast cancer. Biomedicine and Pharmacotherapy, 2023, 161, 114420.	2.5	7
2168	The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomedicine and Pharmacotherapy, 2023, 161, 114465.	2.5	4
2169	Transcriptional analysis in peripheral blood cells of individuals with elevated phthalate exposure â€" Results of the EuroMix study. Environmental Research, 2023, 222, 115377.	3.7	1
2170	Effects of tomato ketchup and tomato paste extract on hepatic lipid accumulation and adipogenesis. Food Science and Biotechnology, 0, , .	1.2	1
2171	Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and Coactivators. Life, 2023, 13, 515.	1.1	2
2172	PPARÎ± Induces the Expression of CAR That Works as a Negative Regulator of PPARÎ± Functions in Mouse Livers. International Journal of Molecular Sciences, 2023, 24, 3953.	1.8	2
2173	The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia. Cells, 2023, 12, 647.	1.8	9
2174	Comparative Transcriptome Analysis Identifies MAPK Signaling Pathway Associated with Regulating Ovarian Lipid Metabolism during Vitellogenesis in the Mud Crab, Scylla paramamosain. Fishes, 2023, 8, 145.	0.7	2

#	Article	IF	Citations
2176	Adult Triploid Rainbow Trout Can Adapt to Various Dietary Lipid Levels by Coordinating Metabolism in Different Tissues. Metabolites, 2023, 13, 396.	1.3	2
2177	PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. International Journal of Molecular Sciences, 2023, 24, 5321.	1.8	0
2178	Lipedema: The Use of Cultured Adipocytes for Identification of Diagnostic Markers. Plastic and Reconstructive Surgery, 2023, 152, 1036-1046.	0.7	2
2179	Novel oral medications for retinal disease: an update on clinical development. Current Opinion in Ophthalmology, 2023, 34, 203-210.	1.3	1
2180	The inflammatory profiles of pulmonary alveolar macrophages and alveolar type 2 cells in SCD. Experimental Biology and Medicine, 2023, 248, 1013-1023.	1.1	0
2181	Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer. Cancers, 2023, 15, 2195.	1.7	15
2182	The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome. Journal of Clinical Medicine, 2023, 12, 2912.	1.0	5
2183	Biological Screening and Crystallographic Studies of Hydroxy Î³-Lactone Derivatives to Investigate PPARÎ³ Phosphorylation Inhibition. Biomolecules, 2023, 13, 694.	1.8	0
2184	Modeling Suicidal Behavior. , 2023, , 1-21.		0
2196	Pemafibrate. , 2024, , 214-223.e2.		0
2201	Nonneurological aspects of the endocannabinoid system: Nonalcoholic fatty liver disease. , 2023, , 507-518.		0
2205	Endocrine disruption. , 2023, , 231-266.		0
2209	Modeling Suicidal Behavior. , 2023, , 2867-2887.		0
2228	The effect of chamomile consumption on glycemic markers in humans and animals: a systematic review and meta-analysis. Journal of Diabetes and Metabolic Disorders, 0, , .	0.8	0